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Cardiovascular disease (CVD) is one of the main causes of death in western society. 
Mortality rates worldwide will further increase since the occurrence of CVD in low 
and middle-income countries is propelling1,2. Risk factors such as hypertension, 
smoking, obesity, abnormal lipids, diabetes mellitus, as well as, stress and lack of 
regular physical activity are the major contributors to cardiovascular morbidity and 
mortality. The primary cause of CVD is atherosclerosis3. The underlying pathogenesis 
of atherosclerosis is a disturbed equilibrium of lipid accumulation and a maladaptive 
immune response4. Early atherosclerotic lesions or so-called fatty streaks can be 
detected from the second and third decade of age, although symptoms and clinical 
complications usually occur in the elderly. Clinical complications can be caused 
by critical narrowing (>70%) of the lumen but are more often the result of plaque 
destabilization in the form of plaque rupture or erosion and subsequent occluding 
thrombosis5. Depending on the resulting end-organ ischemia, myocardial infarction, 
stroke or critical limb ischemia can occur.
Therapies to treat atherosclerotic lesions
Occlusive atherosclerotic lesions can be treated through a drug approach or 
surgical intervention. Drug therapies that are most commonly prescribed are lipid 
lowering- (statins), blood pressure control- and antithrombotic medication. Surgical 
interventions comprise percutaneous transluminal angioplasty (PTA) with or without 
stent placement, endarterectomy or bypass surgery. Endovascular approaches (PTA 
and stenting) are the preferred intervention strategies, but complicated lesions at 
bifurcations, multivessel-disease or recurrent stenosis, still require bypass surgery. 
Bypass surgery is performed to bridge an occluded vessel with anarterial, venous 
or prosthetic conduit. Preferably an autologous arterial vessel segment (internal 
mammary artery) is used since this results in the best patency rates6. However, due 
to the limited length and number, venous (i.e. saphenous vein) conduits are often 
used. Vein graft surgery was first described more than a century ago by the Nobel-
prize winning surgeon Alexis Carrel. The technique of vein grafting in the lower limb 
was independently developed by Holden and Kunlin in the 1950s7. Favaloro et al 
were the first in 1968 that described the technique of coronary bypass grafting8.
Vein graft disease
Nowadays, more than a million coronary artery bypass surgeries are performed 
worldwide per year while the same number of patients undergo lower limb 
infrainguinal bypasses9. Despite the undoubted success of bypass surgeries, 50% of 
the patients suffer from bypass failure within 10 years10,11.  In the first phase directly 
after surgery, about 10% of all vein grafts fail due to acute thrombosis as a result of 
technical problems and de-endothelialization12. Late failure (> 1 month in humans) is 
the result of intimal hyperplasia (vein graft thickening), accelerated atherosclerosis 
and even rupture of the graft7,13. There is a marked resemblance between lesions 
in vein grafts and native atherosclerosis, although some differences in morphology 
10
are noticeable. For instance, vein grafts show more concentric lesions with small 
necrotic cores, less pronounced shoulders and a higher contribution of smooth 
muscle cells (SMCs) and extracellular matrix (ECM)14.  Especially the start of lesion 
formation deviates. During the vein graft procedure, venous segments undergo 
a period of ischemia followed by reperfusion, resulting in generation of damage 
associated molecular patterns (DAMPs) and reactive oxygen species (ROS) that cause 
cytotoxicity of SMCs. Furthermore, DAMPs, ROS and the physical damage during 
surgery affect the endothelium at the luminal surface. After engraftment the venous 
segment, which has been subjected only to an internal pressure of 10mmHg in the 
venous circulation, is immediately subjected to the arterial pressure (100mmHg) 
as well as to immediate increases in flow, longitudinal and circumferential shear 
stress, resulting in additional damage to SMCs and ECM15,16. Platelets and fibrin are 
deposited on the venous wall. Activated platelets, expressing adhesion molecules 
such as P-selectin and E-selectin on their surface, bind to circulating leukocytes that 
attach and infiltrate the vessel wall. Growth factors are subsequently released from 
platelets, macrophages and SMCs in the vessel wall resulting in proliferation and 
migration of SMC to the intima.  Uncontrolled cellular division of SMCs, extensive 
deposition of ECM and influx of macrophages and foam cell formation together, 
form the growing intimal hyperplasia17 (figure 1). SMC proliferation and migration 
and inflammation are thought to be the major players in vein graft disease16,18-21.
In the next paragraphs various biological processes, factors and immune cell types 
that contribute to vein graft disease are described.
Figure 1. A. Time course of the process of vein graft remodeling. EC, endothelial cell; SMC, 
smooth muscle cell; MMP, matrix metalloproteinase; ECM, extracellular matrix. Adapted 
from Muto et al22. B. Typical examples of human vein grafts. Left panel; vein graft with 





Matrix metalloproteinases (MMPs) are a group of zinc-containing endopeptidases, 
which degrade collagen and other ECM components in the vessel wall23. MMP 
subtypes include collagenases (MMP-1, -8, -13), gelatinases (MMP-2, -9), stromelysins 
(MMP-3, -10), matrilysins (MMP-7, -26) and membrane type MMPs (MT-MMPs, 
MMP-14, -15, -16, and -24). Under physiological conditions, MMP activity is regulated 
at the level of transcription, activation of the precursor zymogens, and interaction 
with specific ECM components. SMCs and other cell types in the (diseased) vessel 
wall such as macrophages and endothelial cells produce MMPs. A large repertoire of 
MMPs is found in remodelled vessels and atherosclerotic plaques24. The proteolytic 
activity of MMPs is regulated by tissue inhibitors of matrix metalloproteinases 
(TIMPs), which are also present in the vessel wall25.  A disturbance of the balance 
between MMPs and TIMPs could cause large increases in MMP activity. This can 
lead to pathological changes in the vessel wall structure associated with vascular 
remodeling as well as plaque instability and rupture. Several excellent reviews have 
provided detailed information on the role of MMPs in vascular disease23,26-28. We as 
well as others have shown previously that MMPs are expressed in vein grafts29-31. 
A general MMP inhibitor, Doxycycline, inhibited vein graft thickening by 35%31. 
Gene silencing of MMP-2 and MMP-9 in cultured saphenous vein SMC resulted 
in a decreased invasion through a Matrigel barrier32. Interestingly, vein grafting in 
mice deficient in MMP-9 did not alter vein graft area compared to control mice 
but did show an increase in collagen content33. MMP-3 overexpression resulted 
in increased vein graft thickening by inhibition of SMC migration34. TIMPs are a 
highly investigated topic in vein graft research. Overexpression of TIMP-1, -2 and 
-3 in various vein graft models resulted in inhibition of MMP activity, reduced SMC 
migration and vein graft thickening35-39.
Coagulation System
The coagulation system is part of the hemostasis system, a network of processes 
that include the platelet system, (anti-)coagulation and fibrinolytic pathways, that 
supports the dynamic equilibrium of blood flow and bleeding arrest after injury40. 
The coagulation system overlaps with the immune system since factors of the 
coagulation system can contribute to the non-specific defenses by their ability to 
increase vascular permeability and act as chemotactic agents for phagocytic cells. 
Plasminogen activation system
The plasminogen activation (PA) system, which controls the formation and activity 
of plasmin, plays a key role in modulating hemostasis, thrombosis, and ECM 
remodeling41. The two members of the serine protease family, uPA and tPA (tissue-
type plasminogen activator), are the main plasminogen activators. These proteases 
convert plasminogen into the active form, plasmin. That in turn degrades fibrin to 
fibrin degradation products. Other substrates for plasmin, involved in vein graft 
remodeling, include ECM components, such as laminin and fibronectin, 
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blood coagulation factors, cell surface receptors, and metalloproteinases. Plasmin 
is inhibited by ɑ2-antiplasmin whereas the activity of the plasminogen activators 
is regulated by plasmin activator inhibitor 1 (PAI-1) and to a lesser extent by PAI-2. 
PAI-1 has been shown to regulate proliferation, migration, and apoptosis of SMC 
and endothelial cells. PAI-1 has the potential to enhance intimal hyperplasia by 
stabilizing intravascular fibrin, which often forms in response to vascular injury and 
which can be invaded by SMCs and other cell types. It is suggested that PAI-1 can 
exert pathogenic or protective effects, which may be related to the disease model 
or injury employed42. Interestingly, vein graft thickening was greatly enhanced 
in PAI-1 deficient mice due to increased thrombin activity43. uPA has been found 
essential in extracellular proteolysis, cell migration and matrix remodeling, whereas 
tPA is mainly involved in fibrinolysis44. This was confirmed by overexpression 
of tPA in vein grafts which resulted in reduction of early vein graft thrombosis45. 
Whereas, overexpression of uPA in rat vein grafts resulted in inhibition of  vein graft 
thickening46. 
Annexin A5
Antithrombotic and anticoagulant effects exerted by Annexin A5 (AnxA5) are 
thought to be mediated by forming a mechanical shield over phospholipids (PLs) 
reducing the availability of PLs for coagulation reactions. However, more specific 
properties of AnxA5 might be of importance for its functioning in vascular 
remodeling. These include upregulation of urokinase-type plasminogen activator 
(uPA) and down regulation of surface-expressed tissue factor (TF). AnxA5 has 
anti-inflammatory properties including shielding of phosphatidylserine expressing 
apoptotic cells and association of AnxA5 with the interferon gamma (IFNγ) receptor 
resulting in prevention of inflammatory cell responses upon IFNγ secretion47. 
Furthermore, AnxA5 binds to ox-LDL, microparticles and endothelial cells48. All 
these are significant factors in cardiovascular diseases, therefore, AnxA5 can be 
considered as an important regulator of vein graft disease. 
Innate immune system 
Innate immunity is a preserved mechanism throughout evolution and is present 
from birth. This first line of defense consists of many factors (cells and mechanisms) 
that defend the host from infection in a nonspecific manner. It comprises physical 
barriers, inflammatory factors such as toll like receptors (TLRs) and chemical factors 
such as the complement system, leukotrienes, and prostaglandins, a variety of 
specialized cells (macrophages, mast cells, NK cells), cytokines and chemokines4,49. 
Phagocytic cells
Phagocytes are white blood cells that are capable of ingesting harmful particles and 
present these after processing to lymphocytes. Phagocytes comprise monocytes, 
macrophages, neutrophils, dendritic cell (DCs). Macrophages represent the vast 
majority of inflammatory cells in atherosclerotic lesions. Monocytes roll, attach 
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and invade the vessel wall where they, driven by macrophage colony stimulating 
factor (M-CSF),  become macrophages. Intimal macrophages can engulf lipid 
particles (e.g. oxLDL) resulting in cellular activation, differentiation and foam cell 
formation. Two types of macrophages can be distinguished; M1 macrophages 
involved in pro-inflammatory processes and M2 macrophages that are involved 
in resolution and repair50. Macrophages produce and release a broad panel of 
cytokines and growth factors thereby influencing cells in their surroundings51-53. 
Dendritic cells are thought to originate from Ly-6lo monocytes and are specialized 
in antigen internalization, processing and presentation to T cells51. DCs are found 
in the intimal hyperplasia and adventitia of vein grafts whereas, native saphenous 
veins are found negative for DCs54. DCs are described to have a pro-inflammatory 
role in atherosclerosis and remodeling. Plasmacytoid DCs (pDCs) are a specialized 
subpopulation of DCs capable of producing large amounts of type I interferons 
(IFNs) upon activation of TLR7 and 955. Furthermore, pDCs are also able to trigger 
regulatory T cells (Tregs) and thereby capable of mediating tolerance to cardiac 
grafts56. Neutrophils are involved in the early onset of lesion formation and 
vascular remodeling by producing a broad array of angiogenic growth factors and 
proteases such as MMP-9. Much of the pro-inflammatory activities of neutrophils 
are instructed by neighboring (inflammatory) cells57. Furthermore, neutrophils are 
important accelerators of intraplaque hemorrhage and plaque rupture58,59.
Mast cells
Mast cells originate from CD34+ progenitors cells in the bone marrow. Mast cells 
are large granular cells that can actively release their granules. These granules 
contain several proteases such as tryptase, chymase and histamine, cytokines (IFNγ, 
tumor necrocis factor (TNF)α, interleukin (IL)2, IL13 and IL15), chemokines (CCL2-
5, CXCL10) and also growth factors (vascular endothelial growth factor (VEGF), 
transforming growth factor (TGF)-β)60. Besides the classical activation route of 
binding of IgE to the high affinity receptor FcεRI, mast cells can be activated via 
neurogenic stimulation61, inflammatory stimuli (TNFα, IL1) and complement factors 
C3a and C5a62.  Mast cells have been linked to the development of atherosclerosis, 
but are more frequently reported to be effector cells of atherosclerotic plaque 
rupture and erosion63-65.  Sub-endothelial mast cells are demonstrated to colocalize 
with sites of atheromatous erosions66 and are known inducers of endothelial cell 
apoptosis67. Several mast cell mediators, such as chymase, TNFα, histamine and 
tryptase, have separately been reported to induce endothelial cell permeability 
and apoptosis68-72, suggesting that mast cells can actively induce plaque erosion. 
Furthermore, mast cells can also induce smooth muscle cell73,74 and macrophage 
apoptosis75 and secrete and activate matrix metalloproteinases76,77, all important 
promoters of plaque instability and rupture.
NK cells
Natural killer (NK) cells are a small subset of lymphocytes, initially described for 
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their “natural” capacity to kill cells. This ability depends on the expression of 
activating and inhibiting NK-cell receptors specific for major histocompatibility 
complex (MHC) class I molecules. NK cells respond upon activation by secretion 
of lytic granules containing perforin and granzymes, but also by secretion of IFNγ, 
TNFα and chemokines such as CCL3, CCL4 and CCL5. Furthermore, NK cells influence 
other immune cells such as T cells, macrophages and DCs directly, by cell to cell 
contact or indirectly via cytokines78.  We have previously shown that depletion of 
NK cells resulted in decreased collateral artery development79. Furthermore, NK cell 
depletion in a model for atherosclerosis showed a decrease in lesion formation80. 
Chemokines and cytokines involved in NK cell function are proven modulators of 
vascular remodeling81. This demonstrates that, although NK cells are available in 
limited amounts, they definitely play a role in vascular remodeling. 
Cytokines and chemokines
Cytokines are a large and diverse family of small cell-signaling protein molecules 
that are classed as interleukins, lymphokines, and chemokines, based on their 
presumed function. The functions of several cytokines in vein graft disease are 
extensively researched82-84. For instance, TGF-β is involved in early and late vein 
graft remodeling85-87. TNFα is also highly regulated in early vein graft remodeling 
although inhibiting strategies failed to abrogate vein graft thickening88. Whereas, 
TNFreceptor-1 (TNFR1, p55) as well as TNFR2 (p75) signaling augments vein graft 
thickening89,90. Blockade of IFNγ in allografted aortas resulted in extensive outward 
remodeling91. 
Chemokines are organized into 2 major (CC- and CXC-motif) and 2 minor families (C- 
and CX3C-motif) based on conserved cysteine residues. Chemokine receptors belong 
to the G-protein-coupled receptor superfamily. Differential expression on cells of 
these receptors leads to selective chemokine function. Chemokines are established 
mediators of vascular diseases as described in detail by Schober81, Koenen et al92 
and Shimizu and Mitchell18. One of the CC chemokines that is extensively studied 
in vein graft disease is monocyte chemotactic protein-1 (MCP-1/CCL2). CCL2 and 
its receptor CCR2 are prominently involved in leukocyte recruitment to the vessel 
wall. We have previously shown that 7ND-MCP-1, a dominant receptor antagonist 
of CCL2, reduced vein graft thickening and monocyte invasion in vein grafts in 
hypercholesterolemic ApoE3*Leiden mice. Furthermore, 7ND-MCP-1 inhibited SMC 
proliferation93. CCR2 receptor silencing, by lentiviral application of a short hairpin 
RNA against CCR2, reduced SMC proliferation and migration in vitro. Application of 
shCCR2 in a pluronic gel around the vein grafts resulted in abrogation of vein graft 
thickening94. Interference in the CCL2/CCR-2 route during vein graft development 
by others resulted in comparable results95,96.  A broad spectrum CC chemokine 
inhibitor 35K, inhibited vein graft thickening and macrophage content in vein grafts 
of ApoE-/- mice. In vitro experiments indicated that m35K-expressing cells no longer 
underwent CC chemokine-induced chemotaxis, and m35K-expressing cells showed 
locally depleted RANTES (CCL5) and MIP-1alpha (CCL3)97,98. In arterial graft disease 
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CCL5 infusion resulted in increased intimal thickening99. The role of the CXCL12 
(stromal cell-derived factor-1 (SDF-1))/CXCR4 axis was investigated in relation to 
homing of bone marrow-derived cells. Vein grafting in CXCR4-/- mice resulted in 
reduced vein graft thickening100. Bone marrow cells expressing the fibroblast-specific 
protein 1 (FSP-1) show homing dependent on platelet-derived SDF-1α expression. 
Knock down of FSP-1 in bone marrow cells prevented vein graft thickening101.
Figure 2. A simplified overview on TLR pathways. TLRs signal via the myeloid differentiation 
factor 88 (MyD88) or  the TIR-domain containing adaptor inducing interferon-β (TRIF) 
pathway.   MyD88 activation occurs upon cell surface signaling (TLR1, TLR2, TLR4, TLR6) 
using MyD88 adaptor-like (MAL) as an adaptor or via endosomal (TLR7, TLR9) signaling via Il1 
receptor-associated kinases, IRAK4, IRAK-M, IRAK1, IRAK2 in interaction with TNF receptor 
associated factor-6 (TRAF-6). This complex activates an inhibitor of κB kinase (IKK) complex 
that upon phosphorylation activates nuclear NFĸB activation resulting in transcription of 
pro-inflammatory cytokines. TRIF signaling occurs via activation of IRF3, specifically upon 
TLR3 activation also IRF7 is ligated, resulting in activation of Type I IFNs. TRIF signaling can 
also induce a late activation of NFĸB as shown by the dotted line.
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Toll like receptors
The TLR family belongs to the pattern recognition receptors (PRRs) and consists 
of at least 13 members that recognize PAMPs and DAMPs. PAMPs are conserved 
molecular patterns of microbial origin. DAMPs are endogenous molecules generated 
upon tissue damage and cell death102,103. These latter include ECM components, 
heat shock proteins and high-mobility group box 1 (HMGB-1) proteins, but also 
nucleic acids such as DNA and RNA that are released upon cell death. There is 
evidence that both DAMPs and PAMPs are present in atherosclerotic lesions104-107. 
Depending on their cellular location, TLRs are divided into two groups. TLR4, TLR2, 
TLR1, TLR6 and TLR11 belong to the first group. This group, primarily exposed 
on cell surfaces, recognizes membrane components. The second group is found 
almost exclusively intracellular and includes TLR3, TLR7 and TLR9 (Figure 2). These 
TLRs have nucleic acids as ligands108. Expression of TLRs in atherosclerotic lesion 
includes almost all TLRs and some of them are already constitutionally expressed 
by the vessel wall109. TLR signaling pathways are classified as myeloid differentiation 
primary response gene 88 (MyD88)-dependent or MyD88-independent, this results 
in either activation of inflammatory cytokines or in activation of type I IFNs110.  TLR2 
and TLR4 are the most extensive investigated TLRs in the field of vascular diseases. 
Both TLRs contribute to lesion formation by augmentation of an MYD88 dependent 
inflammatory phenotype111-117. Interestingly, TLR3 seems to have a protective effect 
on atherosclerosis since in ApoE-/-Tlr3-/- mice aggravated atherosclerotic lesion 
formation was seen118. Furthermore, we have shown recently that blocking TLR7 
and 9 results in reduced post-interventional remodeling119.
Complement system
The complement system is a biochemical cascade that is part of the innate immune 
system that responds very fast upon activation. Complement components can link 
with TLRs, activate the coagulation system and contribute to the adaptive immune 
system120-123. Discovered in 1896 by Bordet as a heat-labile component of serum, 
the complement system consists nowadays of a complex network of at least 30 
plasma and cell-bound proteins. This cascade can elicit an efficient and tightly 
regulated inflammatory response resulting in chemotaxis, cytolysis, opsonization 
and phagocytosis of cells (Figure 3). The complement pathway can be activated 
through three major pathways: classical, lectin and alternative pathway as reviewed 
by Walport et al124,125. The role of the complement system in vascular disease is well 
described126,127. Especially, the anaphylatoxins C3a and C5a and their receptors are 
topic of investigation128,129. Various cell types in the atherosclerotic vessel wall express 
C3a and C5a receptors130. Interestingly, C3a contributes to lipid metabolism131 and 
polymorphisms in complement factors affect vascular disease132,133. Plasma C5a 
levels correlate with adverse outcome in patients with severe atherosclerosis134 
whereas in a phase III trial, with patients undergoing coronary artery bypass graft 




Figure 3. A simplified overview of the complement system. There are three distinct pathways 
of complement activation, all of which converge on the complement component C3 that 
is cleaved to generate C3a and C3b. C3b can act to opsonize material for ingestion by 
phagocytic cells and to enhance clearance of immune complexes. C3b can also form 
part of C5 convertase, which cleaves C5 to generate the chemotactic fragment C5a. 
This cleavage results in assembly of the membrane attack complex (C5b-9), which can 
insert into cell membranes and cause lysis of bacteria and damage to nucleated cells. 
Adaptive immune system 
The adaptive immune system has the ability to recognize and remember specific 
pathogens by generating specialized immunity. T and B lymphocytes are the 
most prominent cell types in adaptive immunity and are activated upon antigen 
presentation by antigen-presenting cells. Depletion of T and B cells significantly 
inhibited atherosclerotic lesion formation136,137. T and B lymphocytes are, therefore, 
thought to promote cardiovascular diseases. However, further research resulted 
in a refinement of this conclusion. Both cell types have specialized subtypes which 
are characterized by their own specific cytokines, immunoglobulins and functions. 
These subtypes exert different effects on vein graft remodeling and atherosclerosis 
as excellently reviewed by Andersson et al138.
Classical pathway Lectin pathway Alternative pathway































Murine model for vein graft disease
Models to study vein graft disease are described in a wide variety of species; 
amongst these are pigs, dogs, rabbits, rats and mice30,34,46. Benefits of mice are the 
relative low costs and more importantly the availability of transgenic animals, which 
gives the opportunity to study gene depletion/insertion or mutations. In contrast 
to larger animal models, the location of the interponate is usually not the same as 
in humans due to the small size of the animals. Also the vein graft surgery itself is, 
therefore, more challenging.  In recent years several mouse vein graft models are 
described. These models vary in the location in which the graft is placed, primarily in 
the carotid artery or the aorta. Furthermore, these models differ in the anastomoses 
procedure, via a cuff, end to end or side to side anastomoses139-141. One of the most 
frequently used models for vein graft disease is the model described by the group 
of Xu142. In this model, the caval vein of a donor mouse is interpositioned in the 
carotid artery of a receiver mouse. First, the caval vein is harvested and preserved 
in a solution with 100 IE of heparin at 4°C. The receiver mouse is than fixed in a 
supine position, and an incision is made in the neck. The right parotis gland is freed 
from its surrounding and put aside. The right carotid artery becomes visible and 
is dissected free from the surrounding fat and tissues from the bifurcation down 
to the thorax. Next, the carotid artery is ligated with two 8/0 silk sutures and cut 
midway. On both the proximal and distal artery end a nylon cuff is sleeved which 
is fixated on the cuff-handles with hemostatic clamps. After dissecting the ligature 
from the distal artery end, the artery is everted over the cuff and the artery is 
tightened with an 8/0 suture. This procedure is repeated on the proximal artery 
end. The caval vein is positioned over both the cuffs and fixed with ligatures. First 
the distal clamp is removed to check for back flow and then the proximal hemostatic 
clamp is released. Pulsatile flow through the venous conduit confirms a successful 
procedure. Finally, the parotis gland is put back in position after which the skin is 
sutured with a 6/0 running suture. 
Within 28 days after the surgery, a vein graft develops from a few cell layers at 
the start of the engraftment up to a massive thickened vessel wall. After surgery, 
the endothelial cell lining of the graft is severely damaged due to handling and 
dilatation. This layer renews to an almost intact endothelium within the 28 days. 
With the use of TIE2-LACZ overexpressing mice, the group of Xu showed that this new 
endothelial lining originates solely from the recipient, probably most cells originate 
from adventitial progenitor cells, whereas one-third are derived from bone marrow 
progenitor cells143. Furthermore, in this model about 40% of SMCs originates from 
recipients and 60% from donor vessels144. Also, inflammatory cells and factors 
contribute to the process of vein graft thickening as we have shown previously21. 
When this procedure is performed in mice that are prone to atherosclerosis (LDLR-
/-, ApoE-/-  or ApoE3*Leiden) a vein graft with accelerated atherosclerotic lesions 




Figure 4. A. Micro-CT scan of a vein graft in situ, 28 days after vein graft surgery in 
a hypercholesterolemic Apoe3*Leiden mouse. Massive outward remodeling of the 
vein graft can be observed especially when compared to the right carotid artery. B. 
High magnification inset of vein graft in situ C. Cross section of a native un-injured 
caval vein. D. Cross section of a remodeled vein graft 28 days after vein graft surgery.
Thesis aim
The aim of this thesis is to investigate the role of several “endogenous” factors, 
primarily related to the innate immune system, in a murine model of vein graft 
disease. The focus of this thesis is to identify and unravel the working mechanisms 
of potential targets that inhibit vein graft thickening and remodeling, for future 
therapeutic intervention. Moreover, the vein graft model in the ApoE3*Leiden 
mouse is further exploited as a model for plaque instability, plaque angiogenesis 
and plaque rupture. 
Thesis outline 
In chapters 2 and 3 the effects of MMP inhibition were studied. MMPs are key 
regulators of the extracellular matrix and are, therefore, key regulators of vein graft 
remodeling. The effects of overexpression via plasmid electroporation of the MMP 
inhibitors TIMP-1 and TIMP-3 on vein graft remodeling in hypercholesterolemic 
ApoE3*Leiden mice were investigated in chapter 2.  Particularly, the effect on plaque 
instability and plaque rupture complications in the vein grafts were studied by 
pathological and morphological investigations of the vein graft lesion composition. 
The effect of overexpression (via plasmid electroporation) of the hybrid protein 
TIMP-1.ATF (consisting of TIMP-1 and the receptor-binding amino terminal fragment 
(ATF) of urokinase) on vein graft thickening and vein graft composition in
20
hypercholesterolemic ApoE3*Leiden mice was studied in chapter 3. This TIMP-1.
ATF hybrid protein achieves MMP inhibition at the cell surface by binding of TIMP-
1 to the u-PA receptor. Thereby, hampering the binding of endogenous u-PA to its 
receptor resulting in a combined inhibition of the plasminogen activator system 
and MMP system. In chapter 4, we evaluate the effects of huAnxA5 application 
on vascular function, vascular remodeling after cuff placement and vein grafting 
besides, local vascular and systemic inflammation. Several aspects of plaque 
neovascularization such as plaque angiogenesis, vascular integrity, and vessel 
stabilization were studied in the context of vein graft thickening and intraplaque 
hemorrhage in chapter 5. This was performed by evaluating the effects of systemic 
distribution of VEGF receptor 2 blocking antibodies to unstable vein grafts in 
hypercholesterolemic ApoE3*Leiden mice. The innate immune system component, 
the NK cell and specifically, the role of the C57BL/6 NK gene complex are studied 
in chapter 6. Besides NK cell depletion strategies, we studied the effects of cuff 
placement and vein grafting in C57BL/6, BALB/c mice and CMV1r mice. The latter 
mice have a BALB/c background but contain the C57BL/6 NKC region. The role 
of TLRs in vein graft remodeling is studied in chapter 7 and 8. The presence of 
endogenous ligands for TLRs and especially TLR4 were demonstrated in vein graft 
tissues in chapter 7. Furthermore, in this study a significant role for TLR4 in vein 
graft remodeling was demonstrated with the use of TLR4 deficient mice and local 
TLR4 gene silencing techniques in hypercholesterolemic ApoE3*Leiden mice. The 
focus of chapter 8 lies on the role of the TLR3 pathway and the myD88 independent, 
TRIF pathway, including the transcription factors, interferon regulating factors, 
IRF3 and IRF7 in vein graft remodeling. By using transgenic mice that were knock 
out for the factors TLR2, TLR3, TLR4, IRF3 and IRF7 the involvement of the MyD88 
(in)dependent  pathways and downstream genes, with special focus on the type 
I interferons and type I interferon responsive genes, were studied. In chapters 9, 
10 and 11 we explore the role of various components of the complement cascade 
on vein graft development and remodeling. In chapter 9, we show analyses of the 
effects of C1-esterase inhibitor (C1inh) on early vein graft remodeling. Application 
of C1inh in an in vitro (human) saphenous vein perfusion model was studied besides 
administration of purified C1inh in the vein graft model in hypercholesterolemic 
ApoE3*Leiden mice. In chapter 10, we demonstrate the presence of various 
complement factors and complement regulatory proteins in vein graft lesions. 
Involvement of the central complement component C3,in vein graft development, 
was studied by systemic administration of C3 inhibitors Cobra Venom Factor and 
Crry Ig in hypercholesterolemic ApoE3*Leiden mice. Chapter 11 focuses on the role 
of C5a in relation to mast cells in vein graft disease. For this, we used inhibiting 
and overexpressing techniques to show the involvement of either C5 or mast cells, 
individually. Furthermore, a combined strategy of topical application of C5a in 
combination with systemic inhibition of mast cells by cromolyn was studied. Finally, 
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Abstract  
Objective  The current study describes the incidence and phenotype of plaque 
rupture complications in murine vein grafts. Since matrix metalloproteinases 
(MMPs) are highly involved in atherosclerotic plaque vulnerability and plaque 
rupture, we hypothesized that this model can be validated by overexpression of the 
MMP inhibitor TIMP-1.
Material and methods  First we studied 47 vein grafts in hypercholesterolemic 
ApoE3*Leiden mice for the incidence of plaque complications. In 79% of these grafts, 
extensive lesions with plaque rupture complications like dissections, intraplaque 
hemorrhages or erosions with intramural thrombi were found. Next, in vivo Near-
InfraRed-Fluorescence imaging demonstrated that electroporation mediated TIMP-
1-overexpression reduced local MMP activity in vein grafts by 73% (p<0.01). This 
led to a 40% reduction in lesion-size after 28d (p=0.01) and a more stable lesion 
phenotype with significant more smooth muscle cells (135%), collagen (47%) and 
significant less macrophages (44%) and fibrin (55%) than controls. More importantly, 
lesions in the TIMP-1 group showed a 90% reduction of plaque complications (10/18 
of control mice showed plaque complications versus 1/18 in TIMP-1 treated mice).
Conclusions  Murine vein grafts are a relevant spontaneous model to study plaque 
stability and subsequent hemorrhagic complications, resulting in plaque instability. 
Moreover, inhibition of MMPs by TIMP-1-overexpression resulted in decreased 
plaque progression, increased stabilization and decreased plaque rupture 
complications in murine vein grafts.
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Introduction
Atherosclerosis and subsequent plaque complications are still a major cause of 
morbidity. In acute coronary syndrome, plaque rupture accounts for 75% of the 
deaths and plaque erosion causes the residual 25%1. Numerous factors such as 
endothelial activation, inflammation, cholesterol influx, necrotic core expansion, 
and cell death contribute to plaque instability and plaque rupture2. Furthermore, 
intraplaque angiogenesis contributes to plaque growth and unstable plaques by 
enhancing leukocyte recruitment and accumulation of cholesterol and platelets in 
the plaque3,4.
Essential in plaque instability are matrix metalloproteinases (MMPs), a group of 
zinc-containing endopeptidases, which degrade collagen and other extracellular 
matrix (ECM) components in the vessel wall5. A large repertoire of MMPs is found 
in atherosclerotic plaques6. The proteolytic activity of MMPs is regulated by tissue 
inhibitors of matrix metalloproteinases (TIMPs) which are also present in the vessel 
wall7. Due to the broad activity of MMPs in plaque development, interference in 
their regulation is an attractive strategy to decrease plaque formation and increase 
stability. 
Although several atherosclerotic mouse models display features of intraplaque 
haemorrhage8,9 there is still need for mouse models of spontaneous 
atherothrombosis, the major cause of clinical manifestations. In the present study 
we use the model of vein graft interpositioning10-12 as a model to study plaque 
instability and subsequent plaque complications. 
Clinically, vein grafts are used to bypass an obstructed artery due to atherosclerosis. 
However, up to 40% of the vein grafts need revision within 18 months due to 
thrombosis, intimal hyperplasia and accelerated atherosclerosis13,14.  In murine 
vein grafts atherosclerotic lesions show features of unstable plaque phenotypes as 
observed in patients. Recently, we demonstrated that MMPs are highly expressed 
in these lesions15.  The present study describes a detailed characterization of 
plaque instability and plaque rupture complications observed in vein graft lesions in 
hypercholesterolemic ApoE3*Leiden mice. Subsequently the model was validated 
by studying the effect of systemic TIMP-1 overexpression on lesion progression and 
plaque rupture complications in this model.
Methods
Ethics Statement
This study was performed in compliance with Dutch government guidelines and all 
animal experiments were approved by the animal welfare committee of the Leiden 




Male ApoE3*Leiden mice (bred in our own colony), 10-16 weeks old, were fed a 
hypercholsterolemic diet (ABdiets, Woerden, The Netherlands) from 3 weeks prior 
to surgery until sacrifice. This resulted in plasma cholesterol levels between 12 
and 24 mmol/l ((Roche Diagnostics, kit 1489437, Almere, The Netherlands). Before 
electroporation and surgery, mice were anesthetized with midazolam (5 mg/kg, 
Roche Diagnostics), medetomidine (0.5 mg/kg, Orion, Espoo, Finland) and fentanyl 
(0.05 mg/kg, Janssen Pharmaceutica, Diegum, Belgium). After the procedures the 
mice were antagonized with atipamezol (2.5 mg/kg, Orion) and fluminasenil (0.5 
mg/kg Fresenius Kabi, Schelle, Belgium). Buprenorphine (0.1 mg/kg, MSD Animal 
Health, Boxmeer The Netherlands) was given after surgeries to relieve pain.
Luciferase and TIMP overexpression  
Overexpression of the TIMPs was achieved by electroporation after intramuscular 
injection of a pCDNA3.1 plasmid encoding for human TIMP-1 or TIMP-316  and 
Luciferase as a control, one day before surgery.  The plasmid DNA preparation and 
procedure of electroporation was performed as described previously15.
Vein graft model 
Vein graft surgery was performed by donor caval vein interpositioning in the 
carotid artery of recipient mice as described before17. In brief, thoracal caval veins 
from donor littermates were harvested. In recipients, the right carotid artery was 
dissected and cut in the middle. The artery was everted around the cuffs that were 
placed at both ends of the artery and ligated with 8.0 sutures. The caval vein was 
sleeved over the two cuffs, and ligated. Animals were sacrificed after 28 days, after 
3 minutes of in vivo perfusion-fixation, vein grafts were harvested and fixed in 4% 
formaldehyde, dehydrated and paraffin-embedded for histology18,19.
Histological and immunohistochemical assessment of vein grafts
Paraffin embedded cross sections were stained with hematoxylin-phloxine-
saffron (HPS), Masson’s Trichrome stain and Picrosirius red (collagen). Antibodies 
against CD31 (endothelial cells) and MAC3 (macrophages) were purchased from 
Pharmingen (Heidelberg, Germany). Anti-SMC Actin (Sigma-Aldrich, St. Louis, MO, 
USA) was used to detect SMCs and pericytes. TER119 (erythrocytes) and anti-VEGF 
were purchased from Santa Cruz (CA, USA). Furthermore, Anti-laminin (Abcam, 
Cambridge, UK) and anti-fibrin (Quickzyme, Leiden, The Netherlands) were used. 
For each antibody, isotype-matched antibodies were used as negative controls and 
positive staining was absent in these sections (data not shown).
Morphologic analyses of vein graft rupture complications
Vein graft rupture complications were scored in 47 mice. Lesions where erythrocytes 
were found adjacent to neovessels were regarded as lesions with plaque hemorrhage 
(hem).  A dissection (diss) was defined as a connection between the lumen and the 
32
part of the vessel wall underneath the adventitia filled with fibrin and erythrocytes. 
In case fibrin was found at the luminal side underneath a denudated endothelial 
layer, coinciding with erythrocytes and neutrophils, we defined this structure as 
erosion with intramural thrombosis (er). 
Morphometric analysis of vein grafts
Morphometric analysis of vein grafts harvested after 28d was performed using 
image analysis software (Qwin, Leica, Wetzlar, Germany). For each mouse six 
equally spaced (150 µm apart) cross-sections were used to determine lesion size 
and occurrence of plaque complications over a total vein graft length of 750 µm. 
Since elastic laminae do not exist in these grafts of venous origin, we analysed the 
putative vessel wall area (or lesion area) by measuring total vessel area (the area of 
the vessel wall within the adventitia and the lumen area. Next the lesion area was 
calculated (total vessel area – lumen area).  (Immuno)histochemical staining  was 
quantified by computer assisted analysis (Qwin, Leica). For this immuno-positive 
areas in vein grafts were expressed as percentage of the lesion area. 
In vivo NIRF imaging
 For Near-InfraRed-Fluorescence (NIRF) imaging experiments, MMPSense 680 (VisEN 
Medical) was used. Endogenous MMP-2,-7,-9,-12 and -13 can activate MMPSense in 
vivo, resulting in a fluorescent signal. Four nmol MMPSense was injected i.v. 20h 
before imaging (n=5 mice/group). Images were acquired 28 days after surgery using 
a Pearl Imager (LI-COR Biosciences) and analysed using manufacturer’s software. 
Regions of interest (ROIs) of the vein areas were selected from equivalent-sized 
areas. ROIs were quantified for mean pixel values as shown previously20.
Statistical Analysis
All data are presented as mean ± SEM. Statistical analysis was performed using 
SPSS 17.0 for Windows. To determine statistical significance overall comparisons 
were made using the non-parametric Kruskal-Wallis test. In case of significance, 
each group was separately compared to the control group using the Mann-Whitney 
test. Probability-values <0.05 were regarded significant.
Results 
Vein graft lesion morphology 
The vein graft wall of hypercholesterolemic ApoE3*Leiden mice increases from a few 
cell layers at start of engraftment to a massive thickened vessel wall 28 days post-
surgery. In vein grafts the lumen often was found eccentric, (figure 1A) probably due 
to flow differences in the curvature of the graft21. Surgical handling and dilatation 
of the vein graft result in de-endothelialisation.  Vein grafts are repopulated to an 
almost intact endothelium (black arrows figure 1B and supplemental Figure 1A 
(CD31 staining)) within 28 days. The vein graft lesion consists of a dense network of
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ECM and smooth muscle cells (SMC). Circular orientated SMC were frequently seen 
close to the lumen suggesting a cap-like organization (white arrows, figure 1B and 
supplemental Figure 1B (SMC actin staining). Accumulations of lipid-laden foam 
Figure 1. A. Cross-section stained with a Masson trichrome staining of a vein graft in an 
ApoE3*Leiden mouse 28 days after surgery. Coloured squares depict location of photographs 
B-G. L represents lumen and A; adventitia B. Part of the lesion showing foamcells (white 
arrows) and SMC’s, with a smooth muscle cell rich cap underneath an intact endothelial 
layer (black arrows; endothelial cells) C. Foamcell rich area including the start of a dissection. 
D. A small necrotic core with cholesterol clefts and foam cells can be seen with a SMC rich 
layer and endothelial cells on top. E. Calcification rich area (arrows) near the outer layer of 
the vessel wall. F. Area with extravasated erythrocytes (arrows) and neovascularization (#). 
G. Detailed photograph of dissection and extravasated erythrocytes 150 μm upstream in the 
lesion (arrows; erythrocytes stuck in the dissection). 
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cells were primarily found underneath the cap (supplemental Figure 1C (MAC-
3 staining). Interestingly, plaque rupture complication in the form of a dissection 
from the lumen to the outer lesion was seen frequently in these vein grafts (Figure 
1C and G). Foci of macrophages, foam cells, small necrotic cores and cholesterol 
crystals were found throughout the whole vessel wall, but most often near the 
luminal side (figure 1D). Amorphous calcifications were mostly found in the medial 
part and outer vessel wall area of the graft (figure 1E and supplemental Figure 1D 
(Von Kossa staining). In addition, cartilage, calcified cartilage and (ectopic) bone 
formation were found in these lesions, as shown previously17. In addition to the 
plaque rupture complications, unique for this mouse model is, that neovessels were 
found throughout the vein graft wall. Neovessel showed a preference for the medial 
and outer part. The newly formed vessels were often leaky as erythrocytes were 
found adjacent to these neovessels (Figure 1F). The outer side of the graft include 
the adventitia and connective tissue, consisting of fibroblasts, ECM and neovessels, 
as depicted in figure 1G. 
Vein graft plaque neovasculature
To focus more specifically at the neovessels in the vein grafts specific 
immunohistochemical stainings were performed. Neovessels in the vein graft 
wall are most likely formed through angiogenesis and consist of CD31 positive 
endothelial cells (figure 2A). In a substantial number of vein grafts, a considerable 
amount of erythrocytes could be found in the ECM, adjacent to the neovessels 
(figure 2B and supplemental Figure 2) suggesting leakiness. Expression of Vascular 
Endothelial Growth Factor (VEGF) was analysed. VEGF not only induces angiogenesis 
and endothelial cell proliferation but can also increase vascular permeability22. 
VEGF (figure 2C) then not only was found adjacent to the neovessels but also seems 
to co-localize with macrophages and SMC, both known VEGF producers.  As leaky 
vessels can be the result of abnormal maturation of neovessels23, we subsequently 
stained for laminin, a marker for basement membranes and with anti–SMC-
actin, to detect pericytes and SMCs surrounding the neovessels, both essential 
components for proper maturation. Almost all most neovessels had intact basement 
membranes (figure 2D). In contrast, not all neovessels showed efficient pericyte 
coverage, especially neovessels in regions of erythrocyte extravasation (figure 2E).
Frequency and appearance of plaque rupture complications
In murine vein grafts, plaque rupture complications were frequently found, which 
were subsequently quantified. In 79% of these mice plaque complications were 
observed. 16 out of 47 (34%) vein grafts showed lesions with dissections (Figure 3A). 
Another 34% showed extravasations of erythrocytes within the lesion (Figure 3B). 
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Figure 2. A. Endothelial cell staining (CD31) of neovessels in a vein graft lesion. B. Erythrocytes 
are clearly visible in (*) and outside neovessels indicating that leaky vessels are present. C. 
VEGF staining of a vein graft with extravasated erythrocytes (*), a VEGF positive neovessel 
is depicted with #. D. Basement membrane staining with antibodies directed to laminin. 
Most neovessels in vein grafts stain positive. E. SMC staining of a vein graft. # marks SMC 
positive neovessels and * depicts neovessels lacking pericytes. These neovessels without 
pericytes are frequently found in regions with extravasated erythrocytes. Insets are 10x 
magnifications of vein grafts.
Finally 30% of the vein grafts showed erosion with intramural thrombosis. Occlusive 
luminal thrombi were rarely found instead intramural thrombi with dispersed 
erythrocytes and neutrophils were found (Figure 3C). Strikingly, in some of these 
vein grafts combinations of plaque hemorrhage and dissection (11%, Figure 3D) or 
plaque hemorrhage and erosion (9%, Figure 3E) were found. This demonstrates 
that in these vein grafts complex unstable atherosclerotic lesions were induced.
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Figure 3. A. Vein graft with a dissection (arrow) from the lumen of the vessel wall with small 
fibrin depositions (*) and erythrocytes (#) in the clearly visible gap. B. Vein graft  lesion with 
leaky vessels and extravasated erythrocytes (#) C. Vein graft showing massive intramural 
thrombi consisting of layers of fibrin (*) and diffuse erythrocytes (#) with erosion extending 
to the outer part of the vessel wall. D. Vein graft showing combined leaky vessels with 
extravasated erythrocytes (#) and dissection in the outer part of the vessel wall (black 
arrow). E. Vein graft lesion with leaky vessels showing extravasation of erythrocytes (#) and 
erosion with small mural thrombi (*). 
Lesion size of vein grafts and plaque rupture complications
To study whether a correlation exists between the degree of vein graft lesion size 
and the occurrence of plaque rupture complications, lesion area was quantified in 
vein grafts without complications (ctr), mice displaying dissections (diss), erosion 
with intramural thrombosis (er) or plaque hemorrhage (hem) (n=10/group). Mice 
with plaque hemorrhage or dissections showed, compared to control mice, a 2-fold 
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increase in lesion area (ctr; 0.474±0.052mm² vs. hem; 1.027±0.173mm² p=0.004 
vs. diss; 0.934±0.155mm² p=0.005, figure 4A) whereas mice with erosion showed 
a 3-fold increase (1.423±0.336mm² p=0.045). In contrast, luminal area was 
significantly decreased in vein grafts with plaque hemorrhage and erosion (ctr; 
0.516±0.044mm² vs. hem; 0.377±0.043mm² p=0.033 vs. er; 0.313±0.086mm² 
p=0.021). The luminal area in vein grafts with dissections was also decreased 
compared with controls, although this did not reach significance (0.386±0.042mm² 
p=0.064), figure 4B. Total vessel area (luminal area and lesion area combined), as a 
measure for remodeling, was only significantly different in the group with plaque 
hemorrhage (ctr; 0.990±0.062mm² vs. hem; 1.404±0.153mm² p=0.028 vs. diss; 
1.321±0.148mm² p=0.111 vs. er; 1.736±0.326mm² p=0.064) as shown in figure 4C. 
Finally, it was analysed whether a correlation existed between the length of the 
vein graft segment that displayed plaque rupture complication and the lesion area 
and indeed a weak positive correlation was found (R2: 0.207).
Figure 4. Quantification of vein grafts without complications (Control), and vein grafts with 
complications, namely plaque hemorrhage, dissections or erosions (n=10/group). A. Vessel 
wall area measurements B. Quantification of lumen area C. Total vessel area (combined 
lumen and vessel wall area, as a measure for outward remodeling) D. Correlation between 
the vessel wall area and the length of the complications.
TIMP-1 overexpression results in decreased MMP activity in vein grafts in vivo
Since MMPs play a major role in atherosclerosis, the effects on MMP activity in the 
vein graft in vivo were analysed using NIRF imaging technique. To prove a causal role 
of MMP activity in vein graft lesions, TIMP-1 was overexpressed in mice receiving a 
venous graft. As depicted in figure 5A, MMP activity was detected in the neck
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region of Luciferase overexpressing control mice, thus the area of the vein graft. In 
the TIMP-1 treated group (TIMP-1) a significant reduction of 73% in MMP activity 
was found (616±205AU vs. 2272±932AU; p=0.009, figure 5B) compared to the 
Luciferase group (Luc).
Figure 5. A. Representative Near-InfraRed-Fluorescence images of enzymatic MMP activity 
in mice. No signal was detected in mice without MMPSense. B. Quantification of the MMP 
activity in the vein graft region (n=5/group). 
Morphological analysis of vein grafts after TIMP overexpression 
TIMP-1 overexpression resulted in a decrease in total vessel area of 36% (Luc 
1.42±0.25mm2 vs. TIMP-1 0.90±0.08 mm2 p=0.003), a decrease in lumen area 
of 30% (Luc 0.66±0.08mm2 vs. TIMP-1 0.46±0.04mm2 p=0.005) and a profound 
decrease in lesion area of 40% (Luc 0.75±0.17 mm2 vs. TIMP-1 0.45±0.05mm2 
p=0.010) compared to the Luciferase control group (figure 6A&B) 28 days post-
surgery. Next, we analysed the occurrence of plaque rupture complications. In the 
Luciferase group 10 out of 18 mice showed plaque complications of all three forms. 
Strikingly only 1 of the 18 TIMP-1 group showed a plaque rupture complication, 
namely plaque hemorrhage, which is significantly different compared with the 
Luciferase group (p=0.001). 
To determine whether the observed difference in frequency of plaque rupture
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complications correlates specifically with TIMP-1 expression, or is a result of 
a decrease in lesion area, a comparable experiment was performed using an 
alternative way to reduce MMP activity, by TIMP-3 overexpression. TIMP-3 is a 
MMP inhibitor that has a slightly different substrate specificity than TIMP-1, but 
with similar potency to block MMP activity7. In these TIMP-3 overexpressing mice 
(n=17) a reduction in lesion area of 33% compared to control mice was found 
(p=0.035), with no significant difference between the TIMP-1 and TIMP-3 group 
(p=0.790). When compared to the control group no differences in total vessel 
area (1.42±0.25mm2 vs.1.22±0.09mm2 p=0.266) and lumen area (0.66±0.08mm2 
vs. 0.67±0.05mm2 p=1.000) were found (figure 6B). Subsequently, plaque rupture 
complication events were analysed. In the TIMP-3 group 6 out of 17 mice showed 
plaque rupture complications. This was not significantly different compared to 
the control group (p=0.238) whereas it was significantly increased compared to 
the TIMP-1 group (p=0.030). Moreover, the length of the segments displaying 
complications in the TIMP-1 group clearly was smaller than the length of the 
segments with rupture complications detected in the controls (p=0.002) and TIMP-
3 group (p=0.045). Albeit no differences were found between control and TIMP-3 
group (p=0.071) (Figure 6C). 
Next the effects on vein graft lesion composition were assessed. TIMP-1 
overexpression resulted in a significant enhancement of stability improving factors: 
increased collagen content (TIMP-1: 34.6±2.5% vs. Control: 18.5±2.1% vs. TIMP-3: 
17.4±2.5% p=0.007, figure 6D) and smooth muscle cells presence, figure 6E (SMC 
positive area of the lesion: TIMP-1: 38.6±2.4% vs. Control: 26.2±3.3% vs. TIMP-
3: 28.6±2.5% p=0.003). Moreover, TIMP-1-overexpression resulted in a major 
decrease in factors known for their contribution to plaque destabilization, namely 
macrophages, figure 6F (MAC-3 positive area of the lesion: TIMP-1: 6.7±1.4% vs. 
Control: 11.9±1.7% vs. TIMP-3: 15.5±3.5% p=0.03) and fibrin, figure 6G (Fibrin 
positive area: TIMP-1: 9.9±1.7% vs. Control: 22.2±2.7% vs. TIMP-3: 18.8±2.3% 
p=0.01). No significant differences in plaque stabilizing and destabilizing factors 
were seen between control and TIMP-3 overexpressing mice. 
Discussion 
Vein grafts in hypercholesterolemic ApoE3*Leiden mice show complex lesions 
which resemble, to a large extent, native (human) atherosclerotic plaques. 
Although the accelerated formation of atherosclerotic lesion in this vein graft model 
in hypercholesterolemic ApoE3*Leiden mice is first described in 200212, detailed 
analysis of the histology of the lesion now for the first time reveals several features 
that mimic important aspects of plaque instability and rupture, including intraplaque 
hemorrhage and angiogenesis. These novel aspects of the atherosclerotic vein 
graft lesions make this model an interesting model for studying crucial aspects of 
plaque instability, intraplaque hemorrhage and plaque rupture. Plaque rupture 
complications such as dissection, erosion with intramural thrombosis and leaky
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Figure 6. A. Representative cross-sections of vein grafts in mice overexpressing Luciferase, 
TIMP-1 or TIMP-3, 28 days after surgery (Hematoxilin-Phloxine-Saffron staining).B. 
Quantitative measurements  of total vessel area, luminal area and lesion area. C. Graph 
showing the length of the complications. D. Quantitative measurement of percentage 
collagen in vein grafts in Luciferase, TIMP-1 or TIMP-3 overexpressing mice. E. Quantitative 
measurement of percentage SMC actin from the three groups; In figure 6 F and G quantitative 
measurements for resp. macrophages and fibrin are shown. H-K. For all (immuno)
histochemical stainings, a typical example is given.
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vessels (as depicted in Figures 1 and 3) as well as intraplaque neovascularization 
(Figure 2) shown here, are rarely seen in other murine atherosclerotic models. One 
of the rare models for spontaneous plaque rupture and intraplaque hemorrhage in 
the mouse is the rupture of lesion described to occur in the brachiocephalic artery 
of ApoE deficient mice9,24. In this brachiocephalic artery after 48-54 weeks lesions 
develop that show features of intraplaque  hemorrhage, and in mice fed an pro-
atherogenic diet even plaque rupture can be observed9. However, it takes up to 
14 months to develop these lesions. Moreover, the qualification of these lesions 
as being ruptured plaques is strongly debated24, since the observed intraplaque 
hemorrhage seems to be less complex, lacking clear atherothrombotic events24. 
The fact that in the vein graft model the lesions may form within four weeks, with 
a range of plaque destabilisation features occurring, underscores the advantages 
of the model for studying several aspects of plaque destabilization. Importantly, in 
79% of these vein grafts, features of intraplaque hemorrhage and plaque rupture 
occur spontaneously. Even combined plaque complications were found, illustrating 
the complexity of these lesions. Validation of the plaque rupture model by 
overexpressing TIMP-1 showed that plaque instability could be modulated towards 
a more stable plaque phenotype with less plaque rupture complications.
Although plaque rupture was clearly present, occlusive luminal thrombi, the major 
cause of vascular clinical deaths, were rarely seen in this vein graft model. This can 
be in part caused by the faster coagulation of thrombi in mice due to higher activity 
of endogenous coagulation inhibitors compared to humans25 since mice have lower 
levels of thrombin-activated fibrinolysis inhibitor (TAFI) and plasminogen activator 
inhibitor-1 (PAI-1)26, 27.
A weak positive correlation (R2=0.207) was found between lesion area and the 
percentage of plaque complications. This suggests that plaque complications 
are likely not only the result of increasing plaque size. In this respect, the plaque 
phenotype is probably more important. This is also seen in human lesion where 
most rupture-prone plaques are unstable but not per se stenotic1. Plaque rupture, 
defined as a disruption of a (thin) fibrous cap over a lipid core with direct contact of 
the lipid core with the blood in the lumen resulting in a occlusive luminal thrombosis, 
was not observed in the vein graft model28. This can be attributed by the fact that 
vein graft plaques consist of heterogeneous distribution of SMC, foamcells and 
small necrotic cores17,29 compared to the large necrotic core with an overlying cap 
which are prominent in human atherosclerosis. Although no plaque rupture in the 
classical definition as such was observed, dissections were frequently found in the 
vein graft lesions. Denudation of the endothelium resulted in thrombosis into the 
vessel wall with profound areas of fibrin and erythrocytes. As these thrombi mostly 
intruded a large part of the vessel wall, this resulted in an enormous increase in vessel 
wall area. Inflammatory cells were scarce in these lesions except for neutrophils, 
which is comparable to what Farb et al. found in human plaque erosion30. Another 
interesting finding in this study was the occurrence of neovessels that in majority 
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displayed a non-mature phenotype. Besides a decrease in lumen area and outward 
remodeling of the vein graft, lesions with leaky vessels also displayed enhanced 
vessel wall thickening and infiltration of inflammatory cells around the neovessels. 
This concurs with previous studies on the role of leaky vessels in human plaque 
stability3,23.
MMPs play an important role in the atherosclerotic plaque development, but more 
importantly, in the regulation of plaque instability as demonstrated by knockdown 
or overexpression studies in mice31-37. Moreover, Rouis et al. demonstrated that 
adenoviral overexpression of TIMP-1 resulted in a decrease in atherosclerotic 
lesion area and more stable lesions in ApoE deficient mice38. Johnson et al showed 
no effect of adenoviral TIMP-1 overexpression on brachiocephalic artery plaque 
size, but suggested a change towards a more stable plaque phenotype due to an 
increase in elastin content in the plaque39. 
We have previously demonstrated expression of MMPs in mouse vein grafts 
in vivo15,40.  Furthermore, we and others have demonstrated that TIMP-1 
overexpression can inhibit vein graft thickening15.  Here we studied the effects of 
TIMP-1 on plaque stability and plaque rupture. TIMP-1 overexpression resulted in 
a significant reduction of in vivo MMP-activity of 73% indicating activity of one or 
a combination of the MMPs -2,-7,-9,-12 or -13 in the vein graft. More importantly, 
overexpression of TIMP-1 resulted in reduced vein graft lesion size, reduced 
macrophage and fibrin content, increased collagen and smooth muscle cell content 
and ultimately resulted in a 90% reduction in plaque rupture complications. Also 
the severity of the complications, as scored by the length of the complications, was 
significant lower in the TIMP-1 treated group.  Although overexpression of TIMP-3 
also resulted in a significant decrease in lesion area, it had in contrast to TIMP-1 no 
significant effect on plaque phenotype. TIMP-1 differs from TIMP–3 by being a poor 
inhibitor of the membrane type MMPs (MT-MMPs). Although MT-MMP1 is known 
to be involved in the breakdown of collagen and activation of pro-MMP-2 and -1341, 
inhibition of the other MMPs by TIMP-1 is apparently more important to favour a 
stable phenotype after overexpression.
In conclusion, this study shows that vein grafts in ApoE3*Leiden mice generate 
lesions with spontaneous rupture complications that can be used as a unique 
animal model to study mechanisms of atherothrombotic lesions. Intriguingly, TIMP-
1 overexpression, but not TIMP-3, resulted in a more stable phenotype and most 
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Histological and immunohistochemical assessment of vein grafts
Cross sections of vein grafts were routinely stained with hematoxylin-phloxine-
saffron (HPS) and Masson’s Trichrome stain. For detection of calcifications, a von 
Kossa staining was used, as described previously1. Antibodies against CD31 and 
MAC3 (BD-Pharmingen) were used to detect endothelial cells and macrophages, 
respectively. Anti-SMC Actin (1A4, Sigma) was used to detect smooth muscle cells 
and TER119 (Santa Cruz) for erythrocytes. For each antibody, isotype-matched 
antibodies were used as negative controls and positive staining was absent in these 




The vein graft wall of hypercholesterolemic ApoE3*Leiden mice increases from 
a few cell layers at start of engraftment to a massive thickened vessel wall 28 
days post-surgery. Surgical handling and dilatation of the vein graft result in de-
endothelialisation.  Vein grafts are repopulated to an almost intact endothelium 
(supplemental Figure S1A (CD31 staining)) within 28 days. The vein graft lesion 
consists of a dense network of ECM and smooth muscle cells (SMC). Circular 
orientated SMC were frequently seen close to the lumen suggesting a cap-like 
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organization (supplemental Figure S1B (SMC actin staining)). Accumulations of lipid-
laden foam cells were found primarily underneath the cap (supplemental Figure 
S1C (MAC-3 staining)). Amorphous calcifications were mostly found in the medial 
part and outer vessel wall area of the graft, as shown in supplemental Figure S1D 
(Von Kossa staining). In addition, cartilage, calcified cartilage and (ectopic) bone 
formation were found in these lesions, as shown previously1. The lesions in the 
vein grafts also contain neovessels (supplemental Figure S2A) which are filled 
with erythrocytes (supplemental Figure S2B). Some of these neovessels are leaky 
since erythrocytes can be demonstrated outside these neovessels, as shown in 
supplemental Figure S2C. This figure shows an overlay (with false colors) of the 
consecutive sections of supplemental figure S2A and S2B.
Figure S2.
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Abstract
Objective    Smooth muscle cell (SMC) migration and proliferation are important in the 
development of intimal hyperplasia, the major cause of vein graft failure. Proteases 
of the plasminogen activator (PA) system and of the matrix metalloproteinase 
(MMP) system are pivotal in extracellular matrix degradation and, by that, SMC 
migration. Previously, we demonstrated that  inhibition of both protease systems 
simultaneously with viral gene delivery of the hybrid protein TIMP-1.ATF, consisting 
of the tissue inhibitor of metalloproteinase-1 (TIMP-1) and the receptor-binding 
amino terminal fragment (ATF) of urokinase, reduces SMC migration and neointima 
formation in an in vitro restenosis model using human saphenous vein cultures 
more efficiently than both protease systems separately. Because use of viral gene 
delivery is difficult in clinical application, this study used non-viral delivery of TIMP-
1.ATF plasmid to reduce vein graft disease in a murine bypass model. Non-viral gene 
transfer by electroporation was used to avert major disadvantages of viral gene 
delivery, such as immune responses and short-term expression.
Methods  Plasmids encoding ATF, TIMP-1, TIMP-1.ATF, or luciferase, as a control, 
were injected and electroporated in both calf muscles of hypercholesterolemic 
apolipoprotein E3-Leiden (ApoE3*Leiden) mice (n=8). One day after electroporation, 
a venous interposition of a donor mouse was placed into the carotid artery of a 
recipient mouse. In this model, vein graft thickening develops with features of 
accelerated atherosclerosis. Vein grafts were harvested 4 weeks after electroporation 
and surgery, and histologic analysis of the vessel wall was performed. 
Results  Electroporation-mediated overexpression of the plasmid vectors resulted 
in a prolonged expression of the transgenes and resulted in a significant reduction 
of vein graft thickening (ATF: 36% ± 9%, TIMP-1: 49% ± 5%, TIMP-1.ATF: 58% ± 5%; 
P < .025). Although all constructs reduced vein graft thickening compared with the 
controls, the luminal area was best preserved in the TIMP-1.ATF-treated mice.
Conclusion  Intramuscular electroporation of TIMP-1.ATF inhibits vein graft 
thickening in vein grafts in carotid arteries of hypercholesterolemic mice. Binding 
of TIMP-1.ATF hybrid protein to the u-PA receptor at the cell surface enhances the 
inhibitory effect of TIMP-1 on vein graft remodeling in vitro as well as in vivo and 
may be an effective strategy to prevent vein graft disease. 
50
Introduction 
Intimal hyperplasia and accelerated atherosclerosis are important factors in the 
development of vein graft thickening after vein graft surgery, eventually resulting 
in occlusion of the vessel lumen1,2. This vein graft failure may lead to tissue 
ischemia, and frequently, re-interventions or limb amputations are inevitable if 
the grafts fail3. Smooth muscle cell (SMC) migration and proliferation as well as 
deposition and turnover of extracellular matrix (ECM) proteins occurring early after 
reconstruction largely contribute to the complex process of intimal hyperplasia4,5. 
Together with the influx of lipid-loaded macrophages, accelerated atherosclerosis 
of the vein graft develops6,7. Members of the matrix metalloproteinases (MMP) 
family and the plasminogen activator (PA) system are important in SMC migration 
and the associated degrading and turnover of ECM proteins8. MMPs are a family 
of >25 zinc-dependent proteases, of which most have been detected in vascular 
cells9. They are not only able to degrade (vascular) ECM proteins such as collagen 
and elastin but may also be involved in activation of growth factors and pro-
enzymes10,11. Furthermore, MMPs are up-regulated in vein grafts after vascular 
injury12. Tissue inhibitors of metalloproteinases (TIMP), together with inflammatory 
cells and cytokines, regulate the expression of MMPs in the vein grafts and arteries, 
and overexpression of TIMPs can prevent SMC migration13-15. Adenoviral-mediated 
overexpression of several TIMPs inhibited vein graft thickening in vitro as well as in 
vivo16-18. Urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen 
activator (t-PA), both members of the serine protease family, are also upregulated 
in diseased blood vessels8. Because u-PA is recruited to the cell surface by its 
receptor u-PAR, it plays a central role to pericellular proteolysis. This results in cell 
surface-bound activation of plasmin, which can degrade ECM both directly and 
indirectly through activation of MMP pro-enzymes19. Previously, we demonstrated 
that inhibitory effects of TIMP-1 could be enhanced by the binding of TIMP-1 to the 
aminoterminal fragment of urokinase (ATF), which contains the receptor-binding 
domain of u-PA. By binding TIMP-1 to u-PAR, this protein was not only anchored 
directly to the cell surface but also prevented local activation of plasminogen by 
blocking the binding of u-PA to its receptor (Fig 1). In cultured human saphenous 
vein segments, adenoviral administration of the hybrid protein TIMP-1.ATF 
inhibited matrix degeneration and SMC migration, which resulted in a reduction 
of neointima formation in vitro20.  In the present study, the effect of TIMP-1.ATF on 
vein graft thickening and remodeling in vitro was studied in hypercholesterolemic 
apolipoprotein E3-Leiden (ApoE3*Leiden) mice, using a murine model for vein 
graft disease21. Within 4 weeks after placing a venous interposition in the carotid 
artery of these mice, vein graft thickening with signs of accelerated atherosclerosis 
uniformly develops22. For the successful application of TIMP-1.ATF in vivo, long-term 
and sufficient circulating levels of TIMP-1.ATF protein are essential. Gene therapy 
is an attractive strategy to achieve this: no repeated administration of therapeutic 
proteins is necessary because the therapeutic protein will be produced in vivo. 
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Moreover, other therapies, such as pharmacologic interventions to prevent vein graft 
disease, are still disappointing23. Although adenoviral gene transfer is commonly 
used for in vivo gene transfer in mice, several negative side effects discourage the 
use of these adenoviral vectors. Systemic delivery of adenoviruses such as through 
venous injection results in transduction of predominantly the liver and may lead to 
strong systemic inflammatory and immunologic responses. Local transduction of 
the musculature may be less harmful, but the transduction efficiency in musculature 
is generally low after adenoviral delivery and is accompanied with only short-term 
expression. As an alternative, non-viral intramuscular electroporation-mediated 
gene transfer of a TIMP-1.ATF expression plasmid was used to obtain circulating 
levels of TIMP-1.ATF protein24,25. In this study, we demonstrate that this method 
results in long-term functional serum levels of TIMP-1.ATF. Furthermore, cell surface-
bound inhibition of u-PA and the MMP system with the hybrid protein TIMP-1.ATF 
reduces vein graft thickening and vascular remodeling in hypercholesterolemic 
ApoE*3-Leiden mice.
Figure 1. Schematic representation shows the mechanism of tissue inhibitor of 
metalloproteinase-1 linked to the amino terminal fragment (TIMP-1.ATF) activity. Pericellular 
inhibition of plasmin and matrix metalloproteinase (MMP) activity is accomplished by 
anchoring TIMP-1 via ATF to the urokinase-type plasminogen activator (u-PA) receptor 
(u-PAR). This process is enhanced by competing of TIMP-1.ATF with native u-PA for binding 





To construct all plasmid vectors, mutated ATF, TIMP-1, and TIMP-1.mATF 
complimentary DNA, previously constructed in our lab20, were cloned into a 
pcDNA3.1(+) expression cassette (Invitrogen, The Netherlands). In the human 
aminoterminal fragment of u-PA (hATF), site-specific mutations were introduced to 
create a murinized aminoterminal fragment of u-PA (mATF), thus enabling binding 
to the murine u-PAR26. Photinus pyralis (firefly) luciferase reporter gene, obtained 
from the pGL3 control vector (Promega, The Netherlands), was cloned into the 
same pcDNA3.1 cassette. All plasmid DNA was prepared using DH5α Escherichia 
coli (Invitrogen) and QIAfilter Plasmid Giga Kits (Qiagen, The Netherlands). 
Plasmid DNA was dissolved in Endofree tris (hydroxymethyl)aminomethane-
ethylenediaminetetraacetic acid (TE) buffer (Qiagen) at a final concentration of 3.5 
mg/mL.
Mice
Animal experiments were approved by the Animal Welfare Committee of The 
Netherlands Organization for Applied Scientific Research (TNO, The Netherlands). 
For all experiments, 14-week-old male heterozygous ApoE3*Leiden animals on 
a C57BL/6 background, crossbred for at least 20 generations in our laboratory, 
were used. ApoE3*Leiden mice develop a diet-dependent hypercholesterolemia 
and spontaneous atherosclerosis27,28. Animals were fed with a cholesterol-
enriched high-fat diet, containing 1% cholesterol and 0.05% cholate (Arie Blok 
BV, Woerden, The Netherlands), starting 4 weeks before surgery and continued 
during the entire experiment22.  All mice received water and food ad libitum. One 
week before surgery and at sacrifice, a cholesterol esterase, cholesterol oxidase 
reaction was used to determine cholesterol levels in serum (Chol R1, Roche 
Diagnostics, Woerden, The Netherlands). Mice with an overall mean weight of 27.1 
± 0.3 g were allocated randomly to the four experimental groups (n = 8 per group). 
Intramuscular electroporation. Before electroporation, surgery, and sacrifice, mice 
were anesthetized by an intraperitoneal injection with a combination of midazolam 
(5 mg/kg, Roche), Medetomidine, (0.5 mg/kg; Orion, Espoo, Finland), and fentanyl 
(0.05 mg/kg; Janssen-Cilag, The Netherlands). To obtain circulating levels of mATF, 
TIMP-1, and TIMP-1.mATF protein, pcDNA3.1 vectors encoding for these proteins 
were injected in the calf muscle, followed by electroporation using an optimized 
electroporation protocol as previously published24,29,30. Briefly, plasmid DNA (in total 
50 µg/leg), dissolved in 30 µL TE buffer and 140mM saline, was injected in each of 
the calf muscles, followed by eight 10-millisecond electrical pulses at 200 V/cm with 
a frequency of 1 Hz. The pulses were generated with a Square Wave Electroporator 
ECM 830 and administered using Caliper Electrodes (BTX; Harvard Apparatus, 
Holliston, Mass). As a control, pcDNA3.1-luciferase was used. Electroporation was 
performed 1 day before vein graft surgery.
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Murine vein graft model
One day after electroporation, a venous interposition graft was placed in the carotid 
artery as described by Zou et al21. In brief, caval veins of donor mice serving as vein 
grafts were harvested and preserved in 0.9% saline containing 100 IU heparin. In 
the recipient mice, the right carotid artery was dissected free from its surroundings 
and cut midway. Next, a polyethylene cuff was placed at the end on both sides. The 
artery was everted around the cuff and fixated by a suture ligation at both ends. 
Finally, the caval vein was grafted by sleeving the ends of the vein over two everted 
ends of the carotid artery and fixated with a ligation as well. Please see Fig S1, 
(online only) for photographs of this vein graft model. 
Vein graft thickening quantification and immunohistochemistry
Mice were sacrificed 28 days after surgery for histologic analysis (n=8 per 
group). Tissue segments were harvested after in vitro perfusion fixation with 4% 
formaldehyde, fixated overnight, and paraffin-embedded.
To quantify vein graft thickening, sequential cross-sections were made throughout 
the embedded vein grafts. For each mouse, six representative sections per vessel 
segment were used after being stained for hematoxylin-phloxine-saffron (HPS). 
Image analysis software was used to quantify the vein graft thickening (Qwin; Leica, 
Wetzlar, Germany). Vein graft thickening was defined as the area between the 
lumen and adventitia and determined by subtracting the luminal area from the total 
vessel wall area, because no obvious boundary between intima and media can be 
detected in these venous segments due to the lack of internal elastic lamina31. The 
mean per mouse was used to determine the mean per group. All measurements 
and calculations were done in a single blinded fashion. The composition of vein 
graft thickening was visualized by HPS staining and immunohistochemistry. MMP-2, 
MMP-9, and membrane-type (MT)-MMP-1 were visualized at several time points 
with antibodies against MMP-2 (mouse anti-human), MMP-9 (goat anti-human) 
and MTMMP- 1 (rabbit anti-mouse; all with a dilution of 1:100 and purchased 
from Santa Cruz Biotechnology Inc, Santa Cruz, Calif). Local presence of u-PA and 
u-PAR in the vessel wall was demonstrated with polyclonal human u-PA antibodies 
(1:150; Abgent, San Diego, Calif) and u-PAR (goat anti-mouse, 1:50; R&D Systems, 
Minneapolis, Minn). SMCs were detected with α-SMC actin staining (anti-SM α-actin, 
1:750, Roche Applied Biosciences). Smooth muscle cells immunopositive areas in 
the vein graft thickening were calculated as a percentage of the total vein graft 
area in cross-sections by means of image analysis software (Qwin, Leica). CD45-
positive leucocytes were determined with a CD45 rat anti-mouse antibody (1:200, 
BD Biosciences Pharmingen, San Diego, Calif). The number of positively stained cells 
per microscopic view (original magnification x150) was scored in a single blinded 
fashion.
 
Enzyme-linked immunoabsorbent assay of TIMP-1.mATF
Serum samples were collected to determine the circulating levels of TIMP-1.mATF
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at 7, and 28 days after electroporation. TIMP-1.mATF concentrations were measured 
using an u-PA enzyme-linked immunosorbent assay (ELISA) with a validated standard 
curve of human u-PA and monoclonals produced in our laboratory as described 
previously32. The concentrations are expressed as human urokinase equivalents. 
Statistical analysis
The group size of eight animals was used for all experiments, and was chosen based 
on a standard power calculation, using a power of 90%, an α of 0.05, a standard 
deviation of 15%, and a predicted difference between groups of at least 20%. Data 
are presented as mean ± standard error of the mean (SEM). Statistical significance 
was calculated in SPSS 15.0. software (SPSS Inc, Chicago, Ill). Overall comparisons 
between groups were performed with the one-way analysis of variance, and 
thereafter, differences between groups were determined using the t test. Ordinal 
scores (CD45 immunohistochemistry) were compared using the Pearson χ2 test. 
Values of P< 05 were considered statistically significant.
Results
Expression of MMPs and proteases of the PA system in murine vein grafts
The expression of various members of the MMP family was confirmed by the presence 
of MMP-2, MMP-9, and MT-MMP-1 protein revealed by immunohistochemical 
staining on cross-sections of vein grafts, harvested at several time points (before 
surgery and at T=1, 7, and 28 days after surgery; Fig 2,A). MMP-2 could not be 
detected in untreated caval veins; however, MMP-2 was present in infiltrating 
cells at T = 1 and in infiltrating cells, such as in the thickened vein graft, at a later 
time point. At 4 weeks after surgery, MMP-2 was abundantly present throughout 
the vein graft thickening and was localized to SMC-rich regions as assessed with 
immunohistochemistry on serial sections (anti-SM α-actin positive) and evaluated 
by MMP-2 expression in relation to cell morphology. MMP-9 and MT-MMP-1 could 
be detected in untreated caval veins and was also present in the infiltrating cells at 
the early time points. 
Expression of MMP-9 and MT-MMP-1 increased in time. MMP-9 was also present 
in regions that contain activated endothelial cells and adhering  leucocytes. So, 
during the remodeling processes of vein grafts, an abundant expression of the 
various MMPs could be detected throughout the vessel wall. Immunohistochemical 
staining performed on cross-sections of the vein grafts for u-PA and its receptor 
u-PAR demonstrated the expression of proteases of the plasminogen activator 
system. Both u-PA and u-PAR were seen throughout the whole vessel wall (Fig 2). 
These data show the presence of the major members of the MMP family and the PA 
system in the vein grafts and underscore the rationale for the therapeutic strategy 
to inhibit the activity of these proteases at the cell surface in the vein graft vessel 




Figure 2. Representative cross-sections of untreated murine vein grafts, harvested 4 weeks 
after surgery show expression of matrix metalloproteinases (MMP) and plasminogen 
activator system proteases. MMP-2, MMP-9, membrane-type-MMP-1 (MT-MMP-1), 
urokinase-type plasminogen activator (u-PA), and u-PA receptor (u-PAR) were visualized 
with specific antibodies against these proteases (see Materials and Methods). Panel A. The 
expression of MMP-2, MMP-9, and MT-MMP-1 is shown at several time points during the 
development of the vein graft (untreated vein graft and 1, 7, 14, and 28 days after surgery). 
MMP-2 could be detected in infiltrating cells at T = 1 and also in the thickened vein graft at 
later time points and is abundantly expressed in the thickened vein graft at 28 days, mainly 
colocalizing with smooth muscle cells. Expression of MMP-9 and MT-MMP-1 increases in 
time, whereas MMP-9 can also be detected in activated endothelial cells and adhering 
leucocytes as indicated by arrows. Panel B. At 28 days after surgery, u-PA and u-PAR are 
expressed throughout the whole vessel wall (scale bars represent 50 µm).
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Expression of TIMP-1.mATF after intramuscular electroporation-mediated gene 
transfer
The circulating protein levels of TIMP-1.mATF are depicted in Fig 3. Blood samples 
were collected before electroporation and at 8 and 28 days after intramuscular 
injection and electroporation with the plasmid pTIMP-1.mATF. Serum levels of TIMP-
1.mATF, as determined by ELISA, were 5.8 ± 0.9 ng/mL and 6.3 ± 2.3 ng/mL u-PA 
equivalents, respectively (difference not significant), indicating that the expression 
of TIMP-1.mATF was sustained during the entire experimental period. No TIMP-1.
mATF could be detected in the control groups or in the samples obtained before 
electroporation. 
Figure 3. Plasma levels of TIMP-1.mATF (urokinase type) after intramuscular electroporation 
(in ng/mL) are shown before electroporation, and at 8 and 28 after intramuscular injection 
and electroporation of pTIMP-1.mATF (n=8 per group) as detected with a urokinase-type 
plasminogen activator enzyme-linked immunosorbent assay. No TIMP-1.mATF levels 
could be measured in the control groups and before electroporation. Difference between 
both time points is not significant. The error bars signify the standard error of the mean. 
mATF, Murinized amino terminal fragment; TIMP-1, tissue inhibitor of metalloproteinase-1; 
pTIMP-1, plasmid vector encoding TIMP1.
Effects of TIMP-1.mATF on vein graft thickening
To study the effect of TIMP-1.mATF on vein graft thickening in vivo, hind limbs 
of hypercholesterolemic mice were injected and electroporated with plasmids 
encoding for mATF, TIMP-1, or TIMP-1.mATF, or luciferase as a control. One day
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after electroporation, a venous interposition was placed in the carotid artery of 
hypercholesterolemic ApoE*3Leiden mice (n=8 per group). All mice were fed with 
a mild Western-type diet for 1 month before surgery and electroporation. Mean 
serum cholesterol level in all mice was 12.9 ± 0.8 mmol/L. There were no significant
Figure 4. Quantification and representative hematoxylin-phloxine-saffron (HPS) stained 
cross-sections of vein graft, 28 days after intramuscular electroporation and surgery. Vein 
graft thickening and the ratio between luminal area and total vessel cross-sectional area of 
ApoE3*Leiden mice are shown 4 weeks after electroporation-mediated gene transfer of the 
plasmids encoding amino terminal fragment (pATF), tissue inhibitor of metalloproteinase-1 
(pTIMP-1), TIMP-1.mATF or Luciferase, as a control. Vein graft surgery was performed 1 
day after intramuscular electroporation (n=8 per group). Areas were quantified by using 
six sequential sections per segment and are expressed in mm2 (mean ± standard error of 
the mean). A. Treatment with all plasmids resulted in a significant reduction of vein graft 
thickening compared with the control. B. Ratios between the luminal area and total cross-
sectional area of the vessel were significantly increased after electroporation-mediated 
delivery of all plasmids compared with the control. The difference between TIMP-1.mATF 
and the other groups was significant. C. In HPS staining of vein grafts, although vein graft 
thickening is indicated by black lines, the complete circular surface was used to calculate 
vein graft thickened area. D. Vein grafts of the control and treated animals were stained 
with anti-mooth muscle α-actin (original magnification x150). *P< .05 **P< .01 compared 
with control or indicated by the black line.
58
differences between groups and cholesterol levels, and body weights of all mice did 
not change significantly during the experiment (data not shown). Mice were sacrificed 
4 weeks after vein graft placement, vessel segments were harvested, and vein graft 
remodeling was analyzed by quantitative morphometry. Typical representative 
cross-sections are shown in Fig 4, C. Vein graft thickening was significantly inhibited 
in all groups compared with the control (Fig 4, A). Electroporation with the plasmids 
pATF and pTIMP-1 resulted in a reduction of 36% ± 9% and 49% ± 5%, respectively 
compared with the control (control: 0.62 ± 0.09 mm2, ATF: 0.40 ± 0.05 mm2, and 
TIMP-1: 0.32 ± 0.03 mm2; P = .025 and P<.002). Treatment with pTIMP-1.mATF 
lowered vein graft thickening by 58% ± 5% (TIMP- 1.mATF: 0.26 ± 0.03 mm2; P<.001). 
A significantly stronger inhibition of vein graft thickening, 4 weeks after surgery, 
was observed after electroporation with pTIMP- 1.mATF compared with treatment 
with pATF (P = .022). The ratio of lumen/total cross-sectional area of the vessel 
was also significantly increased in the treated groups compared with the control. 
This indicates a beneficial effect of both TIMP-1 and ATF on (pathologic) vascular 
remodeling (Fig 4, B). Moreover, the effect was even stronger after electroporation 
with pTIMP-1.mATF (P<.05). The effect on plaque composition of the vein graft  
thickening after electroporation was studied by Immunohistochemical analysis for 
the presence of SMCs and CD45-positive leucocytes. Relative SMα actin-positive 
areas were not significantly altered between groups 4 weeks after surgery (control: 
19.9%±4.3%, mATF: 15.0% ±4.2%, TIMP-1: 18.6% ± 2.5%, TIMP-1.mATF: 20.1% 
±3.8%). Also, no significant differences in influx of inflammatory cells, monitored as 
CD45-positive cells, were observed (data not shown).
Discussion
In this study, we clearly demonstrate that in vitro thickening of the vein graft can 
be significantly inhibited after non-viral delivery of mATF, TIMP-1, and the hybrid 
protein TIMP-1.mATF. Moreover, TIMP-1.mATF had the most beneficial profile 
regarding vascular remodeling of the vein graft with preservation of luminal area. 
Previous reports have documented increased MMPs and PA activity in (human) vein 
grafts, and the expression of the TIMPs, the natural regulators of MMPs, during 
vessel wall thickening of human saphenous veins has also been described8,9,33. 
Bypass surgery, a raised shear stress, and an inflammatory cascade increase these 
activities and lead to breakdown of the ECM and enhance SMC migration and 
proliferation, particularly prominent in the first 6 months after the intervention. 
This results in vein graft thickening and compromises long-term graft patency19,34. 
Suppressing these activities in the first months by overexpression of their regulators 
is a promising approach to prevent vascular diseases. In a previous study, we showed 
that intimal hyperplasia was inhibited substantially when the MMP and PA systems 
were restrained simultaneously by adenoviral gene transfer in cultured segments 
of the human saphenous vein20. In the current study, we extended this observation 
to an in vivo situation using a murine model for vein graft disease combined with
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electroporation-mediated gene transfer of expression plasmids encoding for the 
hybrid protein TIMP-1.mATF. 
Various reports describe the effects on vein graft disease of overexpression of 
TIMP-1, -2, and -3. George et al16,17 showed that adenoviral gene transfer of the 
TIMP-1 and -2 gene inhibits SMC migration and neointima formation in human 
saphenous veins in vitro. Later, they inhibited MMP activity in vein grafts in vitro 
with overexpression of TIMP-3. TIMP-2, used as a control in this study, had no effect 
on vein graft thickening in their bypass model, both in vitro and in vivo18. This is in 
contrast with Hu et al35 who studied the effect of local adenoviral-mediated gene 
transfer of TIMP-2 on vein graft remodeling. They describe a reduction in vein graft 
diameter and vein graft thickening35. Finally, Puhakka et al36,37 showed the effect 
of adenoviral delivery of TIMP-1 as well in an arterial model for restenosis as in a 
vein graft model. Although both models showed an inhibitory effect of TIMP-1 on 
restenosis, the effect in the vein graft model only lasted for 2 weeks, and plaque 
size was similar again to the control group 4 weeks after surgery36,37. These studies 
underscore the potency of gene therapy and the therapeutic potential of inhibiting 
MMP activity in preventing vein graft disease. In all described studies, adenoviral-
mediated gene therapy was used to deliver the TIMPs to the target tissue. If clinical 
application is considered, gene therapy has inherited difficulties. Therefore, we 
used intramuscular electroporation, an alternative gene delivery method in the 
present study. With this technique, drawbacks of viral gene delivery, such as low 
transduction efficiency for vascular tissue and the pre-existing immunity, can be 
prevented and long-term transgene expression can be achieved25. Although newer 
generations of adenoviral vectors are less immunogenic and are more efficient 
in vascular infection, these adenoviruses are still not fully usable for the human 
situation38,39. Particularly referring to a clinical setting, this is of importance because 
it is thought that explantable saphenous veins are more suitable for extracorporeal 
adenoviral than for intravenous or intramuscular gene therapy. The fact that 
adenoviral gene transfer, with the complications of short-term expression and 
induction of an inflammatory reaction, should be considered  as less suitable for 
vein graft gene transfer opens up new perspectives for electroporation-mediated 
plasmid-based gene transfer with its relatively beneficial safety profile and long-
lasting expression of the introduced genes. In our study, prolonged circulating 
levels of the transgenes, including the hybrid protease inhibitor TIMP1.mATF, were 
obtained after intramuscular electroporation-mediated gene transfer into the calf 
muscle of the mouse. This resulted in an effect on vascular remodeling in distant 
vein grafts (ie, inhibition of vein graft thickening in grafts interpositioned in the 
carotid arteries). The inhibitory effect of pTIMP-1.mATF was, with a 58% reduction, 
the most powerful, whereas the effect of pTIMP-1 was less strong (49%). Also, 
electro-delivery of pATF reduced vein graft thickening (36%), which is in line with 
our previous findings40. Next to the observed differences in vein graft thickening 
between ATF, TIMP-1 and TIMP-1.mATF, the ratio between luminal area and the 
total cross-sectional area was significantly increased after treatment with pTIMP-1.
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mATF compared with the other groups. This indicates a positive effect on vascular 
remodeling, because the luminal area is relatively large compared with the area of 
total vessel in the pTIMP-1.mATF-treated mice, suggesting a better patency in the 
long run. It is likely that vascular remodeling is inhibited by TIMP-1.mATF because 
by binding to the u-PAR, activation of plasminogen is also blocked together with the 
local activation of MMPs8,20. At sacrifice, no significant reduction in relative SMC 
content was found after TIMP-1.mATF treatment or the individual components. 
Referring to plaque stability, this is a favourable situation41. Synthetic inhibition of 
MMPs with broad-spectrum pharmacologic compounds is an alternative method 
to reduce vessel wall thickening; however, this approach is nonspecific and failed 
to reduce long-lasting neointima formation9,42. Because MMPs not only facilitate 
SMC migration and proliferation by ECM degradation but also affect the activation 
of growth factors and cytokines, the role of MMPs and their inhibitor in vascular 
remodeling is thought to be more complex10,43. For example, MMP-9 together with 
MT-1-MMP and u-PA/u-PAR are involved in inflammatory-related recruitment of 
monocytes10,44,45. In the present study, however no effect of TIMP-1.mATF on influx 
of inflammatory cells as monitored by CD45 staining could be observed.
Conclusions
These data demonstrate that intramuscular electroporation-mediated gene 
transfer of TIMP-1.mATF encoding plasmid vectors in the calf muscle results in 
circulating serum levels of the hybrid protease inhibitor TIMP-1.mATF. These levels 
are sufficient to inhibit vein graft thickening within the first month in vein grafts in 
carotid arteries of hypercholesterolemic ApoE3*Leiden mice. Because TIMP-1.ATF 
binds selectively to the u-PA receptor and blocks both MMP and plasmin activity 
on the cell-surface, this approach may contribute in preventing post-interventional 
restenosis and vein graft disease in bypassed patients.
Clinical Relevance  
Venous bypass graft failure is a serious clinical problem that occurs in up to 40% 
to 60% of patients after bypass surgery, and re-interventions are often required 
both in cardiac and peripheral vascular disease. Smooth muscle cell migration and 
proliferation in the vessel wall, mediated by proteases of the plasminogen activator 
system and matrix metalloproteinase system, are important in the development of 
vein graft disease. Non-viral gene transfer by intramuscular electroporation of the 
hybrid protein TIMP-1.ATF, consisting of the tissue inhibitor of metalloproteinase-1 
(TIMP-1) and the receptor-binding amino terminal fragment (ATF) of urokinase, to 
inhibit these proteases directly at the cell surface, suppresses the development of 
vein graft thickening, without the major disadvantages of viral gene delivery such 
as immune responses and short-term expression, and therefore may be a potential 
therapeutic tool to improve vein graft disease.
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Abstract
Objective   Annexin A5 (AnxA5) has antithrombotic, anti-apoptotic and anti-
inflammatory properties; we investigated its effectiveness against vascular 
inflammation, remodeling and dysfunction in accelerated atherosclerosis.
Methods and Results  Human AnxA5 (1 mg/kg/d or vehicle) was investigated in 
models of vascular injury in hypercholesterolemic ApoE3*Leiden mice. AnxA5 
treatment reduced adhesion of leucocytes by 71% (p=0.015) and macrophages 
by 51% (p=0.014), and medial leukocyte (69%, p=0.031) and macrophage (87%, 
p=0.018) infiltration in a femoral artery inflammation model (perivascular cuff 
for 3d). MCP-1 and TNFα expressing cells were also reduced, indicating reduced 
vascular inflammation. In a vein graft model, 28d AnxA5 treatment reduced vein 
graft thickening (48%, p=0.006), leukocyte infiltration (46%, p=0.003) and plaque 
instability features (threefold). In these mice, reduced plasma concentrations of 
IFNγ (-72%, p=0.040), G-CSF (-41%, p=0.010) and MIP1β/CCL4 (-66%, p=0.020) were 
measured, indicating reduced systemic inflammation.
Endothelium mediated dilatation in ApoE-/- mice fed 16w Western diet was improved 
by 3d of anxA5 treatment, shown by improved systolic and diastolic blood pressure 
reductions in response to 3 µg/kg metacholine, which could be abolished by 
L-NAME, indicating nitric oxide involvement.
Conclusion   AnxA5 reduced local vascular and systemic inflammation, vascular 
remodeling and improved vascular function, indicating a definite therapeutic 
potential against atherosclerotic cardiovascular diseases.
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Introduction
Accelerated atherosclerosis is one of the key features leading to vein graft failure 
next to acute thrombosis and occlusive vein graft thickening and is initiated by 
endothelial dysfunction, accompanied by an inflammatory activation of endothelial 
cells and smooth muscle cells (SMCs)1,2. This activation promotes adhesion of 
activated platelets and leukocytes and increases endothelial permeability, after 
which low-density lipoprotein (LDL) cholesterol accumulates in the vessel wall 
and is taken up by macrophages, which become foam cells3,4. Leukocytes produce 
pro-inflammatory cytokines such as monocyte chemotactic protein (MCP)-1, 
tumor necrosis factor-α (TNFα) and interferon-γ (IFNγ). Leukocytes and cytokine 
expression are also observed in murine vein grafts3,5. IFNγ can activate macrophages 
and stimulate apoptosis, leading to plaque instability which can result in plaque 
disruption and thrombosis6,7. 
Viable cells expose phosphatidylcholine and sphingomyelin on their outer cell 
membrane leaflet and express phosphatidylserine (PS) on their inner membrane 
leaflet. The annexins are a family of phospholipid binding proteins and annexin 
A5 (AnxA5) binds to PS. AnxA5 was originally identified as an anticoagulant and 
antithrombotic protein8-11, but is now known to have several other additional 
properties12,13. PS is highly polarised to the inner cell membrane in normal cells, 
but is externalized in the early phase of apoptosis and inflammatory cell activation. 
AnxA5 binds reversibly, specifically and with high affinity to these cells, as well as 
to aged erythrocytes, endothelial microparticles (EMP), activated platelets and 
oxidized (ox) LDL cholesterol, and is present in high concentrations in atherosclerotic 
plaques. The annexins are thought mainly to act on intracellular mechanisms, but 
AnxA5 also has extracellular functions13-16. Plasma levels of AnxA5 are reported to 
be inversely related to the severity of coronary stenosis and are an indication of the 
extent of atherosclerotic plaques17, to be elevated in hypertensives with systolic 
dysfunction18 and following acute myocardial infarction19. 
AnxA5 also has anti-inflammatory effects, e.g. by association with the IFNγ receptor 
and prevention of inflammatory cellular responses to secreted IFNγ5. Atherosclerosis 
is associated with a reduced capacity of the endothelium to produce vasodilating 
substances upon stimulation, such as nitric oxide (NO). A reduction in endothelium-
mediated dilatation (EMD) is a risk factor for premature cardiovascular disease 
and is associated with increased atherosclerosis development20. Binding of 
AnxA5 to PS may prevent PS-mediated systemic inflammatory effects and affect 
the level of systemic inflammation and circulating cytokines and may thus affect 
endothelial function. The binding to oxLDL cholesterol, to apoptotic cells and the 
potential inhibitory effect on inflammation in combination with its antithrombotic 
effects make AnxA5 a promising therapeutic agent against atherosclerosis. The 
aim of the present study was to investigate if AnxA5 is therapeutically effective 





Please refer to the online Data Supplement for the detailed Methods section. 
Vascular inflammation and remodeling
Experiments were performed on ApoE3*Leiden transgenic mice on a Western-
type diet. Femoral arterial cuff surgery21 and vein graft surgery22 were performed 
as described previously to induce vascular inflammation and remodeling. Mice 
received daily intraperitoneal (IP) injections with 1mg/kg human recombinant 
AnxA5 (Bender Medsystems cat.no. BMS306/50mg. lot no.24926000) in a volume 
of 150µl 0.9% NaCl or vehicle (NaCl). Mice were sacrificed after either 3d (cuff 
experiments) or 28d (vein grafts) for vessel wall and plasma analysis.
Biochemical analysis
Total plasma cholesterol and triglyceride concentrations were measured 
enzymatically as described previously21. AnxA5 plasma concentration was 
determined using a human AnxA5 ELISA kit (Bender MedSystems Products, Vienna, 
Austria). 
To investigate effects of AnxA5 on systemic inflammation, a multiplex biometric 
immunoassay was used for cytokine and chemokine measurements according to 
the manufacturer’s instructions (Bio-PlexTM Mouse Cytokine 23-Plex Panel; Bio-
Rad., Hercules, CA, USA). The plasma concentrations of eotaxin, granulocyte colony 
stimulating factor (G-CSF), granulocyte-monocyte colony stimulating factor (GM-
CSF), IFNγ, interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), 
IL-12(p70), IL-13, IL-17, keratinocyte chemoattractant (KC), MCP-1/CCL2, MIP-1α/
CCL3, MIP-1β/CCL4, RANTES and TNFα were measured. Bio-PlexTM mouse cytokine 
standard values were provided by Bio-Rad Laboratories. Cytokine levels were 
determined using a Liquichip-200 multiplex array reader with Luminex x MAP™ 
technology (Bio-Rad Laboratories). The analyte concentration was calculated using 
software provided by the manufacturer (Bio-Plex Manager Software). 
Lesion quantification
At time of sacrifice, vessels were harvested after 5min in vivo perfusion-fixation 
with formaldehyde (4%), fixated overnight and embedded in paraffin. All vessels 
were stained with hematoxylin-phloxine-saffron (HPS) and with antibodies against 
leukocytes and macrophages to determine vascular inflammation. Femoral artery 
lesions were additionally stained for cells expressing either MCP-1 or TNFα, whilst 
vein grafts were further stained for collagen, AnxA5, fibrin, fibrinogen and apoptotic 
cells to investigate plaque composition. To determine the therapeutic effect of 
AnxA5 on plaque instability features in vein grafts, the number of apoptotic cells 
per cross-section and signs of endothelial erosion (endothelial disruption and 
fibrinogen deposition), leaky vessels (loose intramural erythrocytes) and plaque 
disruptions (erythrocytes in a subendothelial space) were counted. 
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Vascular function 
Experiments were performed on in male ApoE -/- mice on a Western-type diet with 
established endothelial dysfunction. Mice were treated with AnxA5 or vehicle as 
described above once daily for 3d. To investigate if AnxA5 could therapeutically 
affect endothelial function, blood pressure measurements were performed at 
baseline and after IP injection of 3µg/kg metacholine to stimulate endothelial NO-
release and vasodilatation. Blood pressure was measured for up to 5min. When 
baseline pressure was again established, IP injection of 50mg/kg (10µl/g) L-NAME, 
a NO-synthase inhibitor was given. Blood pressure was then measured until a new 
plateau was reached (12-15min), after which an additional IP injection of 3µg/kg 
metacholine was given and blood pressure was measured again for 5min.
Results
Annexin A5 therapy
AnxA5 treatment did not affect body weight, total plasma cholesterol or triglyceride 
concentrations. In the ApoE-/- mice, human AnxA5 plasma concentration, measured 
with ELISA, was 35.3±1.5ng/ml 1h after 1mg/kg injection and fell to 3.2±1.1ng/ml 
6h after injection, which is within the normal range in man, shown in figure 1. In 
mice receiving AnxA5 no bleeding complications occurred and there was one case 
of vein graft thrombosis (in n=10 mice) leading to loss of graft patency after 28d, 
compared to three cases of graft thrombosis in mice receiving vehicle only (n=10).
Figure 1. Plasma concentration (ng/ml) of circulating human AnxA5 in ApoE3*Leiden mice 
after IP injection of 1mg/kg/d AnxA5, detected by ELISA, in time (mean±SEM, n=3).
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Annexin A5 has systemic anti-inflammatory effects
To monitor effects of AnxA5 on systemic inflammation, plasma concentration 
of a set of cytokines and chemokines were defined before surgery, 3d after cuff 
placement and 28d after vein graft surgery, respectively, using a multiplex BioRad 
Luminex analysis. Before surgery, no statistical differences were observed. After 3d, 
plasma concentrations of inflammatory cytokines were increased in all groups due 
to the inflammatory response evoked by cuff placement. However, at 28d after vein 
graft surgery AnxA5 treatment significantly reduced the plasma concentration of 
G-CSF by 40.8% (p=0.010), of IFNγ by 72.2% (p=0.040) and of MIP-1β/CCL4 by 66.1% 
(p=0.020) compared to vehicle. In addition, AnxA5 treatment gave a trend towards 
reduction of the plasma levels of the cytokines IL-12 (p40) (p=0.120) and MIP-1α /
CCL3 (p=0.160), shown in table 1. The total dataset is represented in table 1 in the 
online supplement.
Table 1. Percentage of cell type area out of total vein graft wall area, total cell numbers per 
vein graft wall cross-section and plasma cytokine concentration (pg/ml) in ApoE3*Leiden 
mice 28d after surgery and vehicle only or AnxA5 treatment (mean±SEM, n=10).
Annexin A5 reduces inflammatory cell recruitment after vascular injury
AnxA5 treatment reduced the percentage of femoral arterial endothelial adhesion of 
leukocytes by 71.3% (vehicle: 34.2±3.0%, AnxA5: 9.7±8.9% of the sum of endothelial 
and intimal cells, p=0.015) and of macrophages by 51.4% (vehicle: 24.5±3.5%, 
AnxA5: 11.9±2.3%, p=0.014) after 3d compared to controls. Furthermore, within 
the media the percentage of leukocytes out of all cells in the media was reduced by 
69.0% (vehicle: 19.6±4.6%, AnxA5: 6.1±2.6%, p=0.031) and that of macrophages by 
87.3% (vehicle: 14.2±5.5%, AnxA5: 1.8±0.9% p=0.018). At this time point foam cells, 
recognisable by positive macrophage staining, intracellular lipid deposition and cell 
swelling, could not be detected.
Although plasma levels of MCP-1 and TNFα were not affected by AnxA5 treatment 
in the femoral artery cuff experiment, the arteries were stained for cells expressing 
MCP-1 and TNFα to investigate if AnxA5 reduced local vascular inflammation. It was 
found that AnxA5 treatment reduced the percentage of adherent and endothelial 
cells expressing MCP-1 by 31.0% (vehicle: 49.1±2.2%, AnxA5: 33.9±3.1%, p=0.003) 
and that of TNFα by 42.7% (vehicle: 39.6±8.0%, AnxA5: 22.7±2.2%, p=0.049) after 
3d. Additionally, the percentage of cells in the media expressing MCP-1 dropped 
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by 52.7% (vehicle: 31.1±1.8%, AnxA5: 14.7±2.8%, p=0.001), although no relative 
difference was observed for medial cells expressing TNFα (vehicle: 21.2±6.2%, 
AnxA5: 12.9±2.9%, p=0. 335) at this time point. The data, including representative 
photomicrographs, are shown in figure 2.
Figure 2. A. representative cross-sections of cuffed-femoral arteries of ApoE3*Leiden mice 
treated with vehicle or AnxA5, 3d after cuff placement (leukocyte, macrophage, MCP-1 and 
TNFα staining, magnification 400x, arrows in inserts indicate positive staining). B. and C. 
quantification of cell types in cuffed femoral arteries attaching to the endothelium (B) or 
within the media (C), expressed as the percentage of all cells adhering to the endothelium or 
in the media, in vehicle and AnxA5 treated mice (mean±SEM, n=10). 
Annexin A5 reduces vascular remodeling and preserves vein graft patency
To investigate the therapeutic effectiveness of AnxA5 against vascular remodeling, 
vein graft thickening, measured as the area between the lumen and adventitia in 
cross-sections, was quantified after 28d. This revealed that AnxA5 significantly 
reduced vein graft thickening by 48.0% (vehicle: 0.25±0.05mm2, AnxA5: 
0.13±0.01mm2, p=0.006), thus preserving graft patency, shown in figure 3. 
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Figure 3. Effect of AnxA5 treatment on vein graft thickening in ApoE3*Leiden mice treated 
with vehicle or AnxA5, 28d after surgery. A. representative cross-sections of vein grafts, 
(HPS and AnxA5 staining, magnification 80x, arrows in insert indicates positive staining). B. 
quantification of vein graft thickening, expressed as mm2 thickening in vehicle and AnxA5 
treated mice (mean±SEM, n=10).
Although in the controls AnxA5 could be detected by immunohistochemistry, the 
staining in the vessel wall of the mice injected with human AnxA5 was much more 
intense. This suggests accumulation of human AnxA5 in the vein graft wall, although 
one should be careful with quantification of this immunohistochemistry data. In 
order to identify if AnxA5 therapy altered atherosclerotic plaque composition, the 
presence of several important cell types and extracellular matrix was quantified, 
shown in table 1. AnxA5 treatment reduced the number of leukocytes in the vein 
graft wall per cross-section by 46% (vehicle: 53.1±6.1 cells, AnxA5: 28.8±2.3 cells, 
p=0.003). However, despite reduced wall thickening, there was no difference 
observed in the percentage of macrophage and foam cell area (vehicle: 35.6±7.7%, 
AnxA5: 32.5±7.4%, p=0.723), SMC area (vehicle: 23.0 ±4.0%, AnxA5: 28.4±3.6%, 
p=0.289) or collagen area (vehicle: 35.8±5.5%, AnxA5: 45.7±5.0%, p=0.289) in the 
vein graft wall between mice receiving daily AnxA5 or vehicle.
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Figure 4. A. representative cross-sections of spontaneous plaque disruption features in 
vein grafts of ApoE3*Leiden mice after 28d (HPS and fibrinogen staining, magnification 
80x, arrows in inserts indicate features). B. quantification of length (in μm) and number of 
plaque instability features (total of endothelial erosions, leaky vessel formation and plaque 
disruptions) in vehicle and AnxA5 treated mice (mean±SEM, n=10).
In order to evaluate the therapeutic effects of AnxA5 on plaque stability, apoptotic 
cell numbers and signs of plaque disruptions, characteristic for vein grafts, were 
quantified. AnxA5 treatment did not affect vein graft apoptotic cells numbers per 
cross-section (vehicle: 6.2±2.2 cells, AnxA5: 4.3±0.8 cells, p=0.796) after 28d, shown 
in table 2. Analysis of plaque morphology revealed the presence of disruption 
features and it was found that AnxA5 therapy did reduce the number, length and 
severity of endothelial erosions with fibrinogen lining the vessel wall (vehicle: 3/6 
cases, AnxA5: 2/9 cases) and therefore characteristically distinct from post-mortem 
artifacts, leaky vessel formation with intramural erythrocytes (vehicle: 3/6 cases, 
AnxA5: 0/9 cases) and of severe plaque disruptions with erythrocytes and thrombi 
in a sub-endothelial space (vehicle: 1/6 cases, AnxA5: 0/9 cases), shown in figure 4. 
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Annexin A5 improves endothelial function
To test the effect of AnxA5 on vascular function, endothelial dysfunction was induced 
by feeding ApoE-/- mice a Western-type diet for 16 to 17 weeks and was quantified 
by measuring the reduction of metacholine-induced NO-mediated vasodilatation. 
After this period, mice were given IP injections with 1mg/kg AnxA5 once daily for 3d. 
Mice were then anaesthetized and blood pressure measurements began. There were 
no differences in heart rate and systolic or diastolic blood pressure between groups 
receiving vehicle or AnxA5 at baseline. 
In normal, non-atherosclerotic mice, 3µg/kg of metacholine lead to a transient reduction 
in blood pressure, the response was maximal after 1 to 3min and then returned towards 
baseline after approximately 5min. This effect was blunted in ApoE-/- mice on a Western-
type diet. However, AnxA5 treatment restored EMD, leading to a larger systolic blood 
pressure reduction (vehicle: -5.0mmHg, AnxA5: -22.3mmgHg, p=0.027) and diastolic 
blood pressure reduction (vehicle: -0.8mmHg, AnxA5: -11.0mmHg, p=0.029) in the 
treated animals, shown in figure 5. Blood pressures are reported in table 3 in the online 
supplement. The reduction in systolic pressure was the largest, thus pulse pressure 
was reduced during EMD. Metacholine injection did not lead to changes in heart rate 
(vehicle: -1.5 beats per minute (bpm), AnxA5: -8.5bpm, p=0.379). 
Figure 5. Effect of 3d AnxA5 treatment on impaired endothelial function in ApoE-/- mice, quantified 
as change in A. aortic systolic  and B. diastolic blood pressure (mmHg) in time after IP injection of 
metacholine to induce vasodilatation (mean±SEM, n=10).
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Injection of 50mg/kg L-NAME resulted in similar increases in systolic (vehicle: 
+27.6mmgHg, AnxA5: +29.7mmgHg, p=0.518) and diastolic (vehicle: +15.6mmgHg, 
AnxA5: +18.0mmHg, p=0.350) blood pressure in both groups, accompanied by an 
equal reduction in heart rate (vehicle: -40.0mmgHg, AnxA5: -37.8mmHg, p=0.833). 
Subsequent IP injection of metacholine following L-NAME injection did not result 
in a significant change in heart rate (vehicle: -17.9bpm, AnxA5: -21.0bpm, p=0.559) 
or systolic (vehicle: -5.1mmHg, AnxA5: +1.0mmHg, p=0.060) and diastolic (vehicle: 
-1.3mmHg, AnxA5: +2.2mmHg, p=0.071) blood pressure in either group (online 
supplements, table 2), indicating that AnxA5 could affect vascular function through 
improved NO-signaling. 
Discussion
Our study shows a therapeutic role for AnxA5 against vascular inflammation, 
remodeling and dysfunction, in mouse models for accelerated atherosclerosis 
development. It was demonstrated that injection of human AnxA5 had no adverse 
effects, resulted in a marked reduction in circulating plasma concentrations of 
IFNγ, G-CSF and MIP-1β/CCL4, early inflammatory cell recruitment, adhesion and 
infiltration in the vessel wall after vascular injury, eventually leading to decreased 
vein graft thickening with less plaque instability features. Furthermore, AnxA5 
improved endothelial dysfunction by acting on NO-signaling. This study extends 
the role of AnxA5 as a regulator of inflammatory processes, and demonstrates its 
potential therapeutic use in inflammation-associated vascular disease in addition to 
its known functions in anticoagulation and its use as a marker of apoptosis. 
Although these data can be of clinical significance and could potentially lead to 
new therapeutic strategies, at this point we do not have the complete insight in 
the underlying mechanism of how AnxA5 affects vessel wall pathology. It was 
previously shown that AnxA5 could affect immune reactions on a systemic level. 
The injection of PS-exposing cells induced a delayed-type hypersensitivity reaction, 
which was critically affected by AnxA523. This suggested that the PS receptor can 
act as a switch for immune reactions and AnxA5 will interfere with this function24. 
A multiplex analysis of plasma cytokine levels revealed that the raise in levels of 
circulating cytokines observed 3d after femoral cuff implantation was not affected 
by AnxA5. However, prolonged exposure to AnxA5 reduced plasma levels of G-CSF, 
MIP-1β/CCL4 and IFNγ and certainly did have a systemic immunomodulatory effect. 
IFNγ production by inflammatory cells leads to improved antigen presentation and 
increases atherogenesis. In ApoE-/- mice lacking IFNγ or its receptor, atherogenesis 
was inhibited3,25. In vitro research has shown that AnxA5 can prevent cellular 
responses to secreted IFNγ and these data suggest that AnxA5 influences the IFNγ 
production by circulating cells involved in the early inflammatory processes during 
atherosclerotic lesion formation and vascular remodeling3-5.
Leukocyte, and specifically monocyte, adhesion, differentiation and activation are 
key components in the onset and progression of atherosclerosis and post- 
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interventional accelerated atherosclerosis3. To investigate effects of AnxA5 on local 
vascular inflammation, the ApoE3*Leiden femoral artery cuff model21, characterized 
by inflammatory cell adhesion and infiltration in the vessel wall early after surgery, 
was used. Not only did AnxA5 reduce endothelial-adhesion and medial infiltration 
of both leukocytes and macrophages, it was also found that early local expression 
of the key inflammatory cytokines MCP-1 and TNFα was reduced26,27. However, 
this local reduction of MCP-1 and TNFα levels was not reflected by an alteration 
of plasma levels after 3d, nor after prolonged AnxA5 exposure. Taken together, 
these findings suggest that AnxA5 can be used therapeutically to reduce local 
inflammatory responses after vascular injury. The exact mechanism by which AnxA5 
led to these effects was not elucidated and remains to be investigated. 
To investigate if the reduced early vascular inflammation by AnxA5 could be 
extended to a beneficial clinical therapeutic effect on accelerated atherosclerosis 
in general, AnxA5 was studied additionally in an model for vein graft pathology28. 
Here, accelerated atherosclerosis forms due to vascular damage, endothelial cell 
loss and a pulsatile arterial pressure, similarly to human venous bypass graft disease 
in which rapid foam cells formation, intimal thickening, apoptotic cell exposure 
and plaque instability features are observed, processes that lead to loss of graft 
patency. AnxA5 treatment significantly reduced vein graft thickening after 28d by 
48%, as well as leukocyte infiltration in the vein graft wall by 46%. Although AnxA5 
did not alter plaque content, it nonetheless preserved graft patency greatly.
Complications of atherosclerosis are either the result of reduced blood flow 
due to luminal narrowing or from acute vessel occlusion due to rupture of the 
atherosclerotic plaque. Apoptosis is associated with decreased plaque stability and 
although AnxA5 can affect apoptosis13, no differences in apoptotic cell numbers 
detected with TUNEL staining were observed at 28d after surgery. Since apoptosis 
is known to occur predominately within 14d after surgery in this model29, effects on 
apoptosis by AnxA5 on earlier time points cannot be ruled out. Despite no change 
in apoptotic cells numbers after 28d by AnxA5 treatment, it did reduce vessel 
plaque instability features such as endothelial erosion, leaky vessel formation and 
severe plaque disruption in addition to vessel wall thickening, indicating that AnxA5 
treatment is effective against both vascular inflammation and (the complications 
of) vascular remodeling.
Improvement of endothelial function is an important therapeutic goal in vascular 
diseases. In our study, short-term AnxA5 treatment improved EMD in response to 
metacholine injection to induce vasodilatation, displayed by a larger and longer-
lasting reduction of systolic and diastolic blood pressure in ApoE-/- mice with 
impaired endothelial function. This larger blood pressure reduction was blunted 
by L-NAME administration prior to the metacholine injection, indicating this effect 
was mediated via NO. Since this is important for the central arterial compartment 
compliance30, a large reduction of systolic blood pressure after AnxA5 treatment 
is suggestive for a positive effect on the endothelium in conduit arteries, 
often early affected by native atherosclerosis in humans3,4. Both acute and 
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chronic inflammation is known to hamper EMD, so the effects of AnxA5 on 
endothelial function could be a result of a reduced inflammatory burden (figures 
2 and 3), but also from other mechanisms. For example, endothelial cells can 
release EMP which in turn can trigger endothelial cytokine release and leukocyte 
adhesion. AnxA5 can shield EMP through PS-binding and prevent their endothelial 
cell activation. Thus, although effectiveness was shown, the exact mechanism by 
which AnxA5 improved deteriorated endothelial function in vivo is not yet clear and 
awaits further research.
In normal humans, plasma AnxA5 concentration is normally well below 10 ng/ml, 
and is elevated in certain diseases17-19. In our experiments, 1mg AnxA5/kg/d only 
transiently elevated plasma AnxA5 above these levels (figure 1). In spite of this, 
profound treatment effects were observed. This is probably explained by a rapid 
and strong binding to its target tissue, acting long after free AnxA5 is cleared from 
plasma. Clearance of AnxA5 is much slower from tissue compartments than from 
plasma, which is why it is useful as an apoptosis marker in vivo31.
AnxA5 is already used safely in patients as a diagnostic tool for atherosclerosis14. 
Since the present study shows pronounced anti-inflammatory and anti-atherogenic 
effects of AnxA5 in vivo on accelerated atherosclerosis associated with post-
interventional vascular remodeling and vein graft disease, as well as atherosclerosis-
associated vascular dysfunction, it also indicates a possible therapeutic role for 
AnxA5 in the prevention of accelerated atherosclerosis after vascular surgery and 
coronary interventions.
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All experiments were approved by the Institutional Committees for Animal Welfare. 
Transgenic male ApoE3*Leiden mice (bred in our own laboratory), backcrossed 
for more than 20 generations on a C57BL/6J background and male ApoE-/- mice 
(Taconics, Lille Skensved, Denmark), aged 10-12 weeks at the start of a dietary run-
in period, were used for this experiment. 
Diets
Transgenic male ApoE3*Leiden mice were fed a Western-type diet containing 
1% cholesterol and 0.05% cholate to induce hypercholesterolemia (AB Diets, 
Woerden, The Netherlands). The diet was given three weeks prior to surgery and 
was continued throughout the experiment. Male ApoE-/- mice, 8-10 weeks old, 
received a Western-type diet (Harlan Teklad TD.88137) for 16-17 weeks to induce 
endothelial dysfunction. All animals received food and water ad libitum during the 
entire experiment.
Femoral artery cuff mouse model
To investigate the effect of annexin A5 on vascular inflammation, ApoE3*Leiden 
mice underwent femoral arterial cuff placement1 after three weeks of diet to 
induce vascular inflammation. Mice were anesthetized before surgery with a 
combination of intraperitoneally (IP) injected Midazolam (5mg/kg, Roche, Woerden, 
The Netherlands), Medetomidine (0.5mg/kg, Orion, Espoo, Finland) and Fentanyl 
(0.05mg/kg, Janssen, Berchem, Belgium). The right femoral artery was isolated and 
sheathed with a rigid non-constrictive polyethylene cuff (Portex, Kent, UK, 0.40mm 
inner diameter, 0.80mm outer diameter and an approximate length of 2.0mm). 3d 
after cuff placement, mice were anesthetized as before and euthanized. 
The thorax was opened and mild pressure-perfusion (100mm Hg) with 3.7% 
formaldehyde in water (w/v) was performed for 5min by cardiac puncture in the left 
ventricle. After perfusion, the cuffed femoral artery was harvested, fixed overnight 
in 3.7% formaldehyde in water (w/v) and paraffin-embedded. Serial cross-sections 
(5μm thick) were taken from the entire length of the artery for analysis.
Mice received daily IP injections with 1mg/kg human recombinant annexin A5 
(Bender Medsystems cat.no. BMS306/50mg. lot no.24926000) in a volume of 
150µl, using 150µl 0.9% w/v NaCl (vehicle), injected IP daily as control. 
Carotid vein graft model for accelerated atherosclerosis
To study the effect of annexin A5 on vascular remodeling, vein graft surgery2 was 
done in ApoE3*-Leiden mice after three weeks of diet and performed by one
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surgeon, to exclude the possibility of inter-group variation due to different surgical 
skills. Mice were anesthetized and the right common carotid artery was dissected 
free from its surroundings from the bifurcation at the distal end towards the 
proximal end. The vessel was ligated twice with an 8.0 silk ligature and dissected 
between the middle ties. A cuff was placed over both ends after which these were 
everted over the cuffs and ligated with an 8.0 silk ligature. Littermates were used 
as donor for the inferior caval vein. The carefully harvested inferior caval vein was 
temporarily preserved in a 0.9% NaCl solution, containing 100U/ml of heparin and 
was interpositioned between the ends of the artery. The connections were ligated 
together with an 8.0 silk suture. Pulsations confirmed successful engraftment. Mice 
were sacrificed 28d after vein grafting as described before. Daily annexin A5 and 
vehicle treatments were as described above. Blood samples were taken from the 
tail vein for plasma annexin A5 analysis at 1, 3 and 6h after administration. 
Biochemical analysis
Total plasma cholesterol (Boehringer Mannheim GmbH, kit 236691) and triglyceride 
(Sigma Diagnostics, kit 337-B) concentrations were measured enzymatically. 
Annexin A5 plasma concentration was determined using a human annexin A5 ELISA 
kit (Bender MedSystems Products, Vienna, Austria). 
To investigate effects of annexin A5 on systemic inflammation, a multiplex biometric 
immunoassay was used for cytokine and chemokine measurements according to 
the manufacturer’s instructions (Bio-PlexTM Mouse Cytokine 23-Plex Panel; Bio-
Rad., Hercules, CA, USA). The plasma concentrations of eotaxin, granulocyte colony 
stimulating factor (G-CSF), granulocyte-monocyte colony stimulating factor (GM-
CSF), IFNγ, interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), 
IL-12(p70), IL-13, IL-17, keratinocyte chemoattractant (KC), MCP-1/CCL2, MIP-1α /
CCL3, MIP-1β/CCL4, RANTES and TNFα were measured. Bio-PlexTM mouse cytokine 
standard values were provided by Bio-Rad Laboratories. Cytokine levels were 
determined using a Liquichip-200 multiplex array reader with Luminex x MAP™ 
technology (Bio-Rad Laboratories). The analyte concentration was calculated using 
software provided by the manufacturer (Bio-Plex Manager Software). 
Quantification of cuffed femoral artery and vein graft lesions
Immunohistochemical (IHC) staining was performed on paraffin-embedded sections, 
using positive and negative tissue-specific controls as indicated by the antibody 
manufacturer. All samples were stained with hematoxylin-phloxine-saffron (HPS) 
and specific vessel wall cellular composition was visualized using antibodies against 
leukocytes (anti-CD45 antibodies 1:200, Pharmingen, San Diego, CA, USA) and 
monocytes and macrophages (AIA 31240 1:3000, Accurate Chemical, Westbury, 
NY, USA). To evaluate if annexin A5 could affect the degree of inflammation within 
the arterial wall, cells expressing cytokines known to be important in the restenotic 
process were quantified using antibodies against TNFα (anti-TNFα 1:200, BioLegend, 
San Diego, CA, USA) and MCP-1 (anti-MCP-1 1:100, Santa Cruz Biotechnology, Santa
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Cruz, CA, USA). The number of leukocytes, macrophages, foam cells and cells 
expressing MCP-1 and TNFα attached to the endothelium or in the media of the 
femoral arteries was quantified and is displayed as a percentage of the total number 
of present cells. All quantification in this study was performed on six equally spaced 
(150µm distance) serial stained perpendicular cross-sections throughout the entire 
length of the vessel and was performed by blinded observers.
Vein grafts were stained for collagen (Sirius Red staining) and with antibodies against 
vascular SMCs (α-SM-actin 1:800, Dako, Enschede, The Netherlands), annexin A5 
(anti-annexin V 1:100, Biovision, Mountain View, CA, USA), fibrinogen and fibrin 
(anti-fibrinogen and fibrin, 1:4003) and apoptotic cells (TUNEL staining, Roche, 
Applied Sciences, Almere, The Netherlands). The area containing SMCs, collagen, 
macrophages and foam cells in vein grafts was quantified using computer-assisted 
morphometric analysis (Qwin, Leica) and is expressed as a percentage of the total 
cross-sectional vein graft area. Since there are only a few cell layers within the 
media of murine veins and no clear morphological border exists between the media 
and neointima, the region between lumen and adventitia was used to define lesion 
area and vein graft thickening. To determine the therapeutic effect of annexin A5 
on plaque instability features in vein grafts, the absolute number of apoptotic cells 
and leukocytes and signs of plaque erosion (endothelial disruption and fibrinogen 
deposition), leaky vessels (erythrocytes within newly formed vessels in the vessel 
wall) or plaque dissection (erythrocytes in a subendothelial space) were counted. 
Assessment of vascular function through endothelium-mediated dilatation
The determine therapeutic effects of annexin A5 on vascular function, EMD was 
evaluated in ApoE-/- mice after 16-17 weeks on a Western-type diet. Mice were 
treated with annexin A5 or vehicle as described above once daily for three days. 
Afterwards, mice were anaesthetized with Isofluran (Isoba®vet, Schering-Plough 
Animal Health, Denmark, 4.5% for induction and 1.5-2% for maintenance). A high 
fidelity pressure transducer (Samba Sensor preclin 420LP, Västra Frölunda, Sweden) 
was introduced into the left common carotid artery and transferred into the aortic 
arch. The Samba sensor was connected to a Samba 3200 unit, with 1000Hz as 
sample rate. Data was acquired in Powerlab (AD Instrument, v5) at 2KHz. Mice were 
allowed to stabilize for 15min after surgery.
Blood pressure measurements were performed at basal level and after IP injection 
of 3µg/kg metacholine to stimulate endothelial NO-release and vasodilatation 
(Acetyl-ß-methylcholine-chloride, 98%, Sigma-Aldrich, Stockholm, Sweden). The 
blood pressure was measured for up to 5min. When baseline pressure was again 
established, IP injection of 50mg/kg (10µl/g) Nw-Nitro-L-Arginine-methyl-ester-
hydrochloride 98% (L-NAME), a NO-synthase inhibitor, (Sigma-Aldrich) was given. 
Blood pressure was then measured until a new plateau was reached (12-15min), 
after which an additional IP injection of 3µg/kg metacholine was given and blood 
pressure was measured again for 5min. 
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Statistical analysis
All data are presented as mean ± standard error of the mean (SEM), unless otherwise 
indicated. Overall comparisons between data from groups were performed using 
the Kruskal-Wallis test. If a significant difference was found, groups were compared 
using a Mann-Whitney sum test. All statistical analyses were performed with SPSS 
14.0 software for Windows. P-values less than 0.05 were regarded as statistically 
significant and are indicated with an asterisk (*).
Table 1. Plasma cytokine concentration (pg/ml), determined using a multiplex 
biometric immunoassay in ApoE3*Leiden mice 28d after surgery and vehicle only 




Table 2. Systolic and diastolic aortic blood pressure (mmHg) in ApoE-/- mice with endothelial 
dysfunction and 3d treatment with vehicle or annexin A5, shown at basal level, 3min after 
metacholine injection, after L-NAME injection and after a combination of L-NAME with 
subsequent metacholine injection (mean±SEM, n=10).
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Abstract
Background  Immature plaque neovessels contribute to atherosclerotic plaque 
instability and intraplaque hemorrhage by leaking erythrocytes and leukocytes into 
the plaque. VEGFR2 is highly involved in neovascularization. We have previously 
shown that murine vein graft lesions exhibit plaque neovascularization and that 
intraplaque hemorrhage contributes to lesion growth. We hypothesized that 
inhibition of VEGFR2 results in increased plaque neovessel maturation and therefore 
less intraplaque hemorrhage.
Methods Donor caval veins were engrafted in carotid arteries of recipient 
hypercholesterolemic ApoE3*Leiden mice. Mice were treated with VEGFR2 
blocking antibodies (DC101) and control antibodies (10 mg/kg) at day 14, 17, 21 
and 25. Vein grafts were harvested (t28) and analyzed for vessel wall morphology 
and cell content. Fluorescent double staining of CD31 (endothelial cells) and Ter119 
(erythrocytes) was used to quantify intraplaque hemorrhage and erythrocyte 
leakage. 
Results  Treatment with DC101 resulted in a significant decrease intraplaque 
hemorrhage in the vein graft lesions. This was accompanied by a significant decrease 
in extravasated erythrocytes (control 1±0.02 mm2; DC101 0.04±0.008 mm2). DC101 
treatment however, did not affected endothelial cell growth since the number of 
neovessels per section was equal in both groups (control 52±19; DC101 63±25) and 
also endothelial coverage of the lumen was not affected (control 92±9%; DC101 
94±7%). Interestingly, the vessel wall thickening in the DC101 group was reduced 
with 32% compared to the control group. This coincided with increased collagen 
and SMC content, indicative for a more stable lesion phenotype. 
Conclusions  Inhibition of VEGF receptor 2 resulted in a decrease in vessel 
wall thickening and reduced intraplaque hemorrhage. Targeting of plaque 




Numerous studies have suggested plaque composition as an independent risk 
factor for cardiovascular diseases1,2. Plaque characteristics such as necrotic core 
size, thickness of fibrous caps, lipid content and the presence of calcifications, 
inflammatory cells, plaque neovascularization and intraplaque hemorrhage together 
determine the stability of the plaque3. Intraplaque hemorrhage might induce lesion 
growth, instability and plaque rupture since the extent of intraplaque hemorrhage 
has been shown to correlate with progression stage, inflammatory content of the 
plaque and clinical outcome in cardiovascular events4,5. Dysfunctional neovessels 
that leak erythrocytes, leukocytes, and blood platelets into the plaque are the most 
prominent contributors to intraplaque hemorrhage6.
Neovessels in the plaque originate either from adventitial vasa vasorum or the 
luminal endothelium and are triggered by the hypoxic environment caused by 
metabolically active inflammatory cells, especially macrophage foam cells7,8. 
A gradient of vascular endothelial growth factor (VEGF), the most important 
angiogenic factor, triggers endothelial cells to penetrate into the lesions and form 
a vascular network.  VEGF binds to and mediates its activity primarily through 
the VEGF receptor 2 (VEGFR2)9. The nascent vessels in the newly formed vascular 
network are highly unstable and need supporting mural cells (pericytes) to become 
mature vessels.  Vessel stabilization involves generation of a basement membrane 
and recruitment of pericytes and is strongly regulated by VEGF-VEGFR2 interactions 
and the angiopoietin system10. Immature or dysfunctional neovessels are 
susceptible to inflammatory mediators, which could lead to impaired functionality 
and increased permeability, caused by deteriorated inter-endothelial junctions, 
basement membrane detachment and incomplete pericyte coverage11. 
It has been demonstrated that pro-angiogenic strategies enhances atherosclerotic 
plaque growth and vascular inflammation whereas anti-angiogenic strategies 
reduces atherosclerosis in experimental animal models12-17. Most murine models of 
atherosclerosis however, lack clear plaque neovascularization. Therefore, the direct 
role of angiogenic therapy on plaque neovascularization remains to be determined. 
Recently, we have shown that lesions, induced by vein grafting in mice with an 
atherosclerotic background, are complex and display human-like lesion features 
including plaque neovascularization and intraplaque hemorrhage18, rendering this 
an excellent model to study plaque neovascularization. 
We hypothesized that the maturation state of plaque neovessels would determine 
the extent of leakiness of these vessels and thereby would influence intraplaque 
hemorrhage, plaque stability and lesion progression. For this purpose we 
investigated the role of VEGF receptor 2 blockade by anti-VEGFR2 antibodies19 on 






This study was performed in compliance with Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament.  All animal experiments were 
approved by the animal welfare committee of the Leiden University Medical Center.
Male ApoE3*Leiden mice (bred in our own colony), 10-16 weeks old, were fed a 
diet containing 1% cholesterol and 0.5% cholate to induce hypercholesterolemia 
(ABdiets, Woerden, The Netherlands) from 3 weeks prior to surgery until sacrifice. 
This resulted in plasma cholesterol levels between 20 and 30 mmol/l ((Roche 
Diagnostics, kit 1489437, Almere, The Netherlands). Before surgery, mice were 
anesthetized with midazolam (5 mg/kg, Roche Diagnostics), medetomidine (0.5 
mg/kg, Orion, Espoo, Finland) and fentanyl (0.05 mg/kg, Janssen Pharmaceutica, 
Diegum, Belgium). After the procedure the mice were antagonized with atipamezol 
(2.5 mg/kg, Orion) and fluminasenil (0.5 mg/kg Fresenius Kabi, Schelle, Belgium). 
Buprenorphine (0.1 mg/kg, MSD Animal Health, Boxmeer The Netherlands) was 
given after surgery to relieve pain.
Vein graft model 
Vein graft surgery was performed by donor caval vein interpositioning in the 
carotid artery of recipient mice as described before20. In brief, thoracal caval veins 
from donor littermates were harvested. In recipients, the right carotid artery was 
dissected and cut in the middle. The artery was everted around the cuffs that were 
placed at both ends of the artery and ligated with 8.0 sutures. The caval vein was 
sleeved over the two cuffs, and ligated. Animals were sacrificed after 3 minutes 
of in vivo perfusion-fixation, next, vein grafts were harvested and fixed in 4% 
formaldehyde, dehydrated and paraffin-embedded for histology18.
Treatment
Mice were treated with intraperitoneal injections of rat VEGF-receptor 2 IgG 
monoclonal antibodies (DC101 Bio X cell, West Lebanon NH USA) (n=14) or control 
rat IgG antibodies (10 mg/kg) (n=12) at day 14, 17, 21 and 25. Treatment was started 
at t14 since plaque neovascularization in vein graft lesions was observed from this 
time point on (data not shown).
Histological and immunohistochemical assessment of vein grafts
Paraffin embedded cross sections were routinely stained with hematoxylin-phloxine-
saffron (HPS). Sirius red staining was used to detect collagen. Antibodies directed 
at smooth muscle cell (SMC) actin (Sigma-Aldrich, St. Louis, MO, USA), CD31, CD45 
(both from BD/Pharmingen, Heidelberg, Germany), TER119 (erythrocytes, Santa 
Cruz, CA, USA) angiopoietin (ANG)-1 (LS Bio, Seattle, USA) and ANG-2 (Abnova, 
Heidelberg, Germany). For each antibody, isotype-matched antibodies were used 
as negative controls and positive staining was absent in these sections.
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Morphometric analysis of vein grafts
Morphometric analysis of vein grafts harvested after 28d was performed using 
image analysis software (Qwin, Leica, Wetzlar, Germany). For each mouse eight 
equally spaced (150 µm apart) cross-sections were used to determine lesion size 
and occurrence of intraplaque hemorrhage over a total vein graft length of 1050 
µm. Since elastic laminae do not exist in these grafts of venous origin, we analyzed 
the putative vessel wall area (or lesion area) by measuring total vessel area (the area 
of the vessel wall within the adventitia and the lumen area. Next the lesion area 
was calculated (total vessel area – lumen area).  (Immuno)histochemical stainings 
were quantified by computer assisted analysis (Qwin, Leica). For this immuno-
positive areas in vein grafts were expressed as percentage of the lesion area. Vein 
graft segments were analyzed for influx of leukocytes (CD45) by scoring cells in 6 
consecutive sections per mouse in a semi-quantitative manner. 1: < 50 positive cells 
/section, 2:  50-200 positive cells/section, 3: >200 positive cells.
Morphologic analyses of intraplaque hemorrhage
Intraplaque hemorrhage was scored using CD31/TER119 fluorescent double-
stained sections. Lesions where erythrocytes were found adjacent to neovessels 
were regarded as lesions with intraplaque hemorrhage. Analysis of the extravasated 
erythrocytes was performed by quantification of the total erythrocyte area in the 
lesion, followed by subtraction of the area of erythrocytes within the CD31 stained 
neovessels.
Statistical analysis
Results are expressed as mean±SEM. Data were analyzed by the Mann-Whitney 
test using GraphPad Prism. Probability-values <0.05 were regarded significant.
Results
VEGFR-2 blocking antibodies inhibit intraplaque hemorrhage and erythrocyte 
extravasation
Intraplaque hemorrhage, characterized by extravasation of erythrocytes to the 
perivascular region, was more frequently found in the control group (10 out of 12 
mice), whereas only 7 out of 14 mice in the DC101 treated group exhibited leaky 
vessels.  Moreover, the length of the vein graft segment that displayed intraplaque 
hemorrhage was clearly smaller in the DC101 group than the length of the segments 
displaying intraplaque hemorrhage detected in the control group (p=0.040), Figure 
1A, B.  To further investigate the contribution of extravasated erythrocytes to the 
lesions we analyzed the lesion-area that was occupied by perivascular erythrocytes. 
The DC101 treated group displayed a perivascular erythrocyte-area that was 25-fold 
smaller than that of the control group (control; 1± 0.02 mm2; DC101; 0.04±0.008 
mm2, p=0.047), Figure 1C. Perivascular erythrocytes were observed
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especially, in the regions near the adventitia and in the mid portion of the vein graft 
lesions, Figure 1D.
Figure 1. Intraplaque hemorrhage and erythrocyte extravasation  A. Quantification of the 
length of the vein graft segment that displayed intraplaque hemorrhage. B. Representative 
examples of lesions with intraplaque hemorrhage. C. Quantification of the area of 
the extravasated erythrocytes. D. Representative images of lesions with extravasated 
erythrocytes. Green; erythrocytes, Red; endothelial cells.
Luminal endothelium coverage and neovessel density are not affected by VEGFR-2 
blockade
The vein graft model is characterized by denudation of the luminal endothelium 
in the early stages after engraftment, which is restored at later stages20.  To study 
the involvement of VEGFR-2 in endothelial restoration of the luminal surface, the 
percentage of the lumen that was covered by endothelial cells was quantified by
92
using a specific endothelial cell marker, CD31.  28 Days after surgery, both in the 
group treated with VEGFR-2 blocking antibodies (DC101) and the control group 
the endothelium was almost completely restored (control; 92±9%; DC101; 94±7%, 
p=0.644), Figure 2A, B. Next, we investigated the anti-angiogenic effects of blocking 
VEGFR-2 by analyzing the neovessel density in the vein graft lesions. In the DC101 
group an average of 63±25 neovessels per vein graft sections were observed 
whereas in the control IgG treated group 52±19 neovessels per vein graft sections 
were found. VEGFR2 blockade did not affected the angiogenic capacity of the 
lesions since the number of neovessels per section was not significantly different in 
the groups (p=0.327), Figure 2C. Neovessels were found in all regions of the lesion 
(Figure 1D), although higher densities of neovessels were often seen in the mid-
portion of the lesions.
Figure 2. Re-endothelialization and neovessel density. A. Quantification of endothelial cell 
coverage of the lumen as measured by CD31 staining and expressed as % coverage. B. CD31 
positive endothelial cells lining the luminal surface of the vein graft. Typical examples from 
the control IgG treated group and the DC101 treated group. C. Quantification of the density 
of neovessels in vein graft sections expressed as the number of neovessel per section. D. 
CD31 positive neovessels in the vein graft. Green; erythrocytes, Red; endothelial cells. 
93
5
Figure 3. Angiopoietin (Ang) expression in lesion with and without intraplaque hemorrhage. 
A. Ang-1 (upper panel, 10x and 40x magnification) and Ang-2 (lower panel 10x and 40x 
magnification) staining of a stable vein graft lesion co-stained with SMC actin and 
Erythrocytes. B. Ang-1 (upper panel, 10x and 40x magnification) and Ang-2 (lower panel 
10x and 40x magnification) staining of a vein graft lesion with intraplaque hemorrhage co-
stained with SMC actin and Erythrocytes. Green; Ang, Blue; SMC actin, Red; erythrocytes.
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Angiopoietin expression is augmented in intraplaque hemorrhage regions
Angiopoietins are highly involved in vessel stabilization, Ang-1 is involved in 
recruitment of pericytes whereas Ang-2 is thought to antagonize Ang-1function. We 
therefore examined the expression of Ang-1 and Ang-2 in lesions with and without 
intraplaque hemorrhage. Ang-1 and Ang-2 expression together with SMC actin and 
erythrocyte staining is shown in a stable lesion, Figure 3A. Ang-1 staining (upper 
panel) was found to be sparsely and diffusely expressed in stable lesions with the 
highest expression in the adventitia. In contrast, Ang-2 staining (lower panel) was 
clearly cell membrane bound and expressed on almost all cell types in the vein 
graft lesions including smooth muscle cells. Both Ang-1 and Ang-2 were strongly up 
regulated in areas of intraplaque hemorrhage (Figure 3B). Ang-1 was predominantly 
expressed in intraplaque hemorrhage regions whereas no staining in the SMC rich 
areas of the lesions could be observed. Ang-2 showed increased expression in 
lesions with intraplaque hemorrhage in contrast to stable lesions, this expression 
was not restricted to the intraplaque hemorrhage areas.
Figure 4. Quantitative measurements of vein graft area. A. Representative cross-sections of 
vein grafts in mice treated with control IgG antibodies VEGFR2 blocking antibodies (DC101, 
10 mg/kg), 28 days after surgery (Hematoxilin-Phloxine-Saffron staining). Quantitative 
measurements of B. vein graft thickening, C. total vessel area and D. luminal area.
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VEGFR-2 blocking antibody treatment moderates vein graft thickening
As a result of the decreased intraplaque hemorrhage after DC101 treatment 
we speculated that the lesion area of the vein graft was also affected. Indeed, 
quantification revealed that the DC101 treated group showed a reduction of 32% 
in vein graft thickening compared to the control IgG treated group (control; 1.56± 
0.02 mm2; DC101; 1.05±0.09 mm2, p=0.045), Figure 4A and B. Outward remodeling 
as measured by the total vessel area was increased in the DC101 treated group 
(control; 2.06± 0.34 mm2; DC101; 1.39±0.10 mm2, p=0.053), Figure 4C. The luminal 
area however, was not altered by the DC101 treatment (control; 0.049± 0.16 mm2; 
DC101; 0.034±0.07 mm2, p=0.369), Figure 4D.
Figure 5. Lesion composition. A. Quantitative measurement of the collagen content in vein 
grafts of control and DC101 treated mice expressed as collagen area. B. Relative percentage 
collagen in the vein grafts. C. Quantitative measurement of the smooth muscle cell (SMC) 
content in vein grafts expressed as SMC area. D. Relative percentage SMC in the vein grafts. 
E. Semi-quantitative score of leukocytes (CD45+ cells) in the lesions. 1: < 50 positive cells / 
section, 2:  50-200 positive cells / section, 3: >200 positive cells.
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DC101 treatment results in a more stable phenotype
Next the effects on vein graft lesion composition were assessed. VEGFR2 blockade 
resulted in a significant enhancement of stability improving factors. An enhanced 
collagen content was observed in the group treated with VEGFR2 antibodies 
(control: 0.21±0.04 mm² vs. DC101: 0.31±0.04 mm², p=0.068, Figure 5A), when 
corrected for the differences in vein graft thickening, the relative percentage of 
collagen was significantly increased in the DC101 treated group (control: 16.9±2.4% 
vs. DC101: 26.0±3.1% p=0.049, Figure 5B).  In addition, an increase in smooth 
muscle cell area was observed in the DC101 group as shown in absolute  aSMA 
positive area (control: 0.11±0.01 mm² vs. DC101: 0.25±0.04 mm², p=0.004, Figure 
5C) and when corrected for the vein graft thickening in both groups this was still 
significant different (control: 10.1±1.3% vs. DC101: 22.0±2.3% p=0.01, Figure 5D). 
As a measure for inflammatory status of the lesion, the numbers of leukocytes were 
scored by semi-quantitative analysis of anti-CD45 stained sections. No differences 
in the leukocytes numbers were observed between the groups (control: 1.6±0.18 
arbitrary units vs. DC101: 1.5±0.17 arbitrary units p=0.769, Figure 5E).   
Discussion
Immature intraplaque neovessels have been characterized as the main contributors 
to intraplaque hemorrhage. However, most of the evidence for both processes is 
descriptive in nature4,6,11. In the present study we examined the effects of VEGFR2 
blockade on intraplaque hemorrhage in a murine model of vein graft disease. VEGFR2 
blockade led to a striking decrease in intraplaque hemorrhage. This coincided with a 
significant reduction in extravasated erythrocytes in the lesions and stabilization of 
the lesions.  It has been reported that intraplaque erythrocytes contribute to free 
cholesterol deposition and cholesterol crystal formation in atherosclerotic plaques 
as a result of membrane-cholesterol retention21. Phagocytosis of intraplaque 
erythrocytes and erythrocyte–derived cholesterol by neovessel-associated 
macrophages results in ceroid formation, plaque expansion and promotion of 
unstable lesions6,22. Systematic DC101 treatment resulted in a reduction of vein 
graft thickening and increased plaque stabilizing factors, collagen and SMCs. These 
data imply that blockade of VEGFR2 help to maintain plaque stability.   Binding of 
VEGF to VEGFR2 induces NF-κB activation and elevated expression levels of VCAM-
1, ICAM-1, and E-selectin in endothelial cells leading to increased adherence of 
leukocytes. The number of leukocytes in the vein graft lesions however was not 
affected by VEGFR2 blockade suggesting that this route is not responsible for the 
effects seen.
VEGFR2 is involved in this plaque neovacularization as the main VEGF receptor on 
endothelial cells. Plaque neovessels originate from the adventitia and lumen via 
the process of angiogenesis. VEGFR2 mediates the permeability enhancing effects 
of VEGF in adult endothelial cells and is involved in tip-cell-stalk-cell differentiation 
in the early phase of angiogenesis9. Remarkably, treatment with VEGFR2 blocking
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antibodies did not result in a reduction of neovessel density in comparison to 
control IgG treated vein grafts. Treatment of tumors in murine models with the 
same antibodies (DC101) resulted in clear inhibition of angiogenesis19,23. Pathological 
and mechanistic differences between tumors and atherosclerotic plaques may 
account for the  contrasting effects on angiogenesis by DC101. However, an effect 
of differences in dosages used in the various models cannot be excluded.
For a vessel to become functional it must become mature and stable via basement 
membrane establishment and coverage of pericytes9. We have previously shown 
that most plaque neovessels in vein grafts of hypercholesterolemic mice express 
a basement membrane. The coverage with pericytes was very heterogeneous 
especially, the neovessels in regions of intraplaque hemorrhage lacked pericyte 
coverage18. Incomplete pericyte coverage in regions of intraplaque hemorrhage 
was also observed in human atherosclerotic plaques11,24,25. In  both murine and 
human tumors, it has been demonstrated that VEGF signal blockade increases the 
fraction of vessels that are covered with mural cells26,27. Blockade of VEGFR2 by 
DC101 has been shown to facilitate the recruitment of pericytes to tumor vessels by 
enhancing Ang-1 expression and increasing perivascular matrix metalloproteases 
activity28. The angiopoietin-Tie2 system is essential for stabilization of immature 
neovessels10. Ang-1 decreases endothelial cell permeability and increases vascular 
stabilization via enhancing endothelial cell interactions with the surrounding 
matrix and recruitment of pericytes to growing blood vessels. Ang-2 functions as a 
competitive Ang-1 antagonist in a VEGF-depend manner and mediates angiogenic 
sprouting and vascular regression. Post et al.29 showed that in plaques with high 
neovessel density, the local balance between Ang-1 and Ang-2 is in favor of Ang-
229. This concurs with our finding that in regions of intraplaque hemorrhage Ang-
2 expression exceeds that of Ang-1. Interestingly, both angiopoietins showed 
increased expression in unstable lesions compared to stable lesions this in contrast 
to other studies which observed down regulation of Ang-1 and up regulation of Ang-
2 in regions of hemorrhagic bloodvesssels30.  This is conceivable as VEGF expression 
determines Ang-2 function as an Ang-1 antagonist9 although we have not examined 
VEGF expression in these lesions.
In summary, VEGFR2 blockade inhibits intraplaque hemorrhage and erythrocyte 
extravasation resulting in decreased lesion development and plaque stabilization. 
Increased maturation of plaque neovessels are thought to be the key mechanism 
behind this process. These results indicate that VEGFR2 on the endothelium of 




 (1)  Hellings WE, Peeters W, Moll FL, Piers SR, van SJ, Van der Spek PJ, de Vries JP, Seldenrijk KA, De 
Bruin PC, Vink A, Velema E, de Kleijn DP, Pasterkamp G. Composition of carotid atherosclerotic 
plaque is associated with cardiovascular outcome: a prognostic study. Circulation 2010 May 
4;121(17):1941-50.
 (2)  Takaya N, Yuan C, Chu B, Saam T, Polissar NL, Jarvik GP, Isaac C, McDonough J, Natiello C, Small 
R, Ferguson MS, Hatsukami TS. Presence of intraplaque hemorrhage stimulates progression 
of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. 
Circulation 2005 May 31;111(21):2768-75.
 (3)  Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011 
March;12(3):204-12.
 (4)  Michel JB, Virmani R, Arbustini E, Pasterkamp G. Intraplaque haemorrhages as the trigger of 
plaque vulnerability. Eur Heart J 2011 March 12.
 (5)  Derksen WJ, Peeters W, van Lammeren GW, Tersteeg C, de Vries JP, de Kleijn DP, Moll FL, van 
der Wal AC, Pasterkamp G, Vink A. Different stages of intraplaque hemorrhage are associated 
with different plaque phenotypes: a large histopathological study in 794 carotid and 276 
femoral endarterectomy specimens. Atherosclerosis 2011 October;218(2):369-77.
 (6)  Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. 
Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of 
intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005 October;25(10):2054-61.
 (7)  Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens 
JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnens AP. Hypoxia, hypoxia-inducible 
transcription factor, and macrophages in human atherosclerotic plaques are correlated with 
intraplaque angiogenesis. J Am Coll Cardiol 2008 April 1;51(13):1258-65.
 (8)  Parathath S, Mick SL, Feig JE, Joaquin V, Grauer L, Habiel DM, Gassmann M, Gardner LB, Fisher 
EA. Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on 
macrophage lipid metabolism. Circ Res 2011 October 28;109(10):1141-52.
 (9)  Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 
2011 May 19;473(7347):298-307.
 (10)  Jain RK. Molecular regulation of vessel maturation. Nat Med 2003 June;9(6):685-93.
 (11)  Sluimer JC, Kolodgie FD, Bijnens AP, Maxfield K, Pacheco E, Kutys B, Duimel H, Frederik PM, 
van Hinsbergh VW, Virmani R, Daemen MJ. Thin-walled microvessels in human coronary 
atherosclerotic plaques show incomplete endothelial junctions relevance of compromised 
structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol 2009 April 
28;53(17):1517-27.
 (12)  Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial 
growth factor enhances atherosclerotic plaque progression. Nat Med 2001 April;7(4):425-9.
 (13)  Lucerna M, Zernecke A, de NR, de Jager SC, Bot I, van der Lans C, Kholova I, Liehn EA, van 
Berkel TJ, Yla-Herttuala S, Weber C, Biessen EA. Vascular endothelial growth factor-A induces 
plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood 
2007 January 1;109(1):122-9.
 (14)  Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian 
K, Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and 
progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 2003 April 15;100(8):4736-
41.
 (15)  Hauer AD, van Puijvelde GH, Peterse N, de VP, van W, V, van Wanrooij EJ, Biessen EA, Quax 
PH, Niethammer AG, Reisfeld RA, van Berkel TJ, Kuiper J. Vaccination against VEGFR2 
attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2007 
September;27(9):2050-7.
 (16)  Heinonen SE, Kivela AM, Huusko J, Dijkstra MH, Gurzeler E, Makinen PI, Leppanen P, Olkkonen 
VM, Eriksson U, Jauhiainen M, Yla-Herttuala S. The Effects of VEGF-A on Atherosclerosis, 
Lipoprotein Profile and Lipoprotein Lipase in Hyperlipidemic Mouse Models. Cardiovasc Res 
2013 June 10.
 (17)  Winnik S, Lohmann C, Siciliani G, von LT, Kuschnerus K, Kraenkel N, Brokopp CE, Enseleit 
F, Michels S, Ruschitzka F, Luscher TF, Matter CM. Systemic VEGF inhibition accelerates 
experimental atherosclerosis and disrupts endothelial homeostasis - implications for 
cardiovascular safety. Int J Cardiol 2013 April 2.
99
5
 (18)  de Vries MR, Niessen HW, Lowik CW, Hamming JF, Jukema JW, Quax PH. Plaque Rupture 
Complications in Murine Atherosclerotic Vein Grafts Can Be Prevented by TIMP-1 
Overexpression. PLoS One 2012;7(10):e47134.
 (19)  Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P. Monoclonal antibodies 
targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer 
Metastasis Rev 1998 June;17(2):155-61.
 (20)  Lardenoye JH, de Vries MR, Lowik CW, Xu Q, Dhore CR, Cleutjens JP, van Hinsbergh VW, van 
Bockel JH, Quax PH. Accelerated atherosclerosis and calcification in vein grafts: a study in 
APOE*3 Leiden transgenic mice. Circ Res 2002 October 4;91(7):577-84.
 (21)  Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase 
M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary 
atheroma. N Engl J Med 2003 December 11;349(24):2316-25.
 (22)  Kockx MM, Cromheeke KM, Knaapen MW, Bosmans JM, De Meyer GR, Herman AG, Bult H. 
Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human 
atherosclerosis. Arterioscler Thromb Vasc Biol 2003 March 1;23(3):440-6.
 (23)  Lee YJ, Karl DL, Maduekwe UN, Rothrock C, Ryeom S, D’Amore PA, Yoon SS. Differential effects 
of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. 
Cancer Res 2010 November 1;70(21):8357-67.
 (24)  Dunmore BJ, McCarthy MJ, Naylor AR, Brindle NP. Carotid plaque instability and ischemic 
symptoms are linked to immaturity of microvessels within plaques. J Vasc Surg 2007 
January;45(1):155-9.
 (25)  Le DJ, Ho-Tin-Noe B, Louedec L, Meilhac O, Roncal C, Carmeliet P, Germain S, Michel JB, 
Houard X. Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic 
degradation of angiogenic factors. Cardiovasc Res 2010 January 1;85(1):184-93.
 (26)  Willett CG, Boucher Y, di TE, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin 
SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, 
Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-
specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004 
February;10(2):145-7.
 (27)  Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, 
Thurston G, Yancopoulos GD, McDonald DM. Inhibition of vascular endothelial growth factor 
(VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, 
and appearance of basement membrane ghosts. Am J Pathol 2004 July;165(1):35-52.
 (28)  Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di TE, 
Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor 
response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. 
Cancer Cell 2004 December;6(6):553-63.
 (29)  Post S, Peeters W, Busser E, Lamers D, Sluijter JP, Goumans MJ, de Weger RA, Moll FL, 
Doevendans PA, Pasterkamp G, Vink A. Balance between angiopoietin-1 and angiopoietin-2 is 
in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 
2008;45(3):244-50.
 (30)  Hashimoto T, Lam T, Boudreau NJ, Bollen AW, Lawton MT, Young WL. Abnormal balance in 




C57BL/6 NK Cell gene complex crucially 
involved in vascular  remodeling and 
intimal hyperplasia
Margreet R. de Vries1,2, Leonard Seghers1,2,3, Jeroen van Bergen4, Erna H.A.B. 
Peters1,2, Rob C.M. de Jong1,2, Jaap F. Hamming1, René E.M. Toes5, Victor W.M. van 
Hinsbergh3, Paul H.A. Quax1,2 
1Department of Surgery, Leiden University Medical Center, Leiden, 2Einthoven 
Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 
Leiden, The Netherlands, 3Department of Physiology, Institute for Cardiovascular 
Research, VU University Medical Center, Amsterdam, The Netherlands, 4Department 
of Immunohematology and Blood Transfusion, Leiden University Medical Center, 
Leiden, The Netherlands, 5Department of Rheumatology, Leiden University Medical 
Center, Leiden, The Netherlands
J Mol Cell Cardiol. 2013 Nov;64C:51-58.
Abstract
Objective    NK cells are known to be involved in cardiovascular disease processes. 
One of these processes, vascular remodeling, may strongly differ between 
individuals and mouse strains such as the C57BL/6 and BALB/c. Moreover, C57BL/6 
and BALB/c mice vary in immune responses and in the composition of their Natural 
Killer gene Complex (NKC). Here we study the role of NK cells, and in particular the 
C57BL/6 NKC in vascular remodeling and intimal hyperplasia formation.
Methods and Results  C57BL/6, BALB/c and CMV1r mice, a BALB/c strain congenic 
for the C57BL/6 NKC, were used in an injury induced cuff model and a vein graft 
model. NK cell depleted C57BL/6 mice demonstrated a 43%  reduction in intimal 
hyperplasia after femoral artery cuff placement compared to control C57BL/6 mice 
(p<0.05). Cuff placement and vein grafting resulted in profound intimal hyperplasia 
in C57BL/6 mice, but also in CMV1r mice, whereas this was significantly less in 
BALB/c mice. Significant more leukocyte infiltrations and IFNγ staining were seen in 
both C57BL/6 and CMV1r vein grafts compared to BALB/c vein grafts. 
Conclusions  These data demonstrate an important role for NK cells in intimal 
hyperplasia and vascular remodeling. Furthermore, the C57BL/6 NKC in CMV1r 
mice stimulates vascular remodeling most likely through the activation of (IFNγ-
secreting) NK-cells that modulate the outcome of vascular remodeling.
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Introduction
Vascular remodeling is a multi-factorial process that induces structural alteration 
of the vascular wall1. Remodeling of the vessel wall is a significant factor in the 
manifestation of atherosclerosis, vein graft disease, arteriogenesis2 and restenosis3,4 
but also in pulmonary arterial hypertension (PAH)5 and decidua formation6,7. 
NK cells, a small subset of leukocytes, are known for direct killing of cells depending 
on their expression of NK-cell receptors specific for MHC class I molecules. NK 
cells respond upon activation by secretion of lytic granules containing perforin 
and granzymes, but also by secretion of interferon gamma (IFNγ), Tumor Necrosis 
Factor alpha (TNFα) and chemokines such as CCL3, CCL4 and CCL5. NK cells can be 
activated by CCL2, IL12 and IL18. Furthermore, NK cells  influence other immune 
cells such as T cells, macrophages and dendritic cells directly by cell to cell contact or 
indirectly via cytokines8. Chemokines and cytokines involved in NK cell function are 
extensively researched and are proven modulators of vascular remodeling9. It has 
been demonstrated that NK cells contribute to atherosclerosis10, arteriogenesis2, 
PAH11 and decidua formation (uterine NK cells)6 but their precise role in intimal 
hyperplasia formation and vascular remodeling is not clear.
Patients differ in vascular remodeling capacity, as observed in atherosclerotic 
plaques and collateral artery growth12,13. It is suggested that this is due to differences 
in immune response. This is supported by strain dependent differences in vascular 
remodeling between mouse strains14. Especially differences in vascular responses 
between BALB/c and C57BL/6 are extensively investigated2,15,16. The differences in 
response are associated by a different immune bias between these two strains; 
C57BL/6 mice express a pro-inflammatory, T helper 1 (Th1)-associated profile 
whereas BALB/c mice show a repair-associated or Th2-like immune response17. 
Immuno-genetic differences between these two strains are found in the Natural 
Killer gene complex (NKC). The NKC is a gene locus on chromosome 6 encoding 
multiple activating and inhibitory NK cell receptors such as NKG2D, Nkrp1c (NK1.1), 
CD94/NGK2, and the highly polymorphic Ly49 receptor family18,19. Compared to 
C57BL/6, BALB/c mice lack a 200kb region encoding members of the Ly49 receptor 
family. As a consequence the BALB/c strain has only eight Ly49 genes, whereas the 
C57BL/6 NKC possesses fifteen Ly49 genes20,21. 
Scalzo and colleagues generated a congenic BALB.B6-CMV1r mouse (CMV1r)22. By 
the expression of the entire C57BL/6 NK cell receptor repertoire, these BALB/c mice, 
exhibit a level of resistance towards murine cytomegalovirus (CMV) comparable to 
that of C57BL/6 mice23, rendering these mice resistant to CMV infections, unlike 
the BALB/c mice. We used this strain in comparison to BALB/c and C57BL/6 mice to 
study the involvement of the NKC in vascular remodeling.
Here we show that NK cells are involved in vascular remodeling as demonstrated 
by decreases in intimal hyperplasia in NK deficient mice and after NK cell depletion 
in an injury-induced restenosis model. In particular we demonstrate that the NKC is 
involved in vascular remodeling since expression of the C57BL/6 NKC in BALB/c mice
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results in a vascular remodeling that is comparable with that observed in C57BL/6 
mice, with a shift towards an immune response characterized by IFNγ production. 
Materials and methods
Mice
Animal experiments were approved by the LUMC-animal welfare committee. For all 
experiments male mice were used, aged 12-16 weeks. C57BL/6 mice and BALB/c mice 
(Charles River) were purchased. Jα281-knockout mice (C57BL/6 background) were 
kindly provided by Dr Masaru Taniguchi24. BALBc.B6-CMV1r and NK-cell deficient 
(NK-/-) breeding couples were kindly provided by Dr. W. M. Yokoyama25. All animals 
received chow diet and water ad libitum. For surgery, mice were anesthetized by 
using midazolam (5 mg/kg, Roche), medetomidine (0.5 mg/kg, Orion) and fentanyl 
(0.05 mg/kg, Janssen Pharmaceutica). After the procedures mice were antagonized 
with atipamezol (2.5 mg/kg, Orion) and fluminasenil (0.5 mg/kg Fresenius Kabi).
Cuff induced intimal hyperplasia mouse model
Both left and right femoral arteries were dissected from their surroundings. A non-
constrictive polyethylene cuff (inner diameter 0.4mm, Portex) was placed loosely 
around the femoral artery bilaterally and kept in situ for 21 days26. Tissue handling 
and analysis of intimal hyperplasia was performed as described27. For quantification 
of intimal thickening, elastic laminae were visualized with Weigert’s elastin staining. 
Six sequential representative sections per vessel segment were used to quantify 
the amount of intimal hyperplasia, using image analysis software (Qwin, Leica).
Vein graft mouse model
Venous interpositions were placed in the mouse carotid artery as described 
previously27. Caval veins of donor mice were engrafted in the left carotid artery of 
recipient mice. Mice were sacrificed 28 days after surgery for histological analysis. 
Vein graft segments were harvested after perfusion fixation with 4% formaldehyde, 
fixated overnight and paraffin-embedded. Cross-sections were made throughout 
the embedded vein grafts. Six representative sections per vessel segment were 
stained with Haematoxylin-Phloxin-Saffron (HPS) for histological and morphometric 
analysis (Leica). Vein graft thickening was defined as the area between lumen and 
adventitia and determined by subtracting the luminal area from the total vessel 
wall area.
Immunohistochemistry
NK cells were detected with a FITC labeled DX5 (CD49b) antibody (Ebioscience) and 
DAPI (Vector) on 5 μm-thick frozen section of native femoral artery (n=6), native 
caval vein (n=6), cuffed femoral arteries 21 days after surgery (n=6) and vein grafts 
28 after surgery (n=6), all on a C57BL/6 background.
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Immunohistochemical staining for CD45 and IFNγ were performed on 5 μm-thick 
paraffin-embedded sections of vein grafts that were incubated overnight with a 
primary antibody against CD45 (BD Pharmingen) or IFNγ (Bio-connect). Negative 
controls with isotype matched antibodies were run for each sample. 
Vein graft segments were analyzed by scoring the quantity of cells in a range 
from 1 to 3 in  consecutive sections per mouse. 1: < 25 positive cells/section, 2: 
25-50 positive cells/ section, 3: >50 CD45 positive cells/section. Scores from each 
individual mouse were averaged.
NK cell depletion
For depletion of NK cells, C57Bl6 mice received intraperitoneal injections of 200µg 
of anti-NK1.1 antibody (PK136) or an isotype-matched mouse IgG2a control 
antibody 5 days, 3 days and 1 day before surgery, and twice a week after surgery. 
Depletion was confirmed in peripheral blood by fluorescence-activated cell sorting 
(FACS) -analysis using antibodies against NK1.1 and CD3 (BD Biosciences) just before 
surgery and 14 days after surgery.
NK cell activation assay  
1 x 107 splenocytes were cultured in wells of a 24-wells plate coated with either 
anti-NKp46 antibody (R&D Systems) isotype-matched control (goat IgG, R&D 
Systems) antibody (both at 5µg/well), or in medium containing 0.1 µg/ml Phorbol 
12-Myristate 13-Acetate (PMA) and 0.5 µg/ml ionomycin (Sigma-Aldrich). 
Intracellular staining for IFNγ (BD Biosciences) was performed after a 4h incubation 
at 37˚C in the presence of Brefeldin A. Percentages of IFNγ producing NK cells were 
obtained by gating CD3ε-, DX5+ cells during FACS analysis on BD FACS LSR II using BD 
FACS Diva software v6.0 (BD Biosciences). 
Statistical analysis
Results are expressed as mean±SEM. For in vivo testing comparisons between 
medians were performed using the Kruskall Wallis or Mann Whitney test. For in 
vitro NK cell responsiveness a two-tailed Student’s t-test was used. P-values <0.05 
were regarded statistically significant.
Results
Presence of NK cells in remodeled vascular tissues
To demonstrate NK cells in remodeled vessels, immunohistochemistry was 
performed with antibodies directed at the NK marker LY49H (DX5).  NK cells could 
be demonstrated in tissue sections of cuffed femoral arteries (Figure 1B), although 
in limited amounts. Most NK cells that were seen in these sections were located in 
the adventitial region. Comparable numbers of NK cells were found in 3 days old 
cuffed femoral arteries in C57BL/6, BALB/c and CMV1r mice (online supplement; 
Figure 1). No NK cells were found in sections of uninjured femoral arteries (Figure
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1A) or in native caval veins (Figure 1C, D). NK cells could be detected in the intimal 
hyperplasia of vein grafts 28 day after surgery as demonstrated in Figure 1E and F.
Figure 1. NK cells in remodeled vessels. A. Representative microscopic photograph of an 
uninjured femoral artery (C57BL/6 mouse) stained with FITC-labeled DX5 antibody and 
DAPI. No NK cells could be detected in n=6 uninjured femoral arteries. B. Typical example 
of a FITC-labeled NK cell (arrow) in the adventitia of a cuffed femoral artery 21 days after 
surgery (C57BL/6 mouse). C,D. NK cell were also not found in 6 individual native C57BL/6 
caval veins (C 10x magnification, D 40 X magnification). E,F. NK cells were present in the 
intimal hyperplasia of C57BL/6 vein grafts 28 days after surgery as depicted by the white 
arrows in E (10x magnification) and F (40x magnification). L indicates the lumen.
NK cells, but not NKT cells, contribute to arterial intimal hyperplasia
To demonstrate a role for NK cells in vascular remodeling, NK cells were depleted 
using antibodies directed at NK1.1 in C57BL/6 mice that subsequently received a 
non-constrictive cuff around the femoral artery (n=10 mice/group). Flowcytometric 
(FACS) analysis of peripheral blood samples on the day of surgery confirmed that 
NK-cell depletion had been successful: average NK cell percentages of lymphocyte 
population: NK1.1 0.16±0.02% and IgG control 2.90±0.18% (Figure 2A), depletion 
was sustained as revealed by FACS analysis 14 days after surgery (data not shown).
21 Days after cuff placement, NK1.1 depleted C57BL/6 mice displayed a significant 
reduction of 43% (p<0.05) in intimal hyperplasia compared to controls (Figure 
2B, D). Furthermore, intima/media (I/M) ratio was also significantly reduced by 
approximately 50% (p<0.05) in NK1.1 depleted mice when compared to controls 
(Figure 2C). Since NK1.1 mediated depletion also depletes NKT cells, and NKT cells 
were previously indicated to play a role in atherosclerotic lesion formation28, we 
studied cuff induced intimal hyperplasia formation in NKT deficient Jα281-knockout 
mice (Jα281-/-) on a C57BL/6 background and littermate controls (n=8/group). As 
depicted in figures 2E-G, no differences in cuff induced intimal hyperplasia and I/M
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ratio were observed in Jα281-/- mice when compared to controls. To further confirm 
a role for NK cells in vascular remodeling, cuff surgery was performed in NK-cell 
deficient mice (NK-/-, n=8 cuffs/group) (Figure 2H-J).  NK-/- mice showed a significant
Figure 2. NK cell depletion and vascular remodeling A. Representative flow cytometric 
analysis for NK cells in peripheral blood from NK1.1 depleted C57BL/6 mice and IgG treated 
controls at the moment of surgery. B. Intimal hyperplasia in cuffed femoral artery segments 
of NK1.1 depleted C57BL/6 mice (n=10) and controls (n=10) after 21 days. C. Intima/
Media ratio of NK1.1 depleted C57BL/6 mice and controls after 21 days. D. Representative 
microscopic photographs of elastin stained cuffed femoral artery segments from NK1.1 
depleted C57BL/6 mice and controls after 21 days. E. Average intimal hyperplasia in cuffed 
femoral artery segments of NKT deficient (Jα281-/-) mice (n=8) and controls (n=8) after 21 
days. F. Intima/Media ratio of Jα281-/- and control mice. G. Representative photographs 
of elastin stained cuffed femoral arteries from Jα281-/- mice and controls after 21 days. H. 
Intimal hyperplasia in cuffed arteries of NK-/- (n=8) and controls (n=8) after 21 days. I. Intima/
Media ratio of NK-/- mice and controls after 21 days. J. Photographs of elastin stained cuffed 
femoral arteries from NK-/- mice and controls. * P-value <0.05.
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reduction of 40% (p<0.05) in intimal hyperplasia compared to C57BL/6 controls.  I/M 
ratio was reduced by 34% in the NK-/- mice although this did not reach significance 
(p=0.082) since the media was also reduced slightly (12%, p=0.250).  The significant 
reduction in intimal hyperplasia in NK cell depleted and NK-/- mice, but not in Jα281-
/- mice, indicates a role for NK cells, but not NKT cells, in the formation of intimal 
hyperplasia and vascular remodeling as shown here. 
The C57BL/6 NK gene complex increases arterial intimal hyperplasia in BALB/c 
mice
To study the role of NKC differences between C57BL/6 and BALB/c in vascular 
remodeling, non-constrictive cuffs were placed around both femoral arteries in 
C57BL/6 (n=9), BALB/c (n=7) and CMV1r (n=9) mice. Analysis of the vessels revealed 
that CMV1r mice displayed an approximately 3-fold (p<0.05) increase in intimal 
hyperplasia, as compared to the BALB/c strain, which it originates from (Figure 
3A, B). The extent of intimal hyperplasia in CMV1r mice was equal to that of the 
C57BL/6 mice. Measurement of the media, demonstrated that this was significantly 
thicker (56%, p<0.05) in CMV1r mice as compared to their background BALB/c strain 
(Figure 3C), resulting in a doubling of I/M ratio in the CMV1r mice (Figure 3D). These 
parameters were comparable between C57BL/6 and CMV1r mice.
Figure 3. Morphometric quantification of cuffed femoral artery segments from C57BL/6 
(n=9), BALB/c (n=7) and CMV1r mice (n=9) 21 days after cuff placement. A. Intimal hyperplasia 
in CMV1r, BALB/c and C57BL/6 mice. B.  Representative microscopic photographs of elastin 
and HPS stained cuffed femoral artery segments 21 days after placement. C. Average medial 
area. D. Average I/M ratio in C57BL/6, CMV1r mice and BALB/c mice. * P-value <0.05. 
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The C57BL/6 NK gene complex contributes to profound vein graft remodeling 
To further establish a role for the C57BL/6 NKC in vascular remodeling, we assessed 
the role of the NKC in the mouse model for vein graft disease. In C57BL/6, BALB/c 
and CMV1r mice a venous (caval vein) interposition was placed in their left carotid 
artery and left in situ for 28 days.
Figure 4. Morphometric quantification of vein graft segments from C57BL/6 (n=10), BALB/c 
(n=9), and CMV1r mice (n=9) 28 days after engraftment. A. Representative photographs 
of HPS stained vein graft segments 21 days after engraftment from C57BL/6, BALB/c and 
CMV1r mice. B. Average intimal hyperplasia, C. average total vessel area and D average total 
lumen area. * p-value <0.05; ** p-value <0.01  E. Average size of native caval veins from 
C57BL/6, BALB/c and CMV1r mice. F. Quantification of CD45 positive cells that are present 
in the vessel wall expressed as average leukocyte score. * p-value <0.05.G. Representative 
photographs of CD45 stained vein graft segments, demonstrating differential influx of CD45 
positive cells in to the vessel wall of C57BL/6, BALB/c and CMV1r mice. H. Quantification 
of IFN-γ expressed in the vein grafts expressed as average IFNγ score. * P-value <0.05. I. 
Representative photographs of IFNγ stained vein grafts C57BL/6, BALB/c and CMV1r mice. 
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After 28 days the vein graft segments were analyzed. CMV1r mice displayed a strong 
increase in intimal hyperplasia formation by 104% (p<0.05) when compared to 
BALB/c mice (Figure 4A, B). The intimal hyperplasia in CMV1r mice was slightly, but 
not significantly increased compared to vein grafts in C57BL/6 mice. The total vessel 
area as well as the lumen area in CMV1r mice were significantly (p<0.05) larger than 
that of BALB/c mice, and equaled that of C57BL/6 (Figure 4C, D). From these data 
and in comparison with the initial caval vein diameters of all three strains (Figure 
4E), it can be concluded that both CMV1r and C57BL/6 mice demonstrated massive 
outward remodeling of the vein graft (112 and 131% increase, resp.), whereas 
BALB/c mice showed less outward remodeling (42% of that in C57BL/6 mice).
Increased inflammatory cell influx in CMV1r vein grafts
In order to study potential differences in the inflammatory response induced by 
NK activation, we analyzed the presence of leukocytes in vein graft segments with 
an immunohistochemical staining for the pan-leukocyte marker CD45. A profound 
stronger inflammatory reaction in C57BL/6 and CMV1r mice was observed, this was 
reflected by a larger number of leukocytes infiltrates when compared to BALB/c 
mice (Figure 4A, G). Quantitative comparison of the CD45 staining between the 
three mouse strains, revealed indeed a significant increase in leukocytes in vein 
grafts in both C57BL/6 (45%) and CMV1r (65%) compared to BALB/c vein grafts 
(Figure 4F). These results indicate that the presence of the C57BL/6 NKC locus 
leads to an enhanced influx of immune cells and most likely a pronounced IFNγ 
production. Indeed in both C57BL/6 and CMV1r vein grafts, more IFNγ staining could 
be detected (compared to BALB/c vein grafts) resulting in a significant increase in 
expression of 69% and 58% (p<0.05) respectively (Figure 4H, I). 
NK cell responsiveness is improved in CMV1r compared to BALB/c 
The presence of the C57BL/6 NKC in CMV1r mice causes the development of NK 
cells expressing a different receptor repertoire compared to BALB/c. To investigate 
if differences in this receptor repertoire result in different responsiveness between 
CMV1r and BALB/c NK cells and consequently may cause the differences in leukocyte 
accumulation and increased expression of IFNγ in vein grafts, we analyzed NK cell 
responsiveness by measuring intracellular IFNγ in NK cells upon cross linking of 
their activating receptors29,30. NK cell-mediated IFNγ production induced by NKp46 
or PMA/ionomycin was increased significantly compared to the ‘background’ 
IFNγ production of NK cells incubated with isotype matched control (goat IgG) in 
all mouse strains tested (Figure 5A). On average, the IFNγ response of CMV1r NK 
cells to NKp46 stimulation was more than five-fold higher than the BALB/c NK cell 
response (Figure 5B: CMV1r, 4.6±1.0%; BALB/c, 0.8±0.2%, p<0.05). The responses 
to PMA/ionomycin, a stimulus that bypasses NK cell receptor-proximal signaling, 
showed a similar pattern (Figure 5C: CMV1r, 13.1±1.7%; BALB/c, 7.4±1.6%). For both 
stimuli, IFNγ responses of C57BL/6 NK cells were greater still than those of CMV1r 
NK cells (Figure 5B,C: NKp46, 12.0±0.7%; PMA/ionomycin 23.5±8.5%), indicating
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that genetic differences between C57BL/6 and BALB/c outside the NKC also 
contribute to differences in NK cell IFNγ  production.
Figure 5. Intracellular IFNγ expression in NK cells (CD3-DX5+) from C57BL/6, BALB/c 
and CMV1r mice after stimulation with A. plate-bound control antibody, B. plate-
bound anti-NKp46  or C. PMA/ionomycin. Spleen cells were incubated with these 
stimuli for 5 hours, in the presence of brefeldin A during the final 4 hours of the 
incubation, and then analyzed by flowcytometry. For each mouse, the percentage IFNγ 
–positive cells within CD3-DX5+ cells (NK cells) is depicted. One experiment is shown, 
representative of two independent experiments using 3 mice per strain per experiment. 
Discussion
In the present study we investigated the role of NK cells and the C57BL/6 Natural 
Killer gene Complex in vascular remodeling. First, we verified, that NK cell deficiency 
resulted in reduced vascular remodeling and consequently a reduced intimal 
hyperplasia, whereas NKT cell deficiency did not. Secondly, we demonstrated a role 
for the C57BL/6 NKC in vascular remodeling, since the presence of the C57BL/6 NKC 
in a congenic BALB/c mouse strain induced profound vascular remodeling probably 
as a result of enhanced activity of immune cells characterized by the production of 
IFNγ.
NK cell deficiency induced either genetically or via NK1.1 antibody depletion, 
resulted in significant reduction of intimal hyperplasia in C57BL/6 mice. This is in 
line with a previous study that in LDL-R-/- mice without functional NK cells described 
a significant reduction in atherosclerotic lesion development without affecting 
cholesterol levels10. A role for NKT cells was previously indicated in the induction 
of atherosclerotic lesion formation28. However, in our model intimal hyperplasia 
was not affected in NKT cell deficient Jα281-/- when compared to controls. This 
indicates that invariant NKT cells are not implicated in intimal hyperplasia in a non-
atherosclerotic setting. It should be taken into account that our data cannot exclude 
a role for CD1d restricted NKT cells, which are Jα281-negative and thus still present 
in Jα281-/- mice. 
The question remains how NK cells influence vascular remodeling. Immune cells
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and smooth muscle cells, that reside in the vessel wall during vascular remodeling, 
express factors such as CCL2, IL12, IL15 and IL18 that can attract and activate NK 
cells8. NK cells, although available in limited numbers, are therefore attracted to the 
affected vessel wall as shown here and previously10,31. NK cells possess the ability 
to excrete numerous factors that have been shown to be of importance in vascular 
remodeling. For instance, NK cell granzymes are expressed in atherosclerotic 
lesions32 and granzyme B, the most abundant NK cell granzyme, has a distinct role 
in extracellular matrix remodeling32. Perforin however, does not appear to have 
an effect on atherosclerosis development as shown by Schiller et al33. Various 
chemokines and cytokines expressed by NK cells show positive effects on vascular 
remodeling as reviewed by Schober9. Amongst these, IFNγ is probably the most 
important factor expressed by activated NK cells. SMC proliferation and migration 
are directly inhibited by IFNγ34 and thus potentially decreases intimal hyperplasia 
formation and inhibits vascular remodeling. The intimal hyperplasia in these vein 
grafts consists mainly of SMCs whereas the adventitia and connective tissue 
surrounding the vein grafts harbors numerous macrophages and T-cells that play 
an important role in vein graft remodeling by secretion of cytokines, chemokines 
and growth factors. The activating effect of IFNγ on these macrophages and T-cells 
present in the vessel wall35 probably results in a net positive effect on vascular 
remodeling. 
The second important finding in this study is that introduction of the C57BL/6 NKC 
in the congenic BALB/c strain, the CMV1r mice, resulted in complete reversion of 
the vascular remodeling phenotype of BALB/c towards the profound remodeling 
phenotype of C57BL/6 mice. Since CMV1r mice express the C57BL/6 NKC, our 
data show that vascular remodeling is modulated by at least one of the factors 
that are encoded within the C57BL/6 NKC locus, but absent in the BALB/c NKC 
locus. Compared to the C57BL/6 NKC, the BALB/c NKC contains fewer functional 
genes encoding activating and inhibitory NK cell receptors (8 versus 15 Ly49 genes 
respectively)21. Our data show that these differences have consequences for NK 
cell responsiveness, since CMV1r NK cells were significantly more responsive than 
BALB/c NK cells to activating stimuli in vitro.  This was also reflected in vivo by the 
increase in inflammatory cell influx and IFNγ expression as seen in vein graft in the 
CMV1r mice compared to their BALB/c background strain.
BALB/c mice often display a Th2 response-phenotype associated with reduced 
vascular remodeling, whereas C57BL/6 mice generally display a pro-inflammatory 
Th1-like response, with enhanced IFNγ production and profound vascular 
remodeling17. This is also confirmed by the observed differences in vascular 
remodeling between C57BL/6 and BALB/c in our experiments. Both CMV1r and 
C57BL/6 mice demonstrated more intimal hyperplasia and outward remodeling, 
which is associated with a pro-inflammatory responses36 whereas in  BALB/c 
mice remodeling is less pronounced. The increased inflammatory cell influx and 
augmented expression of IFNγ in vein graft segments in C57BL/6 and CMV1r, but 
not in BALB/c mice, suggests that the hypo-responsive NK cell phenotype might
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indirectly contribute to the induction of a different inflammatory response and 
thereby reduced vascular remodeling. This switch of CMV1r mice from a BALB/c 
response towards a C57BL/6 response is also described in a L-NAME-induced 
hypertension model, in this model the CMV1r mice displayed a comparable 
sensitivity as C57BL/6 mice regarding hypertension and vascular remodeling 
whereas the endothelial response and vascular architecture were BALB/c-like37.
In conclusion, the current study shows a role of NK cells in vascular remodeling by 
demonstrating the involvement of NK cells, and not NKT cells, in intimal hyperplasia 
after induction of vascular injury. Furthermore, we demonstrate that the genetic 
differences in the Natural Killer gene complex explain strain dependent differences 
in vascular remodeling. Presence of the C57BL/6 NKC results in an increased 
inflammatory cascade, which contribute to a different outcome of vascular 
remodeling. These data suggest that a factor for profound vascular remodeling 
resides within the C57BL/6 NK cell gene complex. 
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Figure 1. NK cells are found in comparable numbers in the adventitia of 3 days old cuff 
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Abstract
Objective  To explore the role of TLR4 in vein graft remodeling and disease.
Methods and results  First, expression of TLR4 was analyzed in human Saphenous 
Veins (huSV), either freshly isolated, or freshly isolated huSV ex vivo perfused in an 
extracorporeal circulation or in huSV used as coronary vein grafts. Marked induction 
of focal TLR4 expression was observed in perfused fresh huSV. Moreover, TLR4 was 
abundantly present in lesions in fresh huSV or in intimal hyperplasia in coronary 
vein grafts. Secondly, mouse venous bypass grafting was performed. In grafts of 
hypercholesterolemic ApoE*3Leiden mice increased TLR4 mRNA and protein was 
detected over time by RT-PCR and immunohistochemistry. Furthermore local 
presence of the endogenous TLR4-ligands HSP60, HMGB1, Tenascin-C and biglycan 
in the grafts was demonstrated. 
TLR4 deficiency in C3H-Tlr4LPS-d mice resulted in 48±12% less vein graft wall 
thickening (p=0.04) than in Balb/c controls. Moreover, local TLR4 gene silencing 
in hypercholesterolemic ApoE3*Leiden mice using lentiviral-shRNA against TLR4 
administered perivascularly around vein grafts led to a 44±13% reduction of vessel 
wall thickening compared to controls (p=0.0059). 
Conclusion  These results indicate that TLR4 is involved in vein graft remodeling and 




Vein grafts are important conduits for revascularization during both coronary 
and peripheral bypass surgery although vein grafts sometimes have poor long 
term patency. Early graft failure is usually due to thrombosis but long term graft 
failure is caused by vein graft disease (VGD) induced by wall thickening due intimal 
hyperplasia that is triggered by inflammation. Vein graft wall thickening is in part 
characterized by smooth muscle cell (SMC) proliferation, matrix turnover and influx 
of lipids and inflammatory cells1,2.
The innate immune system contains multiple receptors that recognize a broad 
variety of molecular structures. Toll Like Receptors (TLRs) have a key role in driving 
inflammation regulating the innate response after binding pathogen associated 
molecular patterns (PAMPs) or damage associated molecular patterns (DAMPs), 
respectively3-7. TLR4 is a membrane bound receptor located on a variety of immune 
and non-immune cells including macrophages, endothelial and SMCs. Cell stress 
and tissue damage may cause a release of DAMPS that function as endogenous TLR4 
ligands and lead to activation and up-regulation of the expression of TLR4 resulting 
in a pro-inflammatory response6,8-10. The role of TLR4 in vascular remodeling, 
especially arterial remodeling has previously been demonstrated in various studies 
either directed at atherogenesis and plaque (de)stabilization or directed at the role 
of TLR4 in postinterventional arterial remodeling after angioplasty11-16. However the 
role of TLR4 and its endogenous ligands in remodeling of venous segments e.g. in 
vein graft remodeling is still unknown. Furthermore it is sugested that unactivated 
arterial VSMC do not express TLR4 and that TLRs may have a vessel specific profile 
which may also vary due to changes in cellular activation, differentiation and other 
local processes17. Interestingly non-activated VSMC from huSV do express TLR418. 
To modulate atherosclerotic plaque formation by interfering in the TLR4 pathway, 
systemic therapeutic interventions would be required. However, due to its 
important role in the host defense mechanism, such a systemic approach would 
be undesirable. In contrast, venous bypass grafts do permit local therapeutic 
interventions. From the point of therapeutic interventions in the TLR4 pathway to 
reduce vascular remodeling VGD is of more interest and potential. Local therapy 
against VGD can be done easily e.g. by topical inhibitor application to the adventitial 
layer since adventitial cells contribute extensively to proliferation and migration 
of SMC and subsequent vein graft remodeling19-23. Therefore local gene transfer in 
order to silence TLR4 expression would be an interesting approach for therapy to 
improve graft survival, once the role of TLR4 in VGD is established. 
In the current study we focus on the role for TLR4 in vein graft remodeling by 
illustrating the presence and upregulation of TLR4 and its endogenous ligands in 
both human and murine venous segments used for vein grafting. Moreover, a causal 
role of TLR4 was studied by performing vein grafting in TLR4 deficient mice (C3H-
Tlr4LPS-d mice) or by local TLR4 gene silencing in murine vein graft using a lentiviral 
shRNA construct against TLR4. The latter study was performed in
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hypercholesterolemic APOE3*Leiden mice in order to mimic the situation vein 
grafting in hypercholesterolemic patients as close as possible.
Material and methods
For a detailed description of all materials and methods used see the online 
supplement (available online at http://atvb.ahajournals.org). 
In brief, immunohistochemistry for TLR4 was performed on paraffin embedded 
sections of human saphenous vein (huSV) segments, either freshly isolated, or 
freshly isolated and ex vivo perfused in an extracorporeal circulation for 4h or huSV 
used for at least 5 years as coronary vein grafts. Also murine vein graft segments 
were analyzed for TLR4 expression, but also its endogenous ligands HPS60, HMGB1, 
Tenascin-C and biglycan.
Lentiviral shRNA vectors against murine TLR4 were established based on the 
“Mission” library (Sigma Aldrich, the Netherlands).
Vein grafting in mice was performed by placing a venous interposition (vena cava) 
in the carotid artery of either BALB/c mice, TLR4 deficient (C3H-Tlr4LPS-d) mice or 
hypercholesterolemic ApoE3*Leiden mice. In the ApoE3*Leiden mice grafts were 
treated locally with the lentiviral shTLR4 construct. 
Results
TLR4 presence in human saphenous veins and coronary vein grafts
Human vein graft obtained in the operating room during coronary artery 
bypass grafting procedures one segment directly taken for histologic and 
immunohistochemical examination and the remaining segment was placed 
in a perfusion circuit that was connected to the heart lung machine. Samples 
were perfused with autologous whole blood, with a pressure of 60mm Hg 
(nonpulsatile flow). After 4 hours of perfusion, segments were taken for histologic 
and immunohistochemical examination. Furthermore vein grafts that served as 
coronary arterial bypass grafts for more than 6 years were derived at autopsy. To 
study the presence of TLR4 during remodeling in huSV TLR4 expression was analyzed 
in the freshly isolated huSV, in pre-existing intimal lesions within these segments 
and the coronary vein grafts. In the fresh huSVs TLR4 expression could be detected 
especially in the circular smooth muscle cell layer (Figure 1A). Also the endothelial 
layer and adventitial vessels stained positive for TLR4 (not shown). Some of the 
venous segments contained spontaneous lesions, indicated by intimal hyperplasia 
formation. These lesions represent a focal area of spontaneous remodeling and 
demonstrated a marked presence of TLR4 (Figure 1B). Additionally a profound 
TLR4 expression was observed in severely remodeled coronary vein grafts with a 
saphenous vein origin (Figure 1C). These grafts were obtained at autopsy, had been 
in situ for more than 5 years and are representative sections of remodeled vein 
grafts. 
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Focal TLR4 expression after graft perfusion 
In vein grafting, early damage to the vessel wall is initiated immediately by surgical 
manipulation and after transplantation due to increased shear stress and wall 
tension initiated by increased perfusion pressure. Non-perfused fresh huSV showed 
only little TLR4-positive cells in sub-endothelial longitudinal muscle layer (Figure 
2A). Parallel sections of the same fresh huSV were subjected to 4hrs perfusion with 
autologous blood on arterial pressure. These sections showed an impressive focal 
increase of TLR4 expression within the longitudinal layer (Figure 2B). 
Figure 1.  TLR4 expression on cross-sections of huSV. Freshly harvested huSV stained positive 
for TLR4 on the circular muscle layer A. Pre-existent intimal lesions in freshly harvested huSV 
showed several TLR4 positive spots B. and coronary huSV grafts derived at autopsy showed 
a profound expression of TLR4 in the thickened vein graft wall C. CML= circular muscle layer, 
LML= longitudinal muscle layer, PIL= pre-existent intimal lesion, TIL= thickenend intimal layer.
 
Figure 2.  Freshly isolated huSV was divided into two parts. One part was directly fixated 
(and paraffin embedded) while the other part was placed into an extracorporeal circulation 
system for 4h with arterial pressure before fixation. Cross sections of both huSV parts were 
stained for TLR4. A. The longitudinal muscle layer of directly fixated huSV showed a few TLR4 
positive spots. B. A rapid increase of TLR4 expression was seen in the longitudinal muscle 
layer of huSV after 4h perfusion with arterial pressure. LML= longitudinal muscle layer.
121
7
TLR4 expression in murine vein grafts during remodeling 
As the above presented findings indicate an increase of TLR4 presence during 
huSV remodeling, TLR4 presence on protein and mRNA level was analyzed 
during remodeling in mice. Therefore a murine vein graft model was used that 
represents human vein graft thickening and accelerated atherosclerosis. TLR4 
protein presence was studied by IHC during progression of remodeling over time 
in hypercholesterolemic ApoE3*Leiden mice. A marked expression of TLR4 was 
detectable in these vein grafts. In the early remodeling phase, when the graft is only 
a single to a couple of cell layers thick, TLR4 positive spots were observed (Figure 
3A, B). At t=7 and t=14 days vessel wall thickness has increased markedly. Within 
these segments focal areas of intense TLR4 protein expression could be detected 
(Figure 3C, D). Rabbit IgG isotype control showed no staining (Figure 3E). Expression 
of TLR4 mRNA during remodeling was detected by RT-PCR in hypercholesterolemic 
ApoE3*Leiden mice over time at t=0, 6hours, 1, 3, 7 and 28 days after graft placement. 
A rapid increase in TLR4 mRNA could be detected in the early remodeling phase. 
During intermediate and late phase remodeling TLR4 mRNA remained up regulated 
(Figure 3F) (t=0 vs. 6h p=0.03, t=0 vs. 1d p=0.0039, t=0 vs. 3d p=0.02, t=0 vs. 7d 
p=0.1, t=0 vs. 28d p=0.09. Increase of TLR4 expression may be partly related to an 
influx of 68+ cells (t=0 vs. 6h p=0.6, t=0 vs. 1d p=0.0037, t=0 vs. 3d p=0.0026, t=0 vs. 
7d p=0.0032, t=0 vs. 28d p=0.0003 during remodeling and proliferation/migration 
of SMC (t=0 vs. 6h p=0.07, t=0 vs. 1d p=0.0007, t=0 vs. 3d p=0.17, t=0 vs. 7d p=0.02, 
t=0 vs. 28d p=0.006, Figure 3GH).
Presence of endogenous TLR4 ligands in murine vein grafts                                    
Remodeled grafts have been subjected to proliferation, migration and turnover of 
cells and matrix components. These processes may cause an upregulation of DAMPs 
that can be recognized by TLR4.  We localized several of these DAMPS in vein grafts of 
hypercholesterolemic ApoE3*Leiden mice harvested at t=14d. Proteins in response 
to cellular stress like Heat Shock Protein 60 (HSP60) and High Mobility Group Box 
1 (HMGB1) are known TLR4 ligands. Presence of HSP60 was detected especially in 
the sub-endothelial layer of the thickened vessel wall (Figure 4A). HMGB1, normally 
at rest located inside the nucleus, was now detected in the cytoplasm were it is 
known to act in a cytokine-like way (Figure 4B)24. In addition, matrix components 
that are expressed during matrix turnover were studied. Glycoprotein Tenascin-C 
was demonstrated especially at the matrix rich adventitial site of the graft but also 
near the luminal site in matrix containing areas (Figure 4C). These endogenous 
ligands could potentially colocalize with TLR4 since they were present in the lesions 
site and in areas that also express TLR4 at the same time point (Figure 3D and 
4ABC). Furthermore mRNA expression of matrix component Biglycan (BGN), that 
may function as TLR4 ligand, was studied in time and a more than 10-fold increase 
of mRNA was detectable after 7d. This increase in Biglycan expression remained up 
regulated during the remodeling process (t=0 vs. 6h p=0.25, t=0 vs. 1d p=0.017, t=0 
vs. 3d p=0.21, t=0 vs. 7d p=0.004, t=0 vs. 28d p=0.021, Figure 4D).
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Figure 3.  TLR4 expression on murine vein grafts of hypercholesterolemic ApoE3*Leiden mice 
was detected by IHC and RT-PCR. Over time analysis was done at grafts harvested A. t=1, 
B. 3, C. 7 and D. 14d  after surgery. E. Rabbit IgG isotype control. Arrows indicate positive 
TLR4 staining.  RT-PCR of F. TLR4 G. CD68 and H. αSMactin mRNA at t= 0h, 6h, 1, 3, 7 and 
28d after surgery. A students t-test was used for statistical analysis, * = P<0.05 compared to 
t=0h. 
Functional role of TLR4 in murine vein graft remodeling
To explore whether TLR4 has a functional role in vein graft thickening, an essential 
step in vein graft disease leading to vein graft failure, a venous interposition was
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Figure 4.  Endogenous TLR4 ligands were detected in vein grafts of hypercholesterolemic 
APOE*3Leiden mice. Presence of A. HSP60, B. HMGB1  and C. Tenascin-C was detected by 
IHC in vein grafts 14 days after surgery. D. RT-PCR on matrix component Biglycan mRNA was 
performed at t= 0h, 6h, 1, 3, 7 and 28 days after surgery (n= three-four per time point). A 
students t-test was used for statistical analysis, * = P<0.05 compared to t=0h.
placed in the carotid artery of BALB/c (n=8) and TLR4 deficient (C3H-Tlr4LPS-d) mice 
(n=7). C3H-Tlr4LPS-d mice showed 48±12% (0.264±0.06mm2 vs 0.136±0.02mm2, 
p=0.04) less wall thickening than BALB/c controls (Figure 5A). Graft patency was 
kept by compensatory outward remodeling in the BALB/c mice indicated by a 
significantly larger total vessel wall area (0.60±0.03mm2 vs 0.42±0.05mm2, P=0.01) 
(figure 5B) and thereby only a small difference in ratio lumen/total vessel wall 
area (online supplement figure I). Furthermore the reduced vessel wall thickening 
correlated with a reduced alpha-SMC-actin positive area in the C3H-Tlr4LPS-d mice. 
(0.022±0.003mm2 vs 0.047±0.009mm2, p=0.035) (Figure 5C). 
TLR4 silencing in vitro
To create a tool for local TLR4 gene silencing five lentiviral based shRNAs were 
produced and validated by measurement of murine TLR4/MD2 expression on CHO 
cells by FACS analysis and the best vector was selected (not shown). The selected 
vector showed a dose dependent down regulation of TLR4 protein expression 
(online supplement figure II). Murine 3T3 fibroblasts were then transduced by 
selected lenti-shTLR4 (TRCN0000065787), lenti-control or PBS and subsequently 
stimulated with different pro-inflammatory stimuli to obtain insight on its specificity 
in reducing TLR4 induced NFκB activation. Lenti-shTLR4 gave a significant reduction 
in NFκB activation after administration of TLR4 ligand LPS (P<0.01). Application of 
Pam3Cys, TNFα or IL1β gave no different effects on NFκB activation when compared 
to the controls (online supplement figure III). 
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Figure 5.  Vein graft remodeling in BALB/c and C3H-Tlr4LPS-d mice (BALB/c n=8, C3H-Tlr4LPS-d 
n=7). Areas of vein graft sections were quantified by using 6 sequential sections per vein 
graft of each mouse. A mean of these 6 sections was used as the outcome of vein graft 
remodeling per mouse. Outcomes of analysis are expressed in millimeters squared (mean 
± SEM). A. C3H-Tlr4LPS-d mice showed a significant reduction in vein graft wall thickening 
compared with BALB/c controls. B. C3H-Tlr4LPS-d mice showed a significant smaller total 
vessel wall area. C. The total alpha SMC actin area was significantly smaller in C3H-Tlr4LPS-d 
mice. D. Representative HPS stained sections of BALB/c and C3H-Tlr4LPS-d vein grafts, * = 
P<0.05. Statistical analysis was performed by use of a Mann-Whitney test.
Local TLR4 silencing in hypercholesterolemic APOE3*Leiden mice
To validate the potential of TLR4 as a local therapeutic in vein graft disease, a 
study was pursued using local TLR4 gene silencing to diminish vein graft disease 
in ApoE3*Leiden mice. These mice, when fed a high cholesterolemic diet, are well 
known to develop massive vein graft disease due to neointima formation and 
accelerated atherosclerosis. After graft placement in ApoE3*Leiden mice pluronic
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gel (pg) with PBS (n=8), lenti-control (n=9) or lenti-shTLR4 (n=7) was lubricated 
around the graft. Mice were fed a western type diet for total duration of the 
experiment, starting 3 weeks before surgery. No significant differences between 
groups in cholesterol levels (PBS 9.6±0.9 mmol/L, lenti-control 9.7±1.0 mmol/L and 
lenti-shTLR4 10.2±0.6 mmol/L) and body weights were observed (not shown). 
Local gene silencing of TLR4 led to a 44±13% reduction of vessel wall thickening 
in the graft segment (PBS 0.40±0.04mm2, lenti-control 0.42±0.04mm2, lenti-
shTLR4 0.23±0.03mm2) (PBS vs lenti-shTLR4 p=0.0059, lenti-control vs lenti-shTLR4 
p=0.0052, PBS vs lenti-control p=0.96). A difference in total vessel wall area was 
only found between lenti-control vs. lenti-shTLR4. Additionally a beneficial lumen/
total cross sectional ratio showed a beneficial outcome for the lenti-shTLR4 treated 
group (PBS 0.45±0.05mm2, lenti-control 0.54±0.04mm2, lenti-shTLR4 0.70±0.03mm2) 
(PBS vs lenti-shTLR4 p=0.0012, lenti-control vs lenti-shTLR4 p=0.0079, PBS vs lenti-
control p=0.14) (Figure 6A-D). Furthermore although quantitative interpretation of 
immunohistochemistry has to be done with extreme caution, treatment with lenti-
shTLR4 gave a reduction in focal TLR4 expression in the graft (Figure 6E). After TLR4 
silencing in the vein grafts of ApoE3*Leiden mice the area positive for macrophages 
(MAC3 positive area) and SMC (alpha-SMC-actin positive area) was reduced by 
54% and 61% respectively when compared to the PBS group (details: Table I online 
supplement).
Discussion 
The present study describes the role of TLR4 in vein graft remodeling in human 
and mice with a profound presence TLR4, endogenous TLR4 ligands during 
remodeling and the therapeutic potential for local TLR4 silencing. Abundant TLR4 
presence was noticed in freshly isolated huSV. Additionally in remodeled areas of 
fresh huSV, in fresh huSV after reperfusion and in coronary vein grafts derived at 
autopsy an up regulation of TLR4 protein was observed. In murine vein grafts of 
hypercholesterolemic ApoE3*Leiden mice TLR4 expression is present over time at 
protein and mRNA level and a series of endogenous TLR4 ligands, HSP60, HMGB1, 
Tenascin C and Biglycan was expressed. Furthermore TLR4 deficient mice show a 
significant reduction in vein graft thickening and less outward remodeling after vein 
grafting. Moreover, local gene silencing of TLR4 gives a clear reduction in vein graft 
thickening and a beneficial lumen/total cross sectional area ratio.
Nowadays, TLR4 is considered to be an important factor in inflammatory mediated 
diseases. VGD is strongly mediated by remodeling initiated by wall stress, cell 
damage and inflammation. The level of TLR4 expression may vary amongst different 
vessel specimens and is dependent on activation and local environmental changes 
like wall stress, cell damage and inflammation17. Furthermore these differences may 
also be relevant for the presence and levels of endogenous TLR4 ligands. Therefore 
it is of major importance to evaluate TLR4 expression, function and therapeutic
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potential in a VGD related setting. Here we report presence of TLR4 on the 
circular muscle layer of fresh huSV and a rapid and is dependent on activation 
and local environmental changes like wall stress, cell damage and inflammation17. 
Furthermore these differences may also be relevant for the presence and levels 
of endogenous TLR4 ligands. Therefore it is of major importance to evaluate TLR4 
expression, function and therapeutic potential in a VGD related setting. Here we 
report presence of TLR4 on the circular muscle layer of fresh huSV and a rapid 
increase of focal TLR4 expression within 4 hours of reperfusion in an extracorporeal 
circulation set up with arterial pressure on sections of fresh huSV.  Increased TLR4 
expression may be initiated by damage inducing processes like ischemia/reperfusion 
and increased wall tension/shear stress due to pressure and flow disturbances25, 26. 
Additionally, the initiated damage to the vessel contributes, most likely by inducing 
the release of endogenous ligands, to proliferation and migration of VSMC and 
influx of inflammatory cells like macrophages resulting in thickening of the vessel 
wall. These cells playing an important role in vascular remodeling have been shown 
to express TLR413,18,27,28. In support we notice abundant TLR4 presence within the 
thickened vessel wall of severely remodeled areas in vein grafts of human and 
mouse origin.  Previously, localization of TLR4 has been shown in remodeled arteries 
during atherogenesis and after angioplasty and that presence of TLR4 ligands may 
alter its expression13,14,16.
The discovery that these TLR4 ligands can be of endogenous origin further 
emphasize the importance of TLR4 in inflammatory mediated diseases3. The 
endogenous ligands, most often referred as DAMPs, are most often danger signals 
or degradation products of matrix component that become available in response to 
injury. Bypass surgery itself and the subjection of the transplanted vessel to hypoxia 
and increased blood pressure can cause a release of powerful inducers of cellular 
stress and tissue damage. The observed presence of Heat Shock Protein 60 (HSP60), 
extracellular High Mobility Group Box 1 (HMGB1), Tenascin-C and up regulation of 
Biglycan mRNA during remodeling are nice examples of this. Previously Hochleitner 
et al. described the release of HSP60 after shear stress29 and others showed the 
capability of HSP60 to bind directly to TLR4 thereby initiating proliferation of 
VSMC30. Cellular stress may also cause passive release of HMGB1 by a variety of cell 
types including endothelium and monocytes/macrophages and acts like a cytokine 
capable of binding to TLR4 thereby initiating a pro-inflammatory response8,31, 32. 
Matrix turnover importantly mediates vein graft remodeling. Extracellular matrix 
glycoprotein Tenascin-C is related to tissue repair and injury. Normally Tenascin-C 
is not present in huSV but after graft placement its expression is significantly 
increased in huSV  grafts33,34. If present it is capable of promoting SMC migration35, 
growth36 and effecting important genes in vascular remodeling. Recently Tenascin-C 
was found to be an endogenous TLR4 ligand without the need for CD14 or MD-2 
as accessory molecules for signal transduction and therefore Tenascin-C may 
act in vein grafts also via TLR4 signaling37. The matrix component, Biglycan is co-
immunoprecipitated with TLR4 and by signaling via TLR4 on macrophages it has a
127
7
Figure 6.  Vein graft remodeling after local TLR4 silencing in hypercholesterolemic 
ApoE3*Leiden mice (PBS n=8, lenti-control n=9, lenti-shTLR4 n=7). Areas of vein graft sections 
were quantified by using 6 sequential sections per vein graft vein graft of each mouse. A 
mean of these 6 sections was used as the outcome of vein graft remodeling per mouse. 
Outcomes of analysis are expressed in millimeters squared (mean±SEM). A. Vein graft wall 
thickening was reduced in the lenti-shTLR4 treated group compared to the controls. B. Total 
vessel wall area was smaller in the lenti-shTLR4 group compared to the lenti-control. C. A 
beneficial lumen/total cross-sectional area ratio was observed in the lenti-shTLR4 treated 
group. D. Representative HPS stained sections of focal vein graft wall thickening. E. Focal 
TLR4 expression in vein grafts locally treated with PBS (1), lenti-control (2) and lenti-shTLR4 
(3), *= P<0.01. Statistical analysis was performed with an one-way ANOVA. 
pro-inflammatory effect. Moreover it enhances SMC proliferation36,38. The observed 
increase in Biglycan expression over time in the vein graft point towards an increased 
TLR4 signaling in murine vein grafts with Biglycan as ligand. 
The reduced vein graft wall thickening in the C3H-Tlr4LPS-d mice by reducing total 
SMC amount demonstrates that TLR4 and its endogenous ligands are not just only 
expressed in the remodeling vein graft segments, but TLR4 is also causally involved 
in vein graft remodeling. 
As the current results indicate presence and even causal involvement of TLR4 and 
up regulation of multiple endogenous ligands in VGD, several new targets can be
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proposed for therapeutic interference. Long-term systemic anti-inflammatory 
treatment against TLR4 would be difficult and undesirable due to expected adverse 
side effects. Furthermore targeting of a single DAMP would be not a good option 
since multiple DAMPS are up regulated and are able to trigger TLR4 signalling 
involved in vascular remodeling making it difficult to select them as therapeutic 
targets individually. Local RNA interference (RNAi) for TLR4 may overcome this 
problem. Short hairpin RNA constructs are able to inhibit gene translation into 
protein thereby initiating effective gene silencing39,40. Previously our group showed 
that local graft transduction using a lentivirus can be performed efficiently in vivo41. 
In support, others have shown encouraging results for the applicability of local gene 
therapy42,43.
Therefore local lentiviral infection with the selected TLR4 shRNA was performed in 
on vein grafts positioned in the carotid artery of hypercholesterolemic ApoE3*Leiden 
mice. The specificity of the shRNA construct used was demonstrated by its capacity 
to decrease murine TLR4 expression on transformed CHO cells and to reduce 
NFkB activation in murine fibroblasts after LPS activation.  NFkB activation after 
challenging the cells with other stimuli than the TLR4-ligand LPS, such as Pam3Cys, 
TNFα or IL1b, was not affected demonstrating the specificity of the construct.
Morphometric analysis after silencing TLR4 demonstrates a reduction in vessel 
wall thickening which is supported by a focal decrease in TLR4 expression and a 
reduction in total amount of macrophages in the lesions. Like in the TLR4 deficient 
mice reduction of total SMC in the lenti-shTLR4 treated group correlated with the 
decrease in vessel wall thickening. Furthermore local TLR4 silencing increases the 
ratio of lumen versus total cross sectional area. This indicates a beneficial effect of 
local TLR4 silencing on vein graft remodeling with effects on graft patency on long 
term.
This also might have impact for the treatment of patients since vein grafts can readily 
be treated locally ex vivo during surgery thus presenting a unique opportunity for 
gene transfer or gene inhibition to alter the remodeling response. 
In summary, upregulation of TLR4 expression (both in human and mouse) as well as 
its endogenous ligands in vein grafts during graft remodeling and the reduced vein 
graft thickening in TLR4 deficient C3H-Tlr4LPS-d mice point out important involvement 
of TLR4 and its endogenous ligands in vein graft disease. Furthermore the reduction 
of vein graft vessel wall thickening in hypercholesterolemic ApoE3*Leiden mice 
after local lentiviral shRNA mediated interference in the TLR4 pathway indicate the 
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All animal experiments were approved by the animal welfare committee of our 
institute. 10 week old male BALB/c, C3H-Tlr4LPS-d and ApoE3*Leiden mice, bred in 
our laboratory, were used. C3H-Tlr4LPS-d mice have a BALB/c background but carry 
a mutation that causes a deficiency in TLR4 signaling. ApoE3*Leiden were fed a 
western-type diet (Arie Blok, The Netherlands), starting 3 weeks before surgery and 
continued during the experiment to develop a diet dependent hypercholesterolemia. 
All mice received water and food ad libitum. One week before surgery cholesterol 
levels in serum were determined (Roche Diagnostics, The Netherlands). 
Production of lentiviral shRNA against TLR4
Out of the “Mission Library” (Sigma Aldrich, The Netherlands) 5 sequence-verified 
short hairpin RNA (shRNA) lentiviral-plasmids against TLR4 were isolated and 
produced. Lentiviral packaging vectors (pCMV-VSVG, pMDLg-RREgag/pol, pRSV-
REV) and transfer vector (pLKO.1-puro Vector) were co-transfected in HEK293T 
cells using calcium-phosphate precipitation method. Lentiviral particles were 
concentrated using sucrose cushion centrifugation (30.000rpm, 2h). Quantification 
of lentiviral titer was done by p24 ELISA (ZeptoMetrix, USA). 
The vectors encoded the shRNAs sequences against TLR4 (lenti-shTLR4) as indicated:
TRCN0000065783  NM_021297.1-3054s1c1




* Selected and in vivo applied lenti-shTLR4 
In vitro targeting of murine TLR4 expression 
CHO cells expressing murine TLR4/MD2 and control cells (kindly provided by Dr. A. 
Garritsen, Merck Sharp Dome, The Netherlands) were transduced with the 5 different 
lentiviral based shRNAs in a 0.1:1, 0.5:1, 1:1 and 2:1 ratio (lentiviral particles/cells) in 
DMEM (Invitrogen, The Netherlands) containing 0.8ug/ml polybrene (Sigma Aldrich, 
The Netherlands) with 5% Fetal Calf Serum. After overnight transduction medium 
was replaced by fresh medium. Subsequent TLR4 expression was measured by FACS 
analysis with a TLR4-MD2 FITC antibody (HyCult biotechnology, The Netherlands) 
after 5d.
Transduction of murine 3T3 fibroblasts
NIH 3T3 mouse fibroblasts stably transfected with a 5xNFκB-Luciferase vector as
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described1. After overnight adherence, cells were transduced with, lenti-control 
(lentivirus-GFP) or lenti-shTLR4 (TRCN0000065787) per well (MOI of 7.5) or PBS. 
Medium was discarded after 4h transduction and replaced by fresh medium. Cells 
were cultured for 5d followed by stimulation with LPS, TNFα, Pam3Cys, or IL1β. 
After 6h stimulation, cells were washed with 0.9% NaCl and lysed for 15min on ice. 
Bright-Glo was added and luminescence was measured on the Lumistar Optima.
Murine vein graft model
In the mouse carotid artery a venous interposition was placed as described 
previously2. Caval veins of donor mice were placed as vein grafts in the right carotid 
artery of recipient mice. 
Lentiviral transduction of the vein graft in situ
Before wound closure, in the ApoE3*Leiden mice, 150μl 20% pluronic gel (Sigma 
Aldrich, The Netherlands) containing 1.5*106 lentiviral particles (P24 Elisa, 
ZeptoMetrix, USA) and 0.8μg/ml DEAE (Sigma Aldrich, The Netherlands) was 
lubricated around the graft.  
Vein graft thickening quantification 
Mice were sacrificed 28d (or as stated otherwise) after surgery for histological 
analysis. Vein graft segments were harvested after perfusion fixation with 4% 
formaldehyde, fixated overnight and paraffin-embedded using an automated tissue 
processor (Leica, Germany). Cross-sections were made throughout the embedded 
vein grafts. Six representative sections per vessel segment were stained with 
Haematoxylin-Phloxine-Saffron (HPS) for histological and morphometric analysis 
(Leica, Germany). Vein graft thickening was defined as the area between lumen and 
adventitia and determined by subtracting the luminal area from the total vessel 
wall area. 
Human vein graft tissue
Veins were surplus segments of huSVs that were collected in the operating room 
from patients undergoing coronary artery bypass grafting (CABG). Vessel specimens 
were freshly collected under sterile conditions. One part of the segment was 
directly fixated for histopathological examination and another part was perfused 
on an extracorporeal perfusion circuit connected to the heart-lung machine during 
the CABG procedure with autologous blood and under arterial pressure (60mmHg) 
as described by Stooker3. The study was approved by the local ethics committee. 
Patients were included in the study after providing informed consent. Non-perfused 
fresh huSV segments (n=6 patients) and parallel fresh huSV segments that were 
perfused for 4h respectively (n=6 patients) were analyzed huSV segments that 
have served as coronary bypass for more than 5yrs (n=5 patients) were derived at 
autopsy. Use of patient material after completion of the diagnostic process is part 
of the patient contract in the VU University Medical Center.
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Immunohistochemistry         
Paraffin embedded sections (5µm) were deparaffinized in xylene. Peroxidase 
activity was blocked by incubation in 0.3% (v/v) H2O2 in methanol for 20 minutes. 
Antigen retrieval was performed and tissue sections were pre-incubated with 5% 
bovine serum albumin (BSA), followed by incubation with detecting antibody.
TLR4 presence was stained with TLR4 antibody (sc-10741 rabbit anti-human, Santa 
Cruz, United States)4, HSP60 (rabbit anti-mouse, Abcam, UK), HMGB1 (rabbit anti-
mouse Abcam, UK), Tenascin C (rabbit anti-mouse, Millipore, USA), SMCs with 
α-smooth muscle cell actin staining (Roche Applied Biosciences, Germany) and 
macrophages with MAC3ab (BD Pharmigen, USA). After washing in PBS, sections 
were incubated for 1h with a secondary antibody (Donkey anti-Rabbit, GE Healthcare, 
USA), washed in PBS, incubated for 1h with AB complex (Vector laboratories, The 
Netherlands) and visualized with Novared (Vector laboratories) or DAB (Dako, 
Denmark). Slides were counterstained with haematoxylin. Immunopositive areas 
of SMC and macrophages were calculated as percentage of total vein graft area in 
cross-sections by morphometry (Leica, Germany). To increase the TLR4 detection 
after AB complex slides were incubated for 10 minutes with biotinylated thyramids 
and again 1h with ABcomplex prior to visualization with Novared. 
As control parallel sections were incubated with 1% PBS/BSA alone or with Rabbit 
IgG isotype without adding detecting antibodies. Controls were all negative (not 
shown).
RT-PCR
Total RNA was isolated using Tri-Reagent (Sigma-Aldrich) according to the 
manufacturer’s protocol. The expression levels of TLR4 and Biglycan were analyzed 
by RT-PCR (real time polymerase chain reaction). The relative mRNA expression 
levels were determined by using GAPDH as housekeeping gene and the 2[−ΔΔC(T)] 
method. Values were expressed as fold of respective controls.
Statistical analysis
Values are presented as mean ± standard error of the mean (SEM). Statistical 
significance was calculated in SPSS for Windows-17.0. Differences between groups 
were determined using a non-parametric Mann-Whitney and One-way ANOVA 
(Kruskal-Wallis, non-parametric Dunn’s Multiple Comparison Test) tests. A Student’s 
t-test was used for statistical analysis of in vitro assays. Probability values of less 
than 0.05 were considered statistically significant.
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Figure I Ratio lumen/total vessel wall area of vein grafts of balb/c (n=8) and TLR4 deficient 
(C3H-Tlr4LPS-d) mice (n=7). 
Figure II  In vitro analysis of lenti-shTLR4 silencing. Murine TLR4 expression on CHO cells was 
analyzed after a dose dependent transduction with lenti-shTLR4. Positive control (A). Dose 
dependent transduction of lenti-shTLR4 in a 1:0.1 (B) 1:0.5 (C) 1:1 (D) 1:2 lentiviral particles/




Macrophages: PBS vs. lenti-shTLR4 p=0.037, lenti-control vs. lenti-shTLR4 p=0.054, PBS vs. 
lenti-control p=1.00. SMC: PBS vs. lenti-shTLR4 p=0.00006, lenti-control vs. lenti-shTLR4 
p=0.53, PBS vs. lenti-control p=0.0059.
Figure III Murine 3T3 fibroblast were transduced with PBS, lenti-control or lenti-shTLR4 and 
subsequently stimulated with LPS, 100ng/ml; Pam3Cys, 10µg/ml; TNF-α, 10ng/ml; IL-1β, 
10ng/ml; Non Stimulated. NFkβ activation due to LPS stimulation was significantly reduced 
in the lenti-shTLR4 transduced fibroblasts (F), A students t-test was used for statistical 
analysis * = P<0.01. 
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Objective   As a part of the innate immunity, Toll like receptors (TLRs) are thought 
to be important in the inflammatory process of vein graft remodeling. TLR3 
activates the MyD88 independent pathway via activation of TRIF and key interferon 
regulating factors, IRF3 and IRF7, resulting in induction of type I interferons. The 
aim of this study was to investigate the role of TLR3 pathway constituents on vein 
graft remodeling. 
Methods and Results   Vein grafting was performed by interpositioning the caval 
vein of a donor mouse in the carotid artery of a receiver mouse and subsequently 
the vein grafts were harvested at specific time point for further analysis. Pathway 
analysis by gene set enrichment analysis revealed that in 14 and 28 days old vein 
grafts of hypercholesterolemic ApoE3*Leiden mice  the TLR pathway and the type 
I Interferon pathway belong to the top 15 of significant regulated pathways.  The 
importance of the type I Interferon pathway is further illustrated by the 2-fold 
increase in vein graft wall thickening  in Tlr3-/- mice compared to control mice 
(p<0.001). Also Irf3-/- and Irf7-/- mice showed increased vein graft wall thickening 
(Irf3-/-; 39%, p=0.185, Irf7-/-; 68% p=0.003). Furthermore, the outward remodeling 
increased compared to control mice, resulting in (Tlr3-/-; 52%, p<0.001, Irf3-/-; 26%, 
p=0.081, Irf7-/-; 42%, p=0.049). Morphologic analysis revealed that Tlr3-/-, Irf3-/- and 
Irf7-/- mice showed significant more influx of macrophages than the control mice. 
Expression of typical Type I interferons inducible genes were found decreased in all 
three strains. In contrast, TNFα and CCL2 were only significantly increased in the 
Tlr3-/- mice.
Conclusions   The TLR3 pathway regulates vein graft remodeling in a protective 
way since Tlr3-/-, as well as the key downstream factors  Irf3-/- and Irf7-/- vein grafts 
show increased vessel wall thickening and outward remodeling. This increased 
remodeling in the knockout mice is the result of a pro-inflammatory response as 
reflected by the increase in macrophages and pro-inflammatory cytokines in the 
vein graft wall and a decrease in type I interferon regulated genes.
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Introduction
Autologous (saphenous) veins are commonly used as conduits to bypass occlusive 
atherosclerotic lesions in both coronary and femoral arteries. Unfortunately, vein 
graft failure is a major drawback since, within 10 years, almost half of the patients 
may again require a form of revascularization. In the patho-physiological processes 
of vein graft failure, inflammation is considered to be an important accelerating 
factor1-5. Toll like receptors (TLRs), part of the innate immune system, are important 
in inflammatory reactions via their recognition of exogenous pathogen associated 
molecular patterns (PAMPs) and endogenous damage associated molecular patterns 
(DAMPs). DAMPs are up regulated by cell death and tissue injury. Previously, 
we showed that cell death and tissue injury are part of the process of vein graft 
remodeling in murine vein grafts6. In agreement, DAMPs for TLR2 and TLR4, such 
as the extracellular matrix component EDA (alternatively spliced domain A of 
Fibronectin), Heat shock protein 60 (HSP60), extracellular matrix protein Biglycan 
and chromatin protein, high-mobility group protein B1 (HMGB1), are abundantly 
present in remodeled vein grafts7. Furthermore, TLR4 is functionally involved 
in intimal hyperplasia formation, accelerated atherosclerosis and vein graft 
remodeling7. The role of other TLRs in vein graft development is currently unknown. 
Since TLRs have vessel-specific profiles that further vary due to changes in cellular 
activation and differentiation, and other local processes8, it is of particular interest 
to investigate their role in vein graft remodeling. The Toll like receptor (TLR) family 
consists of at least 13 members. All TLRs, except TLR3, signal via the myeloid 
differentiation primary response gene 88 (MyD88 pathway), which drives the 
induction of the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFĸB) resulting in induction of pro-inflammatory cytokines9. TLR3 
signals via a MyD88-independent pathway with a central role for the adapter TIR-
domain-containing adapter-inducing interferon-β (TRIF) and interferon regulatory 
factor (IRF)3 and IRF7 resulting in induction of type I interferons (IFNs) (Figure 1). 
Interestingly, an unexpected protective role for TLR3 was found on neointima 
and atherosclerosis formation by Cole et al10. Others however, found that TLR3 
augments the inflammatory response to nucleic acids. TLR3 ligation also impaired 
endothelial function and specific deletion of TLR3 in immune cells resulted in 
reduced aortic inflammation and atherosclerotic burden11-14. One should appreciate 
that the response to TLR3 stimulation is not uniform, and differs in specific tissue 
microenvironments8. TLR3 responsive genes, Type I IFNs and IFN-inducible genes 
are involved in bridging innate and adaptive immunity and induction of co-
stimulation15. In viral infections, downstream TLR3 transcription factors IRF3 and 
IRF7 are the most important factors that control the expression of type I IFNs.  IRF3 
signaling results in early induction of the Ifnb gene, whereas IRF7 has a pivotal role 
in the induction of all type I IFN genes16. The role of Type I interferon (inducible) 
genes in vascular remodeling however, is unclear. 
Like most TLRs, TLR4 activation leads to an inflammatory profile resulting in 
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augmentation of lesion formation and remodeling17,18.  TLR4 signaling however, 
depends on both the MyD88 and TRIF pathways for proper functioning9,19. Upon 
activation, TLR4 can be internalized into the endosome after which activation of 
the TRIF pathway follows. This indicates that not only different effects of TLRs are 
critical in vascular disease but also the importance of the underlying pathways as 
well as the presence and/or quantity of endogenous ligands. Therefore, it would be 
important to see if and how TLR3 influences vein graft remodeling.  In this study 
we explored the role of the TLR3 pathway by performing vein graft surgery in mice 
that are deficient in TLR3 and downstream factors IRF3 and IRF7 in comparison with 
TLR4 and TLR2 deficient mice without exogenous ligand stimulation. 
Figure 1. TLR signaling pathways. TLRs signal via specific pathways using transcription factors 
nuclear factor NFĸB in the myeloid differentiation factor 88 (MyD88) route and interferon 
regulating factors IRF3 and IRF7 in the TIR-domain containing adaptor inducing interferon-β 
(TRIF) signaling route. MyD88 activation occurs upon cell surface signaling (TLR1, TLR2, 
TLR4, TLR6) using MyD88 adaptor-like (MAL) as an adaptor or via endosomal (TLR7, TLR9) 
signaling via Il1 receptor-associated kinases, IRAK4, IRAK-M, IRAK1, IRAK2 in interaction 
with TNF receptor associated factor-6 (TRAF-6). This complex activates an inhibitor of κB 
kinase (IKK) complex that upon phosphorylation activates nuclear NFĸB activation resulting 
in transcription of pro-inflammatory cytokines. TRIF signaling occurs via IRF3, specifically 
upon TLR3 activation also via IRF7, resulting in activation of Type I IFNs. TRIF signaling can 




This study was performed in compliance with Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament.  All animal experiments were 
approved by the animal welfare committee of the Leiden University Medical Center. 
For the experiments 10-16 weeks old male mice were used. ApoE3*Leiden mice 
(fed a high cholesterol diet (AB diets)) Tlr2-/- and Tlr4-/- that were kindly provided by 
Dr. Akira (Osaka University, Japan) and the Irf3-/- and Irf7-/- that were kindly provided 
by Dr. Taniguchi (University of Tokyo, Japan) were bred in the local animal facility. 
Control C57BL/6 mice and Tlr3-/- were purchased from Charles River Laboratories. 
Vein graft surgery
Vein graft surgery was performed by donor caval vein interpositioning (caval vein 
of approximately 2 mm length) in the carotid artery of recipient mice as reported 
previously5. Before surgery, mice were anesthetized with midazolam (5 mg/kg, Roche 
Diagnostics), medetomidine (0.5 mg/kg, Orion) and fentanyl (0.05 mg/kg, Janssen 
Pharmaceutical). After the procedure the mice were antagonized with atipamezol 
(2.5 mg/kg, Orion) and fluminasenil (0.5 mg/kg Fresenius Kabi). Buprenorphine (0.1 
mg/kg, MSD Animal Health) was given after surgery to relieve pain. 
Whole-genome expression
In ApoE3*Leiden mice vein graft surgery was performed and mice were sacrificed 
at time point 3, 7, 14 and 28 days after surgery. From 3-4 mice per time point vein 
grafts were collected and total RNA was extracted using RNeasy fibrous tissue 
minikit (Qiagen). RNA integrity was checked by NanoDrop 1000 Spectrophotometer 
(NanoDrop Technologies) and 2100 Bioanalyzer (Agilent Technologies). For whole-
genome expression profiling, amplified biotinylated RNA was generated using 
the Illumina TotalPrep RNA Amplification Kit. For array analysis, MouseWG-6 v2.0 
Expression Beadchips (Illumina) were used. Expression levels were Log2-transformed 
and after quantile normalization, transcripts showing background intensity were 
removed from the analysis. Gene expression levels at the different time points were 
expressed relative to average t0 levels generating ratios for 23.067 regulated genes. 
RNA isolation, cDNA synthesis and RT-PCR
Total RNA was isolated from 10 (20µm thick) paraffin sections of vein grafts 28d 
after surgery (n=6/strain). RNA was isolated according manufacturers protocol 
(FFPE RNA isolation kit, Qiagen). Quantitative PCR (Q-PCR) analysis of 84 type I 
Interferon response-related genes was performed using a RT2 ProfilerPCRArray (SA 
Biosciences) as per the manufacturer’s protocol.  The complete list of the genes 
analyzed is available at http://www.sabiosciences.com/ rt_pcr_product/HTML/
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PAMM-016Z. html. Prior to RT2 profiler array FPPE RNA was reverse transcribed using 
the RT² First Strand Kit (SA Biosciences). RNA for single Q-PCR was reverse transcribed 
using a High Capacity RNA-to-cDNA kit (Applied Biosystems). Commercially available 
TaqMan gene expression assays for hypoxanthine phosphoribosyl transferase 
(HPRT1), and selected genes were used (Applied Biosystems). All Q-PCRs were 
performed on the ABI 7500 Fast system. The 2-ΔΔCt method was used to analyze 
the relative changes in gene expression.
GSEA analysis
Gene set enrichment analysis (GSEA) was performed with the curated gene sets 
from Kegg, Biocarta, the Reactome and published studies, resulting in a total of 
1564 gene sets. For each gene set (pathway) an enrichment score (ES) is calculated20 
representing the difference between expected and observed ranking which 
correlates with the phenotype of the vein grafts at the different time points. 
Histological and immunohistochemical assessment of vein grafts
Vein grafts were harvested after perfusion fixation with 4% formaldehyde, fixated for 
4 hours and paraffin-embedded. Six consecutive sections (with 150 µm interspace) 
per vein graft were routinely stained with hematoxylin-phloxine-saffron (HPS) for 
histological and morphometric analysis (Qwin, Leica). Vein graft thickening or vessel 
wall area was defined as the area between lumen and adventitia and determined by 
subtracting the luminal area from the total vessel wall area. Picrosirius red staining 
was used to visualize collagen content. Antibodies directed at smooth muscle cell 
actin, TLR3 (Sigma), CD45 (BD Pharmingen) TLR2, IRF3, IRF7 (Abcam), Mac-3 and 
TLR4 (Santa Cruz) were used for immunohistochemical stainings. For each antibody, 
isotype-matched antibodies were used as negative controls and staining was absent 
these sections (data not shown). SMC actin and Sirius red stained sections were 
quantified by computer assisted analysis (Qwin, Leica). The immuno-positive area 
measured is expressed as a percentage of the vessel wall area5. Vein graft segments 
were analyzed for influx of leukocytes (CD45) or macrophages (Mac-3) by scoring 
cells in 6 consecutive sections per mouse in a semi-quantitative manner. 1: < 25 
positive cells / section, 2: 25-50 positive cells / section, 3: >50 positive cells.
Statistical analysis
Results are expressed as mean±SEM. Data, except for the GSEA, were analyzed 
by the non-parametric Kruskal-Wallis or Mann-Whitney test using GraphPad 
Prism. Probability-values <0.05 were regarded significant. GSEA; by permuting the 
phenotype labels for the ES, a statistical significance (nominal P value) for the ES is 
provided. An adjustment for the gene set size generated the normalized enrichment 
score (NES). To correct for multiple testing the proportion of false positives is 
calculated to provide the false discovery rate (FDR) corresponding to each NES. A 
combined P-value <0.05 and FDR q-value < 0.05 was considered significant.
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Results
TLR  and type I Interferon pathways are strongly regulated during vein graft 
development
To obtain an overview on how TLRs are regulated during vein graft remodeling we 
analyzed expression of TLRs in hypercholesterolemic ApoE3*Leiden mice with help 
of mRNA array analysis. Most TLRs showed significant up regulation at most time 
points compared to untreated caval veins (t0) (Figure 2A). Interestingly, TLR3 did 
not show any regulation in time whereas TLR4 was only significantly up regulated at 
t3. TLR5 was the only down regulated TLR.  We further analyzed whether IRFs were 
regulated since these are the most prominent transcription factors downstream 
TLR3. Most IRFs showed regulation as illustrated by Figure 2B; especially IRF 7 was 
Figure 2. Regulation of TLRs and IRFs during vein graft remodeling. Array analysis of vein 
grafts in hypercholesterolemic ApoE3*Leiden mice was performed on t3, t7, t14 and t28 in 
comparison to non-injured caval veins (t0). A. Most TLRs show up regulation at all the time 
points. TLR3 is not regulated in time. TLR4 is only significantly regulated at t3 and TLR5 is 
significantly down regulated at t28. B. IRFs show a diverse pattern in regulation; especially 
IRF7 is significantly up regulated, whereas IRF3 shows little regulation. 
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strongly upregulated. To better understand the biologic role of genes regulated in 
time during vein graft development, we performed pathway analysis by GSEA on 
1564 available gene sets. We identified 176 significant up regulated curated gene 
sets at t14 compared to uninjured caval veins (t0) whereas 52 gene sets were down 
regulated at t14. At t28 120 gene sets were significant up regulated and 108 gene 
sets were down regulated compared to t0. Within the top 15 of significant curated 
gene sets on both time points besides the expected extracellular matrix organization 
gene sets, TLR and Type I IFN gene sets can be found in Table 1 illustrating that both 
pathways are involved in vein graft development. 
 
Table 1. Top 40 of significantly regulated gene sets in vein grafts of hypercholesterolemic 
ApoE3*Leiden mice 28 days after surgery as analyzed by gene set enrichment analysis 
(GSEA) with curated gene sets from Kegg, Biocarta, the Reactome and published studies. In 
red, relevant pathways regarding TLR signaling are shown. 
TLR3 deficiency results in enhanced vein graft thickening and outward remodeling
Since TLRs have vessel-specific profiles we first evaluated the expression of TLR3 in 
native caval veins and 28 day old vein grafts of C57BL/6 mice.  Immunohistochemical 
staining of TLR3 (Figure 3A) revealed that most native caval vein SMCs as well as 
endothelial cells stained negative for TLR3 (in contrast to the surrounding adipose 
tissue). In 28 day old C57BL/6 vein graft segments (n=6) almost all inflammatory 
cells, adventitial fibroblasts and endothelium were found positive whereas SMCs 
showed diverse staining (Figure 3A). To investigate whether TLR3 might be involved 
in vein graft remodeling Tlr3-/- (n=9) and control mice (n=10) underwent vein graft 
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Figure 3. Deficiency of TLR3 ameliorates vein graft remodeling.  A. TLR3 staining is absent 
in the vessel wall of native caval veins in C57BL/6 mice except for the surrounding fat tissue 
(left panel). 28 days after surgery intense TLR3 staining could be observed in the adventitia 
of vein grafts (C57BL/6) in fibroblasts and inflammatory cells, whereas SMCs in the vessel 
wall showed a patchy distribution (right panel), inset; overview of vein graft. B. Vein graft 
surgeries were performed in Tlr3-/- mice (n=9) and control mice (n=10). Tlr3-/- mice showed 
a 2-fold increase in the vessel wall area, 28 days after surgery, compared to the control 
mice. C. Outward remodeling as scored by the total vessel wall area (D) graph representing 
the luminal area. E. shows representative photographs of control C57BL/6 and Tlr3-/- mice 
indicating the differences in vein graft size between the strains. F. The number of infiltrating 
leukocytes were significantly increased in Tlr3-/- mice (semi-quantitative scored in arbitrary 
units, 1; <25 cells, 2; 50-100 cells, 3>100 cells). This also accounts for the number of 
infiltrating macrophages (G) semi-quantitative scored in arbitrary units, 1; <25 cells, 2; 50-
100 cells, 3>100 cells.  H. Quantitative analysis of the SMCs content (expressed in mm2) did 
not reveal significant differences between the groups. I. The relative percentage SMCs in the 
vein graft segments was also not significantly different between the control and Tlr3-/- mice 
J. Quantitative analysis of the Sirius red staining revealed an increased collagen content in 
the Tlr3-/- vein grafts. However, when expressed as the relative percentage collagen in the 
vein grafts, no differences were observed between the groups (K).
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surgery. No differences in weight were found between the groups pre- and post-
surgery (data not shown). Interestingly, 28 days after surgery Tlr3-/- mice had 
developed  a 2-fold increase in vein graft wall thickness compared to the control 
mice (figure 3B, E).  This was accompanied by a significant increase in total vessel 
area (figure 3C). Due to this compensatory outward remodeling the lumen area did 
not deviate between the two groups (figure 3D). Next, we focused on the cellular 
composition of the vein grafts. Analyzing the influx of inflammatory cells we detected 
significant more leukocytes in the Tlr3-/- mice compared to the control group (Figure 
3F).  Since macrophages are a well-known source of TLRs we also looked at the influx 
of macrophages. Macrophage numbers were increased in the vein graft wall of the 
Tlr3-/- mice (Figure 3G). A non-significant increase in SMC positive area was found 
in the knockout mice. When corrected for the vessel wall thickness (expressed as 
percentage SMCs in the vessel wall) there was no difference between the Tlr3-/- and 
control mice (figure 3H, I). A comparable effect was seen with the collagen content; 
a significant increase in collagen area was measured but corrected for vessel wall 
area the difference between the groups did not hold (Figure 3J, K). 
Deficiency of downstream TLR3 factors IRF3 and IRF7 results in aggravated vein 
graft remodeling
IRF3 and IRF7 are key regulators of type I IFNs gene expression elicited by virus 
activated TLR3 signaling. Here we explored the role of these IRFs in vein graft 
remodeling. To see whether IRF3 and IRF7 are expressed by vascular tissues, we 
stained caval veins and vein grafts of C57BL/6 mice for both factors. 
Both cytoplasmic as well as nuclear staining was seen indicating that latent and 
active forms of IRF3 and IRF7 are available. IRF3 and IRF7 are constitutively 
expressed by SMC and endothelial cells in caval veins (left panels) and mature vein 
grafts (right panels). In the vein grafts, inflammatory cells also stained positive for 
both factors. SMCs of remodeled vein grafts showed more intense staining of IRF7 
than IRF3. Placement of vein grafts in Irf3-/- mice (n=9) resulted in a trend towards 
increased vein graft wall thickening compared to control mice (n=7) although non-
significant (p=0.185).  Interestingly, Irf7-/- mice (n=8) showed a significant (p=0.003), 
68% increase in size compared to controls (Figure 4C, F). Total vessel wall area, as an 
indicator for outward remodeling, was increased in the Irf7-/- mice (p=0.049) whereas 
the Irf3-/- showed a non-significant trend (p=0.081) in figure 2D. The lumen in all 
three groups was not significantly different (Figure 4E). Analysis of the inflammatory 
aspects of the vein grafts revealed that, in contrast to the Tlr3-/- mice, both the Irf3-/- 
and Irf7-/- mice showed no significant differences in number of leukocytes compared 
to the control group (Figure 4G). The macrophage score however, was in both the 
Irf3-/- (p= 0.059) and Irf7-/- (p=0.038) mice increased compared to the control group 
(Figure 4H). Again as seen in the Tlr3-/- mice, no differences in absolute area of SMCs 
and collagen between the three groups, except for the percentage collagen in the 
vessel wall which was significantly decreased in Irf7-/- mice (Figure 4I-L). 
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Figure 4. IRF 3 and IRF7 deficiency result in enhanced vein graft remodeling. Expression of 
IRFs in caval veins and vein grafts stained for IRF3 (A) and IRF7 (B). C. vein graft thickening 
in Irf3-/- mice (n=9) and Irf7-/- mice (n=8) compared to controls (n=7). Irf7-/- mice showed a 
significant 68% increase in vein graft size. D. Irf3-/- and Irf7-/- mice showed an increase in 
total vessel wall area representing outward remodeling whereas all three groups showed 
comparable luminal areas (E). F. Represents photographs of control C57BL/6, Irf3-/- and Irf7-
/- Hematoxillin, Phloxine and Saffron (HPS) stained sections. G. The number of infiltrating 
leukocytes was not significantly different in all groups (semi-quantitative scored in arbitrary 
units, 1; <25 cells, 2; 50-100 cells, 3>100 cells). H. The number of infiltrating macrophages 
was significantly increased in Irf3-/- and Irf7-/- vein grafts (semi-quantitative scored in 
arbitrary units, 1; <25 cells, 2; 50-100 cells, 3>100 cells).  I. Quantification of the SMC content 
expressed in absolute numbers (mm2)  or percentage (J) did not deviate between the groups. 
K. Quantitative analysis of the collagen content as measured by Sirius red staining, did not 
deviate between the groups. Whereas the relative percentage collagen in the Irf7-/- vein 
grafts was significant decreased (L).
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Both cytoplasmic as well as nuclear staining was seen indicating that latent and 
active forms of IRF3 and IRF7 are available. IRF3 and IRF7 are constitutively 
expressed by SMC and endothelial cells in caval veins (left panels) and mature vein 
grafts (right panels). In the vein grafts, inflammatory cells also stained positive for 
both factors. SMCs of remodeled vein grafts showed more intense staining of IRF7 
than IRF3. Placement of vein grafts in Irf3-/- mice (n=9) resulted in a trend towards 
increased vein graft wall thickening compared to control mice (n=7) although non-
significant (p=0.185).  Interestingly, Irf7-/- mice (n=8) showed a significant (p=0.003), 
68% increase in size compared to controls (Figure 4C, F). Total vessel wall area, as an 
indicator for outward remodeling, was increased in the Irf7-/- mice (p=0.049) whereas 
the Irf3-/- showed a non-significant trend (p=0.081) in figure 2D. The lumen in all 
three groups was not significantly different (Figure 4E). Analysis of the inflammatory 
aspects of the vein grafts revealed that, in contrast to the Tlr3-/- mice, both the Irf3-/- 
and Irf7-/- mice showed no significant differences in number of leukocytes compared 
to the control group (Figure 4G). The macrophage score however was in both the 
Irf3-/- (p= 0.059) and Irf7-/- (p=0.038) mice increased compared to the control group 
(Figure 4H). Again as seen in the Tlr3-/- mice no differences in absolute area of SMCs 
and collagen between the three groups, except that the percentage collagen in the 
vessel wall which was significantly decreased in Irf7-/- mice (Figure 4I-L). 
Deficiency of TLR4 deteriorates vein graft thickening
Besides the well-known MyD88-dependent signaling pathway resulting in activated 
(pro-inflammatory) genes9, TLR4 can signal via downstream pathway factors 
such as TRIF and IRF3 similar to TLR3, resulting in activation of the Ifnb gene.  To 
investigate how the TLR4 pathway is involved in vein graft remodeling we included 
TLR4 deficient mice in our study. We previously showed the inhibiting effects of 
TLR4 deficiency on vein graft remodeling by means of congenic BALB/c C3H-Tlr4LPS-d 
mice7. It is known that BALB/c mice show a T helper 2-like immune response 
whereas the C57BL/6 mice express a pro-inflammatory Th1-like profile21.  To enable 
a fair comparison of the effects of TLR4 deficiency with those of the other TLR 
and IRF deficient strains and not to linger in Th1/Th2 differences, we performed 
vein graft surgeries in C57BL/6 mice deficient for TLR4 (n=7) and littermate control 
mice (n=10).  Both groups showed no differences in weight pre- and 28 days post-
surgery (data not shown). TLR4 expression was first examined in caval veins and 
vein grafts in C57Bl/6 mice (Figure 5A). Vein graft SMCs as well as endothelial cells 
and fibroblasts in the adventitia showed pronounced expression of TLR4 whereas 
native caval veins showed hardly any TLR4 staining. TLR4 deficiency on a C57BL/6 
background resulted, in agreement with the C3H-Tlr4LPS-d mice7, in a significant 40% 
decrease in vessel wall area. No significant differences in outward remodeling and 
lumen area were detected between the groups (Figure 5B-E). The number of CD45 
positive cells was significantly decreased in the Tlr4-/- mice whereas no significant 
difference in macrophage counts could be detected (Figure 5F, G). Additional 
morphologic quantification revealed that the absolute area and percentage SMCs
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in the vessel wall did not differ between the Tlr4-/- and control mice (figure 5H, I) nor 
did the collagen area and percentage collagen (Figure 5J, K). 
Figure 5. TLR4 deficiency results in decreased vein graft thickening and vascular inflammation. 
A. In caval veins TLR4 staining was restricted to a few cells, mainly SMCs (left panel). The 
majority of the SMCs in the vein grafts stained positive as did the inflammatory cells (right 
panel). B. A significant increase in vein graft thickening was seen in the Tlr4-/- mice. In contrast 
both total vessel area and lumen area did not deviate between the Tlr4-/- and control mice (C, 
D). E. representative photographs of vein grafts in Tlr4-/- mice (n=7) and control mice (n=10), 
HPS staining. The number of leukocytes was significantly increased in Tlr4-/-mice whereas 
the macrophage score was not different from that of the control mice (F, G). Analysis of the 
area and percentage SMCs and collagen revealed no significant differences between the 
groups (H-K).  
TLR2 does not seems to be crucial in vein graft development
Since the Tlr4-/- mice demonstrated complete opposing remodeling to the Tlr3-/- 
mice, we wondered if signaling via the MyD88 pathway was primarily responsible 
for the decrease in vein graft remodeling. Therefore we performed vein graft
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Figure 6. TLR2 deficiency does not affect vein graft remodeling A.TLR2 staining is almost 
absent in the caval veins (left panel) whereas most cell types in the vein graft wall (SMCs, 
fibroblasts, endothelial cells and invading inflammatory cells express TLR2 (right panel). 
Vein graft interpositioning in Tlr2-/- mice did not result in differences compared to control 
mice in vein graft thickening, total vessel area and lumen area (B-E). Leukocyte score and 
macrophage score did not deviate between Tlr2-/- and control mice (F-G).Quantification of 
the SMC content expressed in absolute numbers (H) or percentage (I) showed no significant 
differences between the groups also the collagen area as well as the percentage collagen 
were comparable between the groups (J-K). 
surgeries in mice that solely signal via the MyD88 pathway: the Tlr2-/- mice. First, we 
examined the expression of TLR2 in the vein graft segments. Hardly any TLR2 was 
detectable in caval veins, whereas clear staining of TLR2 was found in infiltrating 
inflammatory cells, SMCs and endothelial cells in the vein grafts (figure 6A). Next, 
we performed vein graft surgery on Tlr2-/- and C57BL/6 littermate control mice
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(n=7). No differences in weight were found pre- and 28 days post-surgery between 
the two groups (data not shown). Surprisingly, no difference in vessel wall area 
could be detected between the two groups (Figure 6B, E). Also, total vessel area, 
outward remodeling and lumen area did not deviate either between the groups 
(Figure 6C and 5D). Leukocyte and macrophage numbers were equal between the 
groups (Figure 6F, G) while quantification of the smooth muscle cells (SMCs) area 
as well as percentage in the vessel wall revealed no significant differences between 
the Tlr2-/- and control mice (figure 6H, I) nor did the area or percentage collagen 
(Figure 6J, K) deviate between the groups. 
Type I interferon response genes involved in outward vein graft remodeling
We hypothesized that the outward vein graft remodeling in the TLR3, IRF3 and 
IRF7 deficient  mice were the result of type I interferon (inducible) gene expression 
profiles. To test this hypothesis we performed a specific RT2 profiler array with 
84 type I interferon response genes on pools of Tlr2-/-, Tlr3-/-, Tlr4-/-, Irf3-/-, Irf7-/- 
and control C57BL/6 vein grafts.  A low number of genes was found up regulated 
in the various knockout mice (Figure 7A). Deficiency of TLR3, IRF3 and IRF7, but 
unexpectedly also TLR2 deficiency, resulted in a (non-significant) decrease in 
specific IFN inducible genes such as Ifit1, Ifit3 and Isg15. Also IRF7 and Il6 were 
decreased expressed in these knockout mice as shown in figure 7B. Remarkably, 
Tlr4-/- mice hardly expressed regulation of any of these genes. 
To assess the effect of TLR and IRF deficiency on inflammatory cytokine expression 
we explored the gene expression of CCL2, TNFα and Il10 in the various knockout mice. 
RNA levels of CCL2 (Figure 7C) and TNFα (Figure 7D) were significantly increased in 
the Tlr3-/- mice. Il10 was up regulated to a lesser extent, and non-significant, in the 
Tlr3-/- mice as well as in the Tlr2-/- mice (Figure 7E).
Discussion
Although there is evidence of exogenous pathogens in vascular lesions22, it seems 
unlikely that these account for the complete repertoire of TLR activation. DAMP 
mediated activation of TLRs is thought to be an important process that drives 
immune-activated diseases such as cardiovascular diseases, rheumatoid arthritis 
and lupus23-25. We previously demonstrated the presence of several TLR DAMPS in 
remodeled vein grafts7 whereas Cavasanni et al. showed that RNA from necrotic 
cells could serve as ligand for TLR3 independent of viral stimuli26. Here we focused 
on the effects of TLR activation upon tissue damage and activation as a result of the 
engraftment procedure, flow disturbances and subsequent arterialization phase. 
mRNA array analysis revealed that both TLRs and IRFs are highly regulated during 
vein graft remodeling indicating that both pathways are substantially  involved in 
vein graft development. This is further fueled by GSEA pathway analysis which 
showed that TLR and Type I IFN gene sets belonged to the top 15 of significantly 
regulated gene sets. 
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Figure 7. Deficiencies of TLR and IRF differentially regulate type I interferon (inducible) genes 
and inflammatory cytokines. mRNA of vein graft of TLR2, TLR3, TLR4, IRF3 and IRF7 deficient 
mice were analyzed with reverse-transcription real-time PCR normalized to housekeeping 
genes A. RT2 profiler array of Type I IFNs on pools of TLR and IRF deficient vein grafts; genes 
are shown that are up regulated more than 2-fold in one of the strains. B. Type I IFNs RT2 
profiler array; genes are shown that are down regulated more than 2-fold.   Inflammatory 
cytokines CCL2 (C), TNFα (D) and Il10 (E), data are expressed as fold induction. *p<0.05.
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A prominent role for type I IFN genes in vein graft remodeling is suggested by 
the increased vein graft thickening and outward remodeling as seen in the Tlr3-
/-  mice and the Irf7-/- mice whereas, the  Irf3-/- mice showed near significant 
outward remodeling. This was accompanied by down regulation of typical type 
I IFN inducible genes in the vein grafts and pro-inflammatory responses in the 
vein grafts of Tlr3-/- mice. Type I IFNs contribute to disease progression in auto-
immune diseases by increased pro-inflammatory responses27-29. In animal models of 
cardiovascular diseases, inhibition of IFNβ results in pro-inflammatory responses in 
the monocytic lineage30,31. This is in line with the increased influx of macrophages in 
these knockout strains suggesting that pro-inflammatory responses are responsible 
for the observed outward remodeling. 
In contrast to the Tlr3-/- mice, gene expression of pro-inflammatory cytokines in the 
Irf3-/- and Irf7-/- mice were not affected. Compensatory mechanisms by other TLRs 
in the Tlr3-/- mice are a possible explanation for the increased expression of CCL2 
and TNFα, especially since MyD88 gene transcription was found to be increased 
in Tlr3-/- vein grafts. The main function of IRF3 and IRF7 is transcription of type 
I IFNs, therefore limited effect of IRFs on other genes such as pro-inflammatory 
cytokines are expected9. IRF7 is an inducer of  a positive feedback loop of enhanced 
activation of type I IFNs-(TLR3)-IRF716,32, this may explain the stronger reduction of 
type I Interferon (inducible) genes in the Irf7-/- mice and subsequent effects on vein 
graft thickening and outward remodeling in comparison to the Irf3-/- mice. 
Vein graft thickening was found impaired in the Tlr4-/- mice. This was accompanied 
by a reduction in leukocytes but not the macrophages in the vessel wall. Reduced 
inflammatory responses and reduced vascular burden match the findings 
observed in other TLR4 deficient murine models7,33,34. TLR4 signaling to induce pro-
inflammatory cytokines occurs initially via the MyD88 signaling pathway19. TLR4 
was only significant up regulated at t3 in the array analysis. These results match the 
findings observed in the 28 day old Tlr4-/- vein grafts that regulation of Type I IFN 
(inducible) genes was not detectable, nor regulation of MyD88 or pro-inflammatory 
cytokines suggesting that TLR4 is an early effector in vein graft remodeling. The 
fact that the remodeling was reduced after 28 days in Tlr4-/- mice and no effects 
on type I IFN gene expression is observed suggests that in vein graft remodeling 
TLR4 signaling is rather an early response and associated with MyD88 signaling as 
described previously19 and not linked to the TRIF mediated , IRF3 associated type I 
IFN inducible genes. The latter pathway is linked to a late activation response that 
is observed after internalization of TLR4. 
TLR4 and TLR2 share common features such as the MyD88 signaling route as well 
as endogenous ligands such as HMGB1, Biglycan and HSP60 that were found to 
be expressed in remodeled vein grafts7. In contrast to the Tlr4-/- mice, vein graft 
remodeling was not affected in Tlr2-/- mice. Neither the cellular composition nor 
inflammatory cytokine expression was affected. This effect of limited responses 
without exogenous stimulation was also observed by Schoneveld et al. in a model of 
arterial remodeling, although stimulation of TLR2 with PAM3Cys clearly increased
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vascular burden35. Remarkably, Tlr2-/- vein grafts showed down regulation of some 
typical type I IFN inducible genes e.g. IFIT 1-3, Isg15 and Oas1a whereas IFNa2 and 
IFNa4 were up regulated. To our knowledge no direct links between TLR2 and Type 
I IFNs are reported, however, Liu et al. showed an indirect link: they showed that 
TLR2 can inhibit TLR7/9-dependent induction of type I IFNs via IRAK1 depletion36, 
demonstrating that indirect effectuation of Type I IFNs by TLR2 is possible. Whether 
this particular pathway is applicable to our experiments seems unlikely since we did 
not observed regulation of TLR7, TLR9 or MyD88 in the Tlr2-/- vein grafts at the 28 
day time point. 
Collectively, we here demonstrate that besides the MyD88 dependent pathways, 
the TRIF dependent pathway and downstream type I IFNs are of importance in vein 
graft remodeling. In particular our finding of increased vein graft thickening and 
remodeling in the Irf7-/- mice gives food for thought to the discussion on the role of 
TLR pathways in vascular diseases. These data confirms once more that depending 
of the microenvironment and especially the contribution of immune cells to the 
vessel wall, TLRs exert different sets of pro-inflammatory mediators that ultimately 
determine the extent of vascular remodeling. 
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Objective  Arterial pressure induced vein graft injury can result in endothelial 
loss, accelerated atherosclerosis and vein graft failure. Inflammation, including 
complement activation, is assumed to play a pivotal role herein. Here, we analyzed 
the effects of C1-esterase inhibitor (C1inh) on early vein graft remodeling.
Methods  Human saphenous vein graft segments (n=8) were perfused in vitro with 
autologous blood either supplemented or not with purified human C1inh at arterial 
pressure for 6 hours. The vein segments and perfusion blood were analyzed for 
cell damage and complement activation. In addition, the effect of purified C1inh on 
vein graft remodeling was analyzed in vivo in atherosclerotic ApoE3*Leiden mice, 
wherein donor caval veins were interpositioned in the common carotid artery.
Results   Application of C1inh in the in vitro perfusion model resulted in significantly 
higher blood levels and significantly more depositions of C1inh in the vein wall. This 
coincided with a significant reduction in endothelial loss and deposition of C3d and 
C4d in the vein wall, especially in the circular layer, compared to vein segments 
perfused without supplemented C1inh. Administration of purified C1inh significantly 
inhibited vein graft intimal thickening in vivo in atherosclerotic ApoE3*Leiden mice, 
wherein donor caval veins were interpositioned in the common carotid artery. 
Conclusion  C1inh significantly protects against early vein graft remodeling, including 
loss of endothelium and intimal thickening. These data suggest that it may be worth 
considering its use in patients undergoing coronary artery bypass grafting.
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Introduction
Vein graft failure remains a major clinical problem. As many as 50% of coronary 
artery vein grafts fail within 10 years after coronary artery bypass grafting (CABG). 
The main inducer of vein graft damage is presumed to be the exposure of the vein 
grafts to arterial blood pressure, inducing endothelial injury. Vein graft failure 
then develops through accelerated atherosclerosis, characterized by foam cell 
formation, influx of inflammatory cells and migration of vascular smooth muscle 
cells to the intima of the vein graft. Inflammation is assumed to play a pivotal role 
in propagating vein graft failure1. 
The complement system is a large family of effector and regulatory proteins that 
forms a prominent component of the innate immune system. The involvement of 
complement in cardiovascular disease is well accepted, including atherosclerosis 
of arteries and aortic valves2,3. Furthermore, a role for complement in vein graft 
failure is acknowledged. In patients undergoing CABG the complement system is 
activated. This can occur as a result of, amongst others, the surgical trauma, contact 
of the blood with non-endothelial surfaces during extracorporeal circulation 
and ischemia-reperfusion injury4-6. This activation of the complement system 
in CABG patients is characterized by the plasmatic release of potent vasoactive 
anaphylatoxins C3a, C4a and C5a and the membrane attack complex C5b-97. On a 
tissue level, expression of complement factors C1q, C3, and C9 was found in failing 
venous grafts in mice8, indicating direct involvement of complement activation in 
venous graft failure. Indeed, complement factor C3 inhibition via Crry-Ig-antibody 
treatment reduced vein graft atherosclerosis in mice8 and antibody-based inhibition 
of C5a (pexiluzimab) or the serine protease inhibitor C1-esterase inhibitor (C1inh) 
resulted in better short term clinical outcomes, such as decreased mortality and 
improved cardiac function, in patients undergoing CABG9-12. Although, of these 
latter two, their effect on the venous graft itself remains to be established.
C1inh is a natural occurring protease inhibitor of the serpin family13. C1inh 
inactivates a variety of proteases such as the complement proteases C1r and C1s, 
thereby inhibiting the alternative pathway of complement14. In addition, the contact 
system proteases factor XII and plasma kallikrein and the coagulation protease 
factor XI are inactivated by C1inh13. As such, C1inh treatment was shown to exert 
favorable, anti-inflammatory effects in sepsis patients15 and animal sepsis models16, 
to protect against LPS-mediated increased vascular permeability and endothelial 
cell injury in vitro17 and to inhibit atherosclerotic lesion development after arterial 
injury in mice18. These data suggest that C1inh treatment may be beneficial in CABG 
and protect the venous graft against acute injury to the endothelium and against 
atherosclerotic lesion development. In this study therefore, the effects of C1inh on 
acute vein graft injury were analyzed in perfused human saphenous veins and on 




Human vein graft tissue
Surplus segments of harvested saphenous veins of patients who underwent 
coronary artery bypass grafting (CABG) (n=8) were used with the patients consent. 
These vein segments were collected in the operating room under sterile conditions 
for histopathological examination. Part of these vein graft segments were fixed in 
4% (m/v) buffered formaldehyde immediately after harvesting. The remaining part 
was cut in half. One half was perfused with autologous heparinized blood of the 
same patient and the other half was perfused with this blood supplemented with 
purified human C1inh (4U/mL). The veins were perfused in an experimental set-
up at arterial pressure (60 mm Hg) for 6 hours19 and fixed in 4% (m/v) buffered 
formaldehyde thereafter. The vein sections were then embedded in paraffin for 
immunohistochemical analysis. Samples (+/- 0.5 mL) of the perfusion blood were 
taken every hour. The perfusion blood was centrifuged at 1300xg for 10 minutes 
and the obtained plasma was stored at -80°C until analysis. Our study was approved 
by the ethics committee of the VU Medical Centre and the OLVG, Amsterdam.
Antibodies
The following antibodies were used: mAb mouse-anti-human C1inh (RII; Sanquin 
Research at CLB, Amsterdam, The Netherlands; 10 µg/mL), mAb mouse-anti-human 
CD34 (Dako, Glostrup, Denmark; 1:25 dilution), mAb (mouse) against Bcl-2 (Dako; 
1:150 dilution), pAb rabbit-anti-active caspase-3 (Promega, Madison, WI, USA; 1:250 
dilution), pAb rabbit-anti-human C3d (Dako; 1:1000 dilution), mAb mouse-anti-
human C4d (Serotec, Düsseldorf, Germany, 1:200 dilution), pAb rabbit-anti-human 
Myeloperoxidase (MPO) (Dako; 1:500 dilution), pAb rabbit-anti-mouse macrophage 
(Accurate Chemical, Westbury, NY, USA: 1:3000 dilution) for the detection of 
macrophage derived foam cells within the thickened vessel wall and mAb mouse-
anti-rat smooth muscle α-actin (SMA) (cross-reacts with mouse; Roche, Almere, 
The Netherlands: 1:750 dilution). 
(Immuno)histochemistry 
Paraffin embedded human- or mouse vein graft cross sections (4 µm thick) were 
deparaffinised for 10 minutes in xylene and dehydrated with ethanol. Endogenous 
peroxidase activity was blocked by incubation in 0.3% (v/v) H2O2 in methanol for 
30 minutes. The antigen retrieval step for CD34, C1inh, C3d, C4d, macrophages 
and MPO staining was boiling in 10 mmol/L sodium citrate buffer, pH 6, for 10 
minutes. For caspase-3 and Bcl-2 staining the antigen retrieval step was boiling for 
10 minutes in buffer prepared by dissolution of Tris and EDTA. For the SMA staining 
no antigen retrieval was used. All antibodies and normal sera were diluted in PBS 
containing 1% (w/v) bovine serum albumin (BSA). After pre-incubation with normal 
swine serum (for C3d and active caspase-3) (Dako; 1:10 dilution) or normal rabbit 
serum (CD34, C1inh and Bcl-2) (Dako; 1:50 dilution) for 10 minutes, slides were
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incubated with the primary antibodies for 1 hour. After a wash in PBS the slides 
were incubated for 30 minutes with Envision (Dako) for C4d and MPO; with a biotin-
conjugated swine-anti-rabbit antibody (Dako; 1:300 dilution) for C3d and active 
caspase-3; or with a biotin-conjugated rabbit-anti-mouse (Dako; 1:500 dilution) 
for CD34, C1inh and Bcl-2 For SMA, rabbit anti mouse HRP (Dako 1:300 dilution), 
and for macrophages biotin-conjugated donkey-anti-rabbit (GE Healthcare 1:300 
dilution) were used. After washing in PBS, the slides that were incubated with a 
biotin-conjugated secondary antibody, were incubated with streptavidin–biotin 
complex (Dako; sABC; 1:200 dilution) for 1 hour. All slides were visualized with 3, 
3’-diaminobenzidine (DAB; 0.1 mg/mL, 0.02% H2O2). Slides were counterstained 
with hematoxylin, covered and scored.
Immunoscoring
In human vein grafts, the percentage of residual endothelium was determined by 
dividing the measured part of the lumen surface area that was still covered with 
CD34-positive endothelial cells by the total lumen surface area x 100%. The area 
positive for C1inh, C4d, C3d, Bcl-2, MPO and active caspase-3 staining in each vein 
cross section was measured by computer-assisted morphometry (Image-Pro Plus, 
version 4.5) and then expressed as the percentage of the total vein graft cross 
section surface area.
In mouse vein grafts, for morphometric analysis the cross sections were stained 
with hematoxylin-phloxine-saffron (HPS) and then analyzed using image analysis 
software (Qwin, Leica, Wetzlar, Germany). Since the media in murine veins consists 
only of a few layers of cells, there is no morphological border between neointima 
and media. Therefore, to define vein graft thickening, the region between lumen 
and adventitia was used as the lesion area. For each mouse six equally spaced 
cross-sections were used to determine vessel wall thickening. Quantification of the 
different subsets of cells was performed by computer assisted analysis (Qwin) as 
positive stained area in the graft and expressed as a percentage of total vein graft 
cross section surface area.
Measurement of functional C1inh in serum 
Functional human C1inh in the blood was measured according to a previous 
study20. In short, microtiter plates, coated with the mAb against C1inh (2 µg/mL 
in PBS overnight at 4°C), were washed with PBS containing 0.02% (w/v) Tween20, 
and incubated with plasma samples diluted in PBS, 0.1% (w/v) Tween20, 0.2% (w/v) 
gelatin (PTG) for 90 minutes at 4°C. The plates were washed and incubated with 
biotinylated C1s (1 µg/mL in PTG), final volume 100 µL, for 60 minutes. After a wash 
the plates were incubated with 0.001% (w/v) HRP-labeled streptavidin (Amersham 
International plc, Amersham, UK) for 30 minutes,  washed and incubated with 
0.1 mg/mL 3,5,3’,5’-tetramethylbenzidin (TMB) (Merck) in 0.1 M sodium acetate 
containing 0.003% (v/v) H2O2, pH 5.5. Serial dilutions (in PTG) of pooled normal 




All animal experiments were approved by the TNO Animal Welfare Committee and 
conform to the Guide for the Care and Use of Laboratory Animals (published by the 
US National Institute of Health, No 85-23, revised 1996). For all experiments male 
ApoE3*Leiden mice, age between 16 and 20 weeks, were used. Mice were fed a 
mild cholesterol-enriched diet (containing e.g. 0.5% cholesterol, 0.05% cholate)18 
ad libitum, aiming at plasma cholesterol levels of 10-15 mmol/l). Serum cholesterol 
levels were determined (Boehringer Mannheim GmbH, kit 236691) at time of 
surgery and sacrifice.
Vein graft surgery was performed as previously described21. In summary, caval veins 
were harvested from genetically identical donor mice and placed as an interposition 
in the common carotid artery of ApoE3*Leiden recipients. Therefore, the artery was 
dissected free from its surroundings and ligated. After clamping the vessel, a plastic 
cuff was sleeved over both ends; the artery was everted over the cuff and ligated 
with an 8.0 silk ligature. Subsequently, the caval veins were sleeved over the cuffs 
and ligated, thereby creating a venous interposition. After clamp removal, turbulent 
flow through the vein graft confirmed successful engraftment. Before injection, 
C1inh was dissolved in sterile NaCl 0.9% (w/v) in H2O. Mice received intravenous 
injections (150μL) of the dissolved C1inh according to the following scheme: 30 
minutes before surgery 18.5 U; t = 3 days 12.5 U; t = 7 days 12.5 U, t = 14 days 
12.5 U and t = 21 days 12.5 U. Animals in the control group received intravenous 
injections with vehicle (sterile NaCl 0.9% (w/v) in H2O), within the same scheme. At 
time of sacrifice, 5 minutes of in vivo perfusion-fixation at 100 mmHg with 4% (m/v) 
buffered formaldehyde was followed by harvesting of the vein graft. The vein grafts 
were then embedded in paraffin for (immuno)histochemical analysis.
Statistical analysis
Data analysis was performed with GraphPad and SPSS 17.0. The data were normally 
distributed and to evaluate whether observed differences were significant, One-
way ANOVA analysis combined with Bonferroni’s multiple comparison test or  the 
non-parametric Kruskal-Wallis test were used. A p-value (two sided) of less than 
0.05 was considered to be significant.
Results
C1inh levels in the perfusion blood
The saphenous vein graft segments of patients were perfused with autologous 
blood either or not supplemented with purified human C1inh (4U/mL). The perfusion 
blood was analyzed for the concentration of active C1inh before perfusion and at 1 
hour intervals until 6 hours after perfusion. 
In the blood supplemented with C1inh, the concentration of active C1inh was 
2854 ± 1248 µg/mL  prior to perfusion, compared to 146 ± 56 µg/mL in the un-
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supplemented blood (p<0.001; Figure 1). After 1 hour of perfusion, the C1inh 
concentration in the supplemented blood decreased significantly to 1273 ± 468 µg/
mL (p<0.001). Thereafter, the levels of C1inh in the supplemented blood did not 
change significantly anymore. In the un-supplemented blood the levels of C1inh did 
not change significantly between the different time points. At all time points the 
concentration of active C1inh was significantly higher in the supplemented blood 
versus the un-supplemented blood (p<0.01).  
C1inh protects against acute perfusion-induced endothelium loss
Saphenous vein graft segments of patients were analyzed before and after perfusion. 
Of each patient part of the vein was fixed before perfusion, part was perfused with 
autologous blood and part was perfused with autologous blood supplemented 
with C1inh. Early changes in veins perfused at arterial pressure include substantial 
loss of endothelial cells and cell damage in the media19. Therefore, the putative 
protective effects of C1inh on endothelial loss, cellular apoptosis and infiltration of 
granulocytes were analyzed using immunohistochemistry.
 
Figure 1. C1inh levels in the perfusion blood.C1inh levels in un-supplemented perfusion 
blood (n = 5; white bars) and in C1inh-supplemented perfusion blood (n = 5; black bars), 
measured in samples taken prior to (t = 0) and after 1, 2, 3, 4, 5 and 6 hours of perfusion. 
Data represent mean ± S.D. *p<0.001 compared to un-supplemented blood t = 0; #p<0.001 
compared to C1inh-supplemented blood after 1 hour of perfusion; †p<0.01 compared to un-
supplemented blood at that time point. 
In non-perfused veins, the percentage of residual endothelium was 83 ± 8 % (Figure 
2). After 6 hours of perfusion with un-supplemented blood the percentage of 
residual endothelium was 25 ± 14 %, which was significantly lower than in non-
perfused veins (p<0.001). Supplementation of C1inh to the perfusion blood resulted 
in a significant increase in residual endothelium to 47 ± 17 % (p<0.001), indicating 
that C1inh protects against endothelial loss in vein grafts under arterial pressure.
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Figure 2. Quantitative analysis of the residual endothelium in perfused human veins. The 
percentage of residual endothelium was determined before (non-perfused; n = 8) and after 6 
hours of perfusion with either un-supplemented blood (-C1inh; n = 8) or blood supplemented 
with C1inh (+C1inh; n = 8). The percentage of residual endothelium was determined on vein 
cross sections, immunohistochemically stained for CD34, by dividing the measured part of 
the lumen surface area that was still covered with CD34-positive endothelial cells by the 
total lumen surface area x 100%. Data represent mean ± S.E. *p<0.001 compared to –C1inh; 
†p<0.001 compared to –C1inh.
C1inh in the vein graft wall
The amount deposited C1inh in the vein wall was subsequently analyzed, whereby 
we differentiated between the longitudinal and circular layers of the media. In 
non-perfused veins the percentages of C1inh-positive area were low with 1.7 ± 0.7 
% in the longitudinal layer and 2.5 ± 0.7 % in the circular layer (Figure 3). These 
percentages did not differ significantly. Perfusion with un-supplemented blood 
induced a significant increase in C1inh deposition to 6.8 ± 1.9 % in the longitudinal 
layer (p<0.001) and 16.5 ± 4.1 % in the circular layer (p<0.001). Notably, the C1inh-
positive area in the circular layer was significantly larger than in the longitudinal 
layer (p<0.001). In veins perfused with C1inh-supplemented blood, the C1inh-
positive area was 14.3 ± 1.8 % in the longitudinal layer and 20.4 ± 1.4 % in the 
circular layer, which was significantly larger than in non-perfused veins (p<0.001) 
and veins perfused with un-supplemented blood (p<0,001). Furthermore, also 
here the C1inh-positive area was significantly larger in the circular layer than in the 
longitudinal layer (p<0.001). Thus, C1inh supplementation resulted in an increase in 
C1inh deposition in the media of the vein wall.
C1inh reduced complement deposition in the vein wall
The effect of C1inh supplementation on complement deposition (factors C3d and 
C4d) in the vein wall was also analyzed as a marker for cell damage in the media. 
In non-perfused veins the C3d-positive area was 0.5 ± 0.2 %, whereas no C4d was
164
Figure 3. Quantitative analysis of C1inh in perfused human veins. A. The percentage of the 
surface area positive for C1inh was determined in non-perfused veins (white bars; n = 8), 
veins perfused with un-supplemented blood (crosshatched bars; n = 8) and veins perfused 
with C1inh-supplemented blood (black bars; n = 8). C1inh was scored in both the longitudinal 
and circular layer. Data represent mean ± S.E. *p<0.001 compared to the respective layers 
in non-perfused veins; †p<0.001 compared to the longitudinal layer of veins perfused with 
un-supplemented blood; #p<0.001 compared to the respective layers in veins perfused with 
un-supplemented blood; ‡p<0.001 compared to the longitudinal layer of veins perfused with 
C1inh-supplemented blood. B. Example of C1inh in the vein wall. This vein was perfused with 
C1inh-supplemented blood for 6 hours. Shown are the longitudinal and circular layer. Arrow 
I shows residual endothelial cells; arrow II shows C1inh in the circular layer (magnification 
250x). 
detected (Figure 4). After 6 hours of perfusion with un-supplemented blood the 
percentage C3d-positive area increased significantly to 5.5 ± 1.8 % (p<0.001) as did 
the percentage of C4d-positive area to 7.9 ± 0.9 % (p<0.001). These complement 
depositions were found not only in the media but also on residual endothelial cells. 
Supplementation of C1inh to the perfusion blood resulted in a significant decrease 
in the C3d-positive area 0.5 ± 0.2 % (p<0.001) and the C4d-positive area to 2.4 ± 
0.3 % (p<0.001), which did not differ significantly compared to non-perfused veins. 
C1inh thus led to reduced complement depositions in the vein wall, indicating an 
inhibitory effect on complement.
Neutrophilic granulocytes in the vein graft wall
Complement activation can lead to chemo-attraction of neutrophilic granulocytes. 
Therefore, the infiltration of MPO-positive granulocytes was quantified. In non-
perfused veins no neutrophilic granulocytes were found (not shown). Perfusion, 
both with or without supplemented C1inh, resulted in a minor, not significant 




Figure 4.  Quantitative analysis of C3d and C4d in perfused human veins. The percentages 
of the surface area positive for C3d (white bars) and for C4d (black bars) were determined 
in non-perfused veins (n = 8), veins perfused with un-supplemented blood (- C1inh; n = 8) 
and veins perfused with C1inh-supplemented blood (+ C1inh; n = 8). Data represent mean ± 
S.E. *p<0.001 compared to C3d in non-perfused veins; †p<0.001 compared to C4d in non-
perfused veins;  ‡p<0.001 compared to C3d in –C1inh; #p<0.001 compared to C4d in –C1inh.
Apoptosis in the vein graft wall
It has been shown that C1inh can prevent cellular apoptosis directly via an effect on 
the Bcl-2/Bax ratio22. Therefore, the effect of C1inh on apoptosis in perfused veins 
was analyzed via immunohistochemical detection of activated caspase-3 and Bcl-
2. However, neither in non-perfused veins, nor in veins perfused, with or without 
supplemented C1inh, staining of activated caspase-3 or the anti-apoptotic Bcl-2 
was found (not shown).  
Mouse vein perfusion
We show here in perfused human saphenous veins that C1inh protects against 
acute vein graft injury. Subsequently, the effects of C1inh treatment on vein 
graft atherosclerosis development were studied in a venous bypass model in 
ApoE3*Leiden mice.  Intravenous administration of C1inh resulted in a significant 
decrease in vein graft thickening 28 days after engraftment, from 0.39 ± 0.05 mm2
in the vehicle group to 0.27 ± 0.03 mm2 in the C1inh group (Figures 5A-C; p = 0.04). 
The vessel wall circumference, a measure for in- or outward remodeling, also 
decreased significantly upon C1inh treatment from 0.78 ± 0.04 mm2 (vehicle group) 
to 0.64 ± 0.03 mm2 (C1inh group) (Figure 5D; p = 0.03), whereas the luminal surface 
was not different between the groups (0.38 ± 0.05 mm2 in the vehicle group and 
0.36 ± 0.03 mm2 C1inh group (p = 0.4)). 
In the C1inh treated group thickened vein grafts displayed equal amounts of smooth 
muscle cells when corrected for total vessel wall area (vehicle: 18.1±3.5%, C1inh: 
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27.1±2.6%, p=0.120; example Figures 5F-G). Also no difference in relative foam cell 
contribution was seen (control: 12.6±41.4%, C1inh: 10.8±1.8%, p=1.000; example 
Figures 5H-I). Serum cholesterol did not differ between the vehicle- and C1inh 
groups (not shown). Thus, also on the long term, administration of C1inh shows a 
protective effect on vein grafts. 
Figure 5.  Morphologic analysis of C1inh in murine vein grafts. A,B. Representative cross 
sections of vehicle and C1inh treated vein grafts 28 days after surgery; a decrease in vein 
graft thickening is seen in the C1inh treated group (B) compared to the vehicle group (A). C. 
Quantification of vein graft thickening. *p<0.04. D. Quantification of total vessel area (vessel 
circumference). *p=0.03. E. Quantification of luminal area (n=6). Data represent mean ± SE. 
F,G. Representative photographs of smooth muscle cell staining (anti-SMA); no differences 
in the percentage of SMA-positive area was found between the groups. H,I. Representative 
photographs of macrophage staining; no differences in percentage of macrophage-positive 




Bypass graft surgery using venous grafts is one of the most frequently used 
therapies in cardiovascular surgery to treat atherosclerotic occlusive disease of 
coronary arteries23. However, vein grafts frequently fail because of acute damage 
or through accelerated development of atherosclerosis. Here we found that C1inh 
treatment protected vein grafts under arterial pressure against acute endothelial 
loss and against atherosclerosis development.
We have shown before that perfusing human saphenous veins at arterial pressure 
induced acute damage characterized by the loss of virtually all endothelium and 
considerable ultra-structural damage in smooth muscle cells of the media19. Shear 
stress as a result of over-distension of the thin-walled vein grafts under arterial 
pressure appears to be the main inducer of early vein graft remodeling. Indeed, 
in animal vein graft models peri-venous support to counteract vein distension 
significantly reduced neointima formation and intimal hyperplasia24,25. And in 
the perfusion model used also in the present study, peri-venous support almost 
completely attenuated endothelial loss19,26. Here we show in this model that C1inh 
supplementation to the perfusion blood reduced endothelial loss by approximately 
50%, indicating that the mechanisms underlying shear stress-induced acute 
endothelial loss include inflammatory mechanisms inhibited by C1inh. An important 
inflammatory system inhibited by C1inh is the complement system. It is possible that 
C1inh protects the endothelium via this inhibitory ability as complement activation 
products, including C5a, have been shown to induce apoptosis in different cells and 
tissues, including endothelial cells27,28. Indeed, in our study complement depositions 
were found on residual endothelial cells, indicating a possible involvement of 
complement in vein graft endothelial cell death. On the other hand C1inh has been 
shown to inhibit apoptosis independent of complement in cardiomyocytes22 and 
we cannot exclude C1inh exerting this effect in our perfusion model. However, we 
found no staining of activated caspase-3 or the apoptotic regulator Bcl-2, indicating 
the absence of apoptosis in the perfused veins. It has to be noticed that the loss of 
endothelial cells in this perfusion model was seen earlier to occur mainly within the 
first hour of perfusion19, which may explain the lack of apoptosis detection after 6 
hours of perfusion. 
In the media, earlier studies using this perfusion model showed ultra-structural 
changes, such as vacuolization of smooth muscle cells and collagen fragmentation. 
Interestingly, these ultra-structural changes predominantly occurred in the circular 
layer of the media, the layer experiencing the highest blood pressure19,26. These 
early changes apparently do not lead to apoptosis of smooth muscle cells within 6 
hours of perfusion, as suggested by the absence of active caspase-3. Furthermore, 
only small depositions of complement were found in the media of perfused veins, 
coinciding with a very limited non-significant increase in neutrophil infiltration, 
indicating limited cell death of smooth muscle cells this early after perfusion. 
Remarkably though, we found considerably more extensive depositions of C1inh in
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the media, also in veins perfused without supplemented C1inh. Interestingly, most 
of the C1inh deposited in the circular layer. It therefore seems that endogenous 
mechanisms play an important role in the induction of local C1inh deposition in the 
vessel wall. So far we do not know whether it originates from the perfusion blood 
or is produced locally in the media. The fact that significantly more C1inh deposits 
there in veins perfused with blood supplemented with C1inh suggests that at least 
part of it originates from the perfusion blood. Therefore, most C1inh deposits in 
the circular layer coinciding with most ultra-structural cellular damage19,26 in the 
perfused human vein, suggesting that C1inh may protect the media. Indeed, in 
the vein graft model in mice we found that infusion of C1inh in the circulation 
significantly protected the whole vein, both intima and media, against arterial 
pressure induced vein graft remodeling. It has been shown before that C1inh can 
protect against neointimal plaque formation after arterial injury in mice18. Now we 
show similar effects of C1inh on early atherosclerotic changes in vein grafts in mice. 
In conclusion, it is known that loss of vein graft endothelium leads to a high risk 
of vein graft failure29 and that strategies to accelerate re-endothelialization of the 
graft via infusion of endothelial cells reduces early vein graft remodeling30,31. In this 
study we show that C1inh significantly reduced endothelial loss in perfused human 
saphenous veins and protected vein grafts against early atherosclerotic changes 
in mice. It may therefore be worth considering its use in CABG patients, especially 
since C1inh has already been used in patients for the treatment of hereditary 
angioedema, sepsis and myocardial infarction32. Herein, a therapeutic strategy 
of C1inh administration during surgery and intermittent in the first 3 weeks after 
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Abstract
Objective  Venous bypass grafts may fail due to development of intimal hyperplasia 
and accelerated atherosclerosis. Inflammation plays a major role in these processes. 
Complement is an important part of the immune system and participates in the 
regulation of inflammation. However, the exact role of complement in the process 
of accelerated atherosclerosis of vein grafts has not yet been explored.
Methods and Results  To assess the role of complement on the development of vein 
graft atherosclerosis, a mouse model, in which a venous interposition is placed in 
the common carotid artery, was used. In this model  vein graft thickening appears 
within four weeks. The expression of complement components was studied using 
immunohistochemistry on sections of the thickened vein graft. C1q, C3, C9 and the 
regulatory proteins CD59 and Crry could be detected in the lesions four weeks after 
surgery. Quantitative mRNA analysis for C1q, C3, CD59 and Crry revealed expression 
for these molecules in the thickened vein graft, whereas C9 did not show local 
mRNA expression. Furthermore, interference with C3 activation using Crry-Ig was 
associated with reduced vein graft thickening, reduced C3 and C9 deposition and 
reduced inflammation as assessed by analysis of influx of inflammatory cells, such 
as leucocytes, T-cells and monocytes. Also changes in apoptosis and proliferation 
were observed. When C3 was inhibited by Cobra Venom Factor, a similar reduction 
in  vein graft thickening was observed. 
Conclusion  The complement cascade is involved in vein graft thickening and may be 
a target for therapy in  vein graft failure disease.
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Introduction
Bypass graft surgery with venous grafts is one of the most frequently used therapies, 
both in cardiac as in peripheral vascular surgery, to treat atherosclerotic occlusive 
disease. However, graft patency is often compromised by formation of intimal 
hyperplasia (IH) and accelerated atherosclerosis, resulting in vein graft thickening. 
Failure rates as high as 50% after 10 years1 have been reported, and re-interventions 
are often required.
The process of vein graft thickening is characterized by adhesion and influx 
of inflammatory cells and migration of vascular smooth muscle cells to the 
intima of the vein graft2. Moreover, macrophages in the intima take up oxidized 
lipoproteins and become foam cells contributing to the development of accelerated 
atherosclerosis3-5. There is little information available about the mechanisms 
underlying these processes, but it is universally assumed that inflammation and, 
consequently the immune system plays a pivotal role5-7.
A major component of the immune system is the complement cascade8,9. 
Complement consists of a group of proteins, membrane-bound receptors 
and regulatory enzymes. Centrally in the complement cascade is complement 
component C3. Cleavage of C3 can be induced via three separate pathways; the 
classical pathway, alternative pathway and lectin pathway, all activated by specific 
substrates. Activation via one of the three pathways results in formation of C3 
convertases. The convertases are capable of cleaving C3 into C3a and C3b, starting 
a cascade that ultimately results in activation of C5 and subsequently in formation 
of terminal complement component C5b-9 (also called Membrane-Attacking-
Complex (MAC). Furthermore, cleavage of C3 eventually leads to formation of 
potent chemotactic factors, such as C5a. 
The role of complement in several inflammatory conditions is well recognized 
and described. It plays a major role in host defense to micro-organisms, hyper-
acute rejection after organ transplantation, in ischemia-reperfusion injury and in 
several auto-immune diseases. Atherosclerosis, like vein graft disease, is a form of 
vascular inflammation accompanied by intimal thickening, and several studies have 
been published pointing at a role for the complement system in the process. This 
hypothesis is supported by the detection of complement components in human 
atheroma while expression of several of these complement components is up 
regulated in atherosclerotic tissue. Furthermore, animal studies using knock-out 
mice and rabbits deficient in complement have been performed; however these 
show conflicting results10,11. Data concerning the role of complement activation in 
vein graft thickening are lacking.
As mentioned above, C3 is the central component in complement activation. 
Inhibition of C3 activation provides good insight in the role of complement as a 
whole, since formation of biologically active end-products (e.g. C5b-9, C5a and C3a) 
is blocked. Several substances can be used to modify activation of C3. One of the 
most widely used compounds is Cobra Venom Factor, derived of venom of Naja
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species. It functions as a C3b-like molecule and leads to unregulated C3 activation 
resulting in depletion of the complement cascade, however it is associated with 
generation of phlogistic component fragments from C3 and C5 indirectly leading 
to tissue activation. A more elegant approach to block C3 activation is using Crry-
Ig, a recombinant protein of the mouse membrane complement inhibitor Crry 
(complement receptor-related gene y) fused to IgG1-hinge12. Crry-Ig demonstrates 
decay-accelerating activity for both the classical and alternative pathways of 
complement as well as cofactor activity for factor I-mediated cleavage of C3b and 
C4b and thus prevents increased activation of C3. 
To study the role of complement activation in vein graft disease, we used a mouse 
model for vein graft disease in hypercholesterolemic ApoE3*Leiden mice. This mouse 
model highly resembles graft morphology in patients regarding leukocyte adhesion 
and influx, foam cell accumulation, calcification in the vessel wall and development 
of a thin fibrous cap13. Not only expression of several complement factors, on 
both RNA and protein level, in the thickened vein graft was shown, but it was also 
demonstrated that  treatment with Crry-Ig, which inhibits C3 activation, resulted 
in a significant decrease of intimal hyperplasia and accelerated atherosclerosis in 
murine vein grafts. With this study we show that activation of complement cascade 
plays a pivotal role in the development of vein graft thickening.
Methods
Mouse model
All experiments were approved by the institutes’ Animal Welfare Committee. For 
all experiments male C57BL/6 ApoE3*Leiden mice14, age between 15 and 20 weeks, 
were used. During the experiment, animals were fed a high-fat high-cholesterol 
diet15, starting 3 weeks prior to surgery to induce hypercholesterolemia. All mice 
received water and food ad libitum. Cholesterol levels in serum were determined 1 
day before surgery and at sacrifice. Mice were anesthetized by an intra-peritoneal 
(i.p.) injection with a combination of Midazolam (5mg/kg, Roche, Woerden, The 
Netherlands), Medetomidine (0.5mg/kg, Orion, Espoo, Finland) and Fentanyl 
(0.05mg/kg, Janssen, Berchem, Belgium). 
Vein graft surgery was performed as described previously16. In summary, caval veins 
were harvested from genetically identical donor mice to serve as grafts and were 
preserved in 0.9% NaCl containing 100U/ml of heparin at 4˚Celsius. The right carotid 
artery was cut in the middle and a polyethylene cuff was placed at both ends of the 
artery. The artery was everted around the cuff and ligated with a silk 8.0 suture. 
Then the graft was sleeved over the two cuffs and ligated. Pulsations of the vein 




Crry-Ig was produced as described12. Crry-Ig treatment started one day prior to 
surgery and animals received 3mg of Crry-Ig i.p. every other day during the complete 
study period. The control group received a monoclonal murine IgG antibody 
(reactive with human CRP and no cross-reactivity in mice) of the same subtype in 
the same concentration every other day. This approach was previously described to 
be the proper control for Crry-Ig treatment17.
Cobra Venom Factor (CVF)
CVF (Quidel Corporation, San Diego, USA) was dissolved in sterile 0.9% NaCl. Animals 
received daily i.p. injections with 20IU/kg/day of CVF to deplete C3, throughout the 
whole study period starting one day prior to surgery. Animals in the control group 
received daily injections with sterile 0.9% NaCl.
Morphometric assessment of vein grafts
Mice were sacrificed after either 7 or 28 days after surgery. Vein grafts were in 
vivo perfused with 4% formaldehyde, harvested and embedded in paraffin. Serial 
perpendicular cross sections were made of the specimen. All samples were routinely 
stained with hematoxylin-phloxine-saffron (HPS).
Morphometric analysis of vein grafts, harvested after 28d, was performed using 
image analysis software (Qwin, Leica, Wetzlar, Germany). Since only few layers of 
cells are in the media of murine veins and no morphological border exists between 
neointima and media, vein graft thickening, i.e. the region between lumen and 
adventitia, was used to define lesion area. For each mouse five equally spaced 
cross-sections were used to determine vessel wall thickening.
Immunohistochemisty
To detect expression of complement factors, immunohistochemistry was 
performed on paraffin embedded sections of vein grafts harvested after 28d. The 
presence of C1q was assessed using  rabbit-anti-mouse primary antibodies (Roche 
Applied Science, Basel, Switzerland) and C3 was detected with a rabbit-anti-mouse 
antibody (developed in our laboratory18). Anti-C9 ( rabbit-anti-rat, cross reactive 
with mouse C919), was a kind gift of Prof. B.P. Morgan (Cardiff University, Cardiff, 
UK). The antibody used to detect the complement regulatory enzyme CD59a 
(monoclonal rat-anti-mouse) was a kind gift of Dr. Harris, (Cardiff University) and 
Crry was detected with a rat-anti-mouse anti-Crry  antibody (BD Biosciences, 
Alphen a/d Rijn, the Netherlands). Complement components were quantified using 
computer assisted morphometric analysis (Qwin), and expressed as total immuno-
positive area as percentage of total vein graft area in cross-sections. 
In grafts, smooth muscle cells (SMC) were stained using mouse-anti-rat anti-SM 
α-actin antibodies (cross reacts with mouse; Roche Applied Biosciences). Collagen 
was histochemically stained by Sirius Red. Leukocytes were detected using anti-
CD45 antibodies (Pharmingen, San Diego, USA). Different subsets of leukocytes
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were specified. The amount of macrophage derived foam cells within the thickened 
vessel wall was visualized by AIA31240 antibody (Accurate Chemical, Westbury, 
NY, USA). T-cells were detected using anti-CD3 antibodies (Serotec, Raleigh, USA). 
Cellular proliferation was quantified using PCNA staining (Calbiochem, San Diego, 
USA), whereas apoptotic cells were identified by TUNEL (Roche Applied Biosciences). 
Quantification of all stainings, except those for smooth muscle cells and foam cells, 
occurred by counting the positive number of cells/slide and expressed as percentage 
of  total number of nuclei (determined by Nucleus Red staining). Smooth muscle 
cell, collagen and foam cell quantification, due to their high occurrence in the vein 
grafts, was performed similar as the quantification of complement components.
RNA isolation, cDNA synthesis and RT-PCR
RNA was isolated from caval veins and vein grafts harvested on several time points 
(t=6 and 24 hours after surgery and 3, 7 and 28d after surgery, n=4 per time point), 
using RNA Isolation Mini Kits for Fibrous Tissue (Qiagen, Venlo, the Netherlands; 
using the manufacturers protocol). DNase treatment was included (RNase Free 
DNase set, Qiagen). RNA (250 ηg) was reverse-transcribed using the Ready-To-Go 
You-Prime-First-Strand Beats (Amersham Biosciences, Uppsala, Sweden). 
Reverse-transcribed products were studied using semi-quantitative RT-PCR 
(Robocycler Gradient96, Stratagene, Cedar Creek, Texas, USA), with primers for 
C1q, C3, C9, CD59 and Crry (for sequences see Table 1). Samples were amplified 
for 35 cycles (30sec. at 94˚C, 30sec at 56˚C and 90sec. at 65˚C) following an initial 
denaturation cycle for 2 min. at 94˚C. The last cycle was followed by extension 
of 4 min at 74˚C. PCR products were visualized on 1.2% Agarose gel containing 
EthidiumBromide.
Table 1. Primer sequences and length of PCR product of genes analyzed in RT-PCR.
Statistical Analysis
All data were presented as mean±SEM. Statistical analysis was performed using 
SPSS 11.5 for Windows. Differences between groups were analyzed with a Student 
T-test. P-values<0.05 were regarded statistically significant.
Results
Presence of complement components in intimal hyperplasia of murine vein grafts
Twenty-eight days after surgery, mice (n=6) were sacrificed and vein grafts were
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harvested in order to detect complement factors and regulatory enzymes by 
immunohistochemistry (Figure 1). These factors were elicited on the basis that 
each represents a specific part of the complement cascade (e.g. C1q; early classical 
pathway, C3; central component, C9 part of the membrane attack complex, CD59 
and Crry; regulatory molecules).
Figure 1. Expression of complement factors in thickened murine vein graft of ApoE3*Leiden 
mice, 28 days after surgery. Massive intima hyperplasia formation vein graft thickening is 
observed, as indicated with arrows (HPS). The cellular composition (consisting of smooth 
muscle cells and macrophage-derived foam cells) of the thickened vein graft is shown. 
Immunohistochemical detection of complement factors C1q, C3 and C9. Both C1q and C3 are 
abundantly present in the deeper parts of the intimal hyperplasia co-localizing with foam 
cells. Furthermore, C1q and C3 are expressed in the endothelial layer and in inflammatory 
cells (mainly macrophages) adhering to the vessel wall and present in the adventitia. C9 is 
not detectable in the endothelium and inflammatory cells. However, like C1q and C3, it is 
present in the deeper parts of the intimal hyperplasia. Regulatory enzymes CD59 and Crry 
in vein grafts demonstrate a different expression pattern. CD59 shows a diffuse expression 
throughout the thickened vein graft, whereas expression of the membrane-bound Crry 
shows a patchy, cell bound distribution, and is mainly localized in the media and adventitia 
of the murine vein graft. Magnification 150x.
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Massive presence of C1q was seen in thickened vein grafts, mainly deep in the 
intimal hyperplasia co-localizing with foam cells. Furthermore, inflammatory cells 
attached to the endothelium and in the adventitia of the veins showed positive 
staining. C3 was predominantly expressed in the same regions as C1q, being in 
macrophage derived foam cells, adhering and adventitial inflammatory cells and 
also in the endothelium. In addition, C9 co-localized highly with macrophages in the 
thickened intima but was not expressed by endothelial cells.
Complement inhibitor CD59 was detected diffusely distributed in all layers of the 
vessel wall. The membrane-bound Crry showed a patchy distribution in cells of the 
media and adventitia. Endothelial cells showed positive staining in about one-third 
of cells. 
 
Presence of RNA coding for complement components in murine vein grafts
Local production of complement component was examined by RNA analysis of vein 
grafts. Sixteen mice underwent vein graft surgery and were sacrificed on several 
time points (t= 6h, 24h, 3d, 7d and 28d). Also normal, not yet interposed, caval veins 
of donor mice were included. RT-PCR was performed for C1q, C3, C9, CD59 and Crry 
(Figure 2).
Minimal expression of C1q mRNA was seen in caval veins. In vein grafts, C1q 
mRNA was not detectable in the first 24 hours after surgery. However, 3 days 
after surgery, C1q mRNA was clearly present and expression remained constant 
for the rest of the study period. C3 showed an explicit expression in vein grafts 
in all stages of remodeling. Interestingly, an equal expression was seen in caval 
veins, showing that also without a remodeling process going on in the vessel, 
local production of C3 occurs. mRNA expression of complement component C9 
could not be detected in vein grafts, whereas expression in liver tissue (positive 
control) appeared clearly positive, indicating that C9-protein is not produced 
locally in vein grafts. Crry mRNA was clearly detectable in normal caval veins. 
Figure 2. Expression of C1q-, C3-, Crry-, and CD59-mRNA in the caval vein and murine 
vein grafts harvested at several time points after surgery (n=4 per time point). β-Actin 
was included as a housekeeping gene and sterile H2O was used as a negative control.
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Down-regulation of Crry mRNA expression was seen in the first days after surgery, 
whereas after 7d an increased expression was seen to the level of normal caval 
veins. Complement inhibitor CD59 showed robust expression in normal caval veins, 
whereas expression in the remodeling vein graft was present but appeared lower.
Figure 3. Effect of Crry-Ig treatment on development of intimal hyperplasia and accelerated 
atherosclerosis in murine vein grafts. Quantitative analysis of the effect of Crry-Ig treatment 
on development of intimal hyperplasia and accelerated atherosclerosis in murine vein grafts 
and C1q, C3 and C9 deposition in the vein grafts. Representative cross section demonstrating 




Effect of Crry-Ig treatment on vein graft thickening and complement expression 
The studies above suggest involvement of the classical pathway on vein graft 
thickening. Earlier studies demonstrated efficient blockage of complement 
activation by Crry-Ig. Twelve ApoE3*Leiden mice were randomly divided into two 
treatment groups. One group received 3mg (i.p.) Crry-Ig every other day; controls 
received an injection with 3mg of non-relevant monoclonal antibody of the 
same isotype every other day. No significant differences were observed between 
groups in preoperative bodyweight, bodyweight at sacrifice and cholesterol levels 
before surgery and at sacrifice.  Vein grafts were harvested after 28d and vein 
graft thickening was quantified. Crry-Ig treated mice exhibited approximately 50% 
less vein graft thickening, when compared to controls (control 0.36±0.07mm², 
Crry-Ig 0.18±0.01mm², p=0.028). Luminal area was equal in both groups (control 
0.53±0.04mm², Crry-Ig 0.40±0.06mm², p=0.28). Consequently, total vessel wall 
area was significantly larger in the control group (0.56±0.05mm²) when compared 
to Crry-Ig treated vein grafts (0.89±0.07mm², p=0.016), indicating reduced outward 
remodeling in the Crry-Ig treated group. C1q quantity in vein grafts was not affected 
by Crry-Ig and demonstrated no differences with control IgG treated mice (control: 
25±4%, Crry-Ig: 25±2%, p=0.48). A significant decrease of C3 deposition was 
observed in Crry-Ig treated mice, compared to controls (control: 37±4%, Crry-Ig: 
21±3%, p=0.007). Moreover, presence of C9 protein, was reduced in Crry-Ig treated 
vessels (control 19±3%, Crry-Ig 9±2%, p=0.007). Data are summarized in Figure 3.
Effect of Crry-Ig treatment on cellular composition of remodeling vein grafts
To study the effect of blocking complement activation on cellular composition, 
24 mice underwent surgery, were treated with either Crry-Ig or a non-relevant 
monoclonal antibody (as described above) and were sacrificed after 7 or 28d (n=6 
in each group).
Overall, as expected, vein grafts harvested after 28d contained more cells than 
the ones harvested after 7d, and Crry-Ig treated grafts contained less cells as their 
untreated controls after 28d (control 7d: 228±59, Crry-Ig 7d: 227±32, n.s and control 
28d: 2296±565, Crry-Ig 28d: 1143±69, p=0.044). 
SMC content was analyzed in vein grafts harvested after 28d, since in the first week 
after engraftment all SMC disappear in this model13. In the Crry-Ig treated group, 
thickened vein grafts had a significant higher relative SMC content than the control 
group (control: 33±5%, Crry-Ig: 47±3%, p=0.04). The amount of collagen deposition, 
however, did not significantly differ between both groups (control 33±4%, Crry-Ig 
29±2%, p=0.5). 
Influx of CD45-positive leukocytes was especially seen after 7d and strongly reduced 
by Crry-Ig treatment (control: 31.3±10.2%, Crry-Ig: 9.6±1.5%, p=0.034). At 28d the 
relative amount of CD45-positive leukocytes was much lower and not significantly 
different between groups (control: 1.8±0.4%, Crry-Ig: 1.9±0.9%, p=0.44). In the 
seven-day vein grafts monocytes in both groups were predominantly adhering to 
the vessel wall and invading in the vein graft. Crry-Ig treatment resulted in a 42%, 
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yet not significant reduction, in adhering monocytes (control: 7.0±1.8%, 4.1±0.9%, 
p=0.08). After 28d, AIA31240-immunostaining revealed mainly macrophage-
derived foam cells in the plaque area. A significantly lowered foam cell content 
was seen in vein grafts of Crry-Ig treated animals (Crry-Ig: 16±1%, control: 25±5%, 
p=0.043) after 28d. Regarding CD3-positive T-cells, a significant difference could 
be seen after 7d (control: 1.9±0.6%, Crry-Ig: 0.7±0.1%, p=0.05), however after 28d, 
this difference could not be observed (control: 1.8±0.6, Crry-Ig: 1.2±0.3%, p=0.21). 
Results are summarized in Table 2.
Effect of Crry-Ig treatment on cytokinetics of remodeling vein grafts
To get insight on the possible mechanisms of the effect of complement inhibition 
on vein graft remodeling, we analyzed the effects of Crry-Ig treatment on cell 
proliferation and apoptosis. Regarding proliferation, Crry-Ig treatment resulted in 
reduced cellular proliferation after 7d as assessed by PCNA immunohistochemistry 
(control: 10.6±1.3%, Crry-Ig: 6.7±1.2%, p=0.036) After 28d, cellular proliferation 
declined and no differences were seen between both groups (control: 2.3±0.7%, 
Crry-Ig: 1.8±0.6%, p=0.3). Surprisingly, Crry-Ig treatment led to increased numbers 
of TUNEL-positive apoptotic cells in vein graft 7d after surgery (control: 0.7±0.4%, 
Crry-Ig: 3.0±0.6%, p=0.005). However, after 28d, the number of apoptotic cells was 
decreased in both groups to such a level that no conclusion was justified. All data 
are summarized in Table 2.
Table 2. Effect of Crry-Ig treatment on cellular composition and cytokinetics of remodeling 
vein grafts, both 7 and 28 days after surgery (determined by immunohistochemistry, n=6 for 
each value). Positively stained cells are expressed as a percentage of total number of cells. 
np: analysis not performed.
Effect of CVF treatment on vein graft thickening
To demonstrate that the observed effect is not Crry-Ig-specific, an alternative 
treatment affecting C3 activation was tested. Therefore, Cobra Venom Factor (CVF) 
was administered. Vein grafting was performed in 12 mice and 6 were treated 
with CVF (20IU/kg/day). Mice were sacrificed after 28d. Quantification of vein graft 
thickening revealed a 63% reduction of intimal hyperplasia in CVF-treated animals
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(0.15±0.01mm²), when compared to controls (0.41±0.10mm², p=0.016). Luminal 
surface did not differ significantly between groups (CVF: 0.49±0.06mm², control 
0.59±0.07mm², p=0.47).
Discussion
This study argues for a causal role for complement activation in general, and 
C3 activation in particular, in the process of venous bypass graft thickening. To 
our knowledge, this is the first study that not only demonstrates presence of 
complement components in vein grafts but also provides evidence that inhibition 
of C3 activation results in a marked decrease of vein graft thickening in vivo.
Intimal hyperplasia formation and accelerated atherosclerosis in vein grafts is 
considered to be the result of an inflammatory process5-7. This process is initiated 
by mechanical vessel damage and hypoxia during surgery and by altered shear 
stress that the vein is being subjected to after surgery. Several animal models are 
developed to mimic this process. In this study a mouse model is used, in which caval 
veins of donor mice are placed as interposition in the common carotid artery16. 
When performed in hypercholesterolemic mice, vein graft thickening occurs with 
signs of accelerated atherosclerosis13. The morphology of the observed lesions 
highly resembles what is seen in human vein grafts, underlining the relevance of 
this model. 
Since the complement cascade is an important part of the innate immune system 
and is also involved in initiation of adaptive immune responses, it might be one of 
the mediators of inflammatory processes in remodeling vein grafts. 
The presence of complement components (C1q, C3 and C9) and regulatory molecules 
(CD59a and Crry) in murine vein grafts was shown by immunohistochemistry. 
Furthermore, we analyzed local synthesis of complement components, defined as 
mRNA expression in vein grafts. Although synthesis of complement components 
is believed to be localized in the liver, recently evidence of extra-hepatic synthesis 
of complement components has been published. RT-PCR analysis of vein grafts at 
various time points after surgery revealed local expression mRNA coding for C1q, 
C3, CD59 and Crry. No local production of C9 could be detected, indicating that C9 
protein deposited in vein grafts, as seen by immunohistochemistry, is produced 
elsewhere. 
Although C3 mRNA expression was detectable in the vessel wall of  caval veins, 
no up- or down regulation of C3 on mRNA level could be detected in vein grafts. 
Several possible explanations for this finding could be given. One might be that, 
although mRNA C3 is produced locally in vein grafts, this may not tell us much about 
C3 activity and protein presence. Furthermore, C3 is mainly produced in the liver, 
as most of the complement components, and is abundantly present in plasma. This 
liver derived C3 might be crucial for mediating the effects on vein graft thickening, 
whereas the role of locally produced C3 is unclear. In addition, factors involved in 
regulating local levels of (active) C3 and the effects of C3 downstream molecules on
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points at tempered C3 levels in vein graft remodeling are not completely understood. 
We were unable to detect activated complement factors or MAC, because of the 
lack of specific antibodies against murine activated complement components e.g. 
murine iC3b, C5b-9 or C5a.
Since C3 is the central protein in the complement cascade, it was used as a specific 
target for our interventional experiments. C3 activation was blocked using Crry-Ig, 
an inhibitor for all activation pathways by the inhibition of C3 convertases. Crry-
Ig treatment resulted in a significantly lower C3 and C9 deposition in vein grafts, 
accompanied by an inhibition of  vein graft thickening of approximately 50%. 
Analysis of cytokinetics and cellular composition of vein grafts at 7 and 28 days, 
provided insight in the mechanism by which complement inhibition may affect vein 
graft remodeling. When C3 was inhibited by Crry-Ig, one of the first phenomena 
seen is reduced adherence and influx of leucocytes, possibly as a result of absence 
of (complement activation-derived) chemotactic stimuli. This inflammatory activity 
in remodeling vein grafts. Reduction in inflammatory activation of the vein graft 
wall is thought to be the main cause of reduced vein graft thickening. Reduction of 
leucocyte adhesion and influx is accompanied by reduced numbers of proliferating 
cells in the remodeling vein graft and induction of apoptosis. This induction of 
apoptosis is unexpected, since reduced inflammation is usually accompanied by 
reduced apoptosis. No specific cell type or location could be associated to the 
observed apoptosis.
After 28 days, plaque composition was significantly altered in the Crry-Ig treated 
group, favoring SMC and reduced numbers of foam cells. Increase numbers of SMC 
in thickened vein grafts reflect a desirably state, since this is believed to be one 
of the main contributions to plaque stability20.  The observation that vein graft 
thickening can also be hampered by CVF (another potent C3 activation inhibitor) 
shows that the phenomena seen after Crry-Ig treatment, are not Crry-Ig specific, but 
are caused by C3 inhibition. Inhibition of vein graft thickening following treatment 
with Crry-Ig also suggests that circulating complement components play a role in 
the remodeling process. 
The demonstrable C1q in vein grafts suggest involvement of the classical pathway. 
Interestingly, we found a reduced C1q mRNA expression in the early phases after 
surgery, followed by enhanced expression in later stages. Regrettably, very little 
is known about in vivo C1q mRNA regulation in various cell types. However, since 
C1q in this model is predominantly expressed by monocytes and macrophages, 
and macrophage C1q mRNA expression has been shown to alter during the various 
stages of macrophage maturation in vitro21, this reduced C1q mRNA expression in 
the early stages might be due to a temporary lowered C1q mRNA expression as a 
consequence of ongoing maturation during the transition of adhering monocytes 
into tissue macrophages. 
Furthermore, we found that in the early phases after surgery, Crry mRNA expression 
was decreased, and therefore diminishing complement inhibition potential of the 
vein graft. This might be one of the causes responsible for complement activation
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in ischemia-reperfusion, recently Stahl et al described the role of the alternative in 
this model. 
However, other questions need to be considered. For instance, what triggers 
complement activation in venous bypass grafts, and which of the activation routes 
are accountable for activation? There are several possibilities. 
A venous interposition can be seen as an autologous transplant; it undergoes 
ischemia-reperfusion injury during the procedure. In other models for ischemia-
reperfusion the production of “natural antibodies” by CD5 positive B1 cells is 
described, leading to deposition of IgM antibodies and thereby triggering the 
classical pathway22. This is confirmed by the study of Fitzmaurice23, he was able to 
detect immunoglobulins and C3 depositions in human saphenous vein grafts. We 
show the presence of C1q protein and mRNA in various phases of the remodeling 
process, suggesting that the classical pathway actually might play a role. Besides 
the classical pathway as the major activating pathway of the complement system 
pathway in (intestinal) ischemia-reperfusion injury24 and Thurman et al found that 
the alternative pathway alone was required for renal ischemia-reperfusion injury25. 
In addition, LDL depositions in the vessel wall might be responsible for complement 
activation in this model. Torzewski et al previously described co-localization of C5b-
9 and enzymatically altered LDL in deeper parts of the intima of early atherosclerotic 
lesions26. Furthermore, it was shown that this enzymatically modified LDL is 
atherogenic and can induce complement activation via the alternative route in 
vitro27,28. However, since fat deposition and foam cell formation occurs relatively 
late in the model used in this study and the observed effects on cellular influx were 
present after 7d, it is not likely that this route of complement activation plays a role 
in this model.
Furthermore, the vein graft is liable to an arterial blood pressure and an increased 
shear stress, causing damage to the vein graft wall. Also the surgical procedure 
leads to damage of the vein graft. This results in a mechanical denudation of the 
endothelium and apoptosis of remaining endothelial cells. It has been described 
before, that apoptotic (endothelial) cells can induce complement activation both 
via the classical29 and alternative pathway30. 
Which of the three activation pathways, alone or in combination, is responsible for 
the activation of complement and by what kind of injury this activation is triggered 
remains to be determined and further research is necessary to indicate the role of 
each of these modalities in vein graft disease. 
When translating data from mouse studies to the human situation, several 
issues should be taken into account. Firstly, mice do not develop spontaneously 
atherosclerosis. Therefore usually genetically-altered hypercholesterolemic mice 
are used to induce atherosclerotic lesions, either spontaneously after prolonged 
exposure to a hypercholesterolemic environment or in an accelerated way after 
vascular intervention. Although the ApoE3*Leiden mice used in this study suffered 
relatively mild hypercholesterolemia (serum cholesterol between 8-10 mmol/l), 
cholesterol levels still exceed serum levels seen in most of the patients. As previous
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complement cascade, is an important early trigger for vein graft thickening. 
Therapy reports have shown, severe hypercholesterolemia might induce increased 
vascular inflammatory reactions13,31 and consequently atherosclerotic lesion 
formation. Furthermore, due to anatomic variations between human and mice, it 
can be assumed that after engraftment, as a result to the 10-fold increase in blood 
pressure, more extensive graft distension and subsequent vascular damage and 
SMC apoptosis is occurring in (only a few cell-layers thick) murine vein grafts when 
compared to the human counterpart.
In conclusion, several complement factors (both on protein and mRNA level) are 
present in thickened vein grafts, and treatment with Crry-Ig (interfering in C3 
activation) results in marked reduction of vein graft thickening. This reduction 
coincides with reduced numbers of leucocytes in early stages of vein graft 
remodeling, and increased numbers of smooth muscle cells in the later stage. 
Therefore, we have provided evidence that activation of C3, and thereby the that 
interferes in the function of C3 might be an interesting new target in order to 
overcome the clinical problem of vein graft disease. 
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Abstract 
Objective  Failure of vein graft conduits due to vein graft thickening, accelerated 
atherosclerosis, and subsequent plaque rupture is applicable to 50% of all vein 
grafts within 10 years. New potential therapeutic targets to treat vein graft disease 
may be found in components of the innate immune system, such as mast cells and 
complement factors, which are known to be involved in atherosclerosis and plaque 
destabilization. Interestingly, mast cells can be activated by complement factor 
C5a and, therefore, a direct role for C5a-mediated mast cell activation in vein graft 
disease is anticipated.  We hypothesize that C5a-mediated mast cell activation is 
involved in the development and destabilization of vein graft lesions. 
Methods and Results  Mast cells accumulated in time in murine vein graft lesions 
and C5a and C5a-receptor (CD88) expression was up-regulated during vein graft 
disease in Apolipoprotein E- deficient mice. Mast cell activation with dinitrophenyl 
resulted in a profound increase in vein graft thickening and in the number of plaque 
disruptions.  C5a application enhanced vein graft lesion formation, while treatment 
with a C5a-receptor antagonist resulted in decreased vein graft disease. C5a 
most likely exerts its function via mast cell activation since the mast cell inhibitor 
cromolyn totally blocked C5a enhanced vein graft disease. 
Conclusion  These data provide evidence that complement factor C5a-induced mast 
cell activation is highly involved in vein graft disease, which identifies new targets to 
prevent vein graft disease.
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Introduction
Venous bypass grafting, frequently used in cardiac and peripheral vascular surgery, 
often fail acutely due to thrombosis and on the long term through vein graft 
thickening, accelerated atherosclerosis, and plaque rupture1,2.  Recently, our group 
and others have conclusively demonstrated that perivascular mast cells contribute 
to atherosclerotic plaque progression and destabilization in mice3-5. Although 
many similarities exist between atherosclerosis and vein graft disease (VGD), it is 
still unknown whether mast cells play a causal role in the development of VGD. 
Furthermore, the triggers that lead to mast cell activation in atherosclerosis or VGD 
are still unresolved.  A potential mechanism for  mast cell activation in patients 
is via the complement system6. Complement factors are expressed during the 
development of atherosclerosis7. In particular, C3a and C5a have been detected 
in advanced atherosclerotic plaques8 and we have previously demonstrated that 
complement factor C3 and C1q are involved in VGD in mice9,10.
C5a is one of the major biologically active components of the complement cascade 
downstream of C3 and exerts its functions mainly via the canonical C5a receptor 
(C5aR, CD88). C5a induces chemotaxis of numerous cell types including mast cells 
and monocytes11. It has been demonstrated that plasma C5a levels correlate with 
an adverse outcome in patients with severe atherosclerosis12. Moreover, in a phase 
III trial with patients undergoing coronary artery bypass surgery or aortic valve 
replacement, the administration of an antibody against C5, which is the precursor 
to C5a, showed decreased mortality13. 
In the current study, we aimed to investigate the role of mast cells and complement 
factor C5a in a mouse model of VGD.  We show that either omission or stimulation of 
mast cells or C5a results in modulation of vein graft thickening (VGT). Furthermore 
we demonstrate that C5a mediated the activation of mast cells is strongly involved 
in the processes implicated in VGD. These data strongly suggest that mast cells and 
the C5a-C5aR axis play a central role in the development of VGD and show that C5a 
is a potent mast cell activator during cardiovascular disease processes.
Methods
A detailed description of the Methods is available in the online Data Supplement. 
This study was performed in compliance with Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament.  All animal experiments were 
approved by the animal welfare committee of the Leiden University Medical Center 
(approval reference numbers 09148 and 10091).  Vein graft surgery was performed 
by donor caval vein interpositioning (caval vein of 2 mm length) in the carotid 
artery of recipient mice. These were either C57BL/6 control mice, apolipoprotein 
E–deficient (ApoE-/-) or mast cell-deficient Kit(W-sh/W-sh) male mice (10-20 weeks old). 
Before surgery, mice were anaesthetized with midazolam (5 mg/kg, Roche
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Diagnostics), medetomidine (0.5 mg/kg, Orion) and fentanyl (0.05 mg/kg, Janssen 
Pharmaceutical). The adequacy of the anaesthesia was monitored by keeping track 
of the breathing frequency and the response to toe pinching of the mice. After 
the procedure the mice were antagonized with atipamezol (2.5 mg/kg, Orion) and 
fluminasenil (0.5 mg/kg Fresenius Kabi). Buprenorphine (0.1 mg/kg, MSD Animal 
Health) was given after surgery to relieve pain. 
A detailed flow-chart displaying the in vivo experimental setup is shown in the 
Supplementary material online, Figure S1. In all experiments vein grafts were left 
in situ for 28 days (with exception of the time courses). Formalin fixed, paraffin 
embedded, vein grafts were histological and morphometrically analysed as 
previously described4,14. Cholesterol levels were determined before surgery 
and at sacrifice. Furthermore, sysmex analysis of blood cells was performed for 
all experiments and no significant differences were detected in the % of WBC 
populations between the treatment groups and their appropriate controls. In 
Supplementary material online, Table S1, white blood cell analysis of the C5a and 
cromolyn (Cro) experiment is shown.
First, we aimed to demonstrate the presence of mast cells, C5a and C5aR in vein grafts 
of hypercholesteroleamic ApoE-/- mice.  For this, we used immunohistochemistry 
and RT-PCR analysis on time courses of paraffin and RNA material of three to four 
mice per time point. Analyses were performed as described in the Supplemental 
material online. 
Secondly, the involvement of mast cells in VGD was determined by analysis of the 
vein graft lesions in either mast cell deficient Kit(W-sh/W-sh) mice (n=8 mice/group) or 
by investigating the effect of local mast cell activation with dinitrophenyl hapten 
(DNP) on vein graft remodeling in ApoE-/- mice. After skin-sensitizing, ApoE-/- mice 
(n=11/group) were subjected to vein graft surgery and subsequently the vein grafts 
were treated locally with DNP in pluronic gel15. 
Thirdly, the effect of interfering in C5a signaling was investigated. ApoE-/- mice (n=7/
group) were challenged perivascularly with either 0.5µg or 5µg of recombinant 
mouse C5a (HyCult Biotechnology) or vehicle in pluronic gel. The effects of inhibiting 
C5a function were also studied. ApoE-/- mice (n=7/group) were treated daily with 
subcutaneous injections of the C5a receptor antagonist hydrocinnamate-[OP-(D-
Cha)WR] (PMX205) (0.3mg/kg)16 or vehicle solution, starting 1 day prior to surgery. 
To determine whether C5a effects were mast cell dependent, a group of C5a 
stimulated ApoE-/-  mice (5µg/mouse in pluronic gel) or PBS gel controls were treated 
twice weekly with the mast cell stabilizer Cro (50 mg/kg, Sigma) and compared with 
mice treated with PBS (n=9/group). 
Finally, to confirm whether C5a activation of mast cells could be a functional 
pathway in human atherosclerotic lesions, the presence of mast cells, C5a and 
C5aR in human specimens were analyzed. Human vein graft (n=8) and carotid 
endarterectomy (n=25) tissues were obtained in accordance with guidelines set out 
by the ‘Code for Proper Secondary Use of Human Tissue’ of the Dutch Federation of
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Biomedical Scientific Societies (Federa) and conform with the principles outlined in 
the Declaration of Helsinki.
All data are presented as mean ± SD. For the time courses, statistical analysis was 
performed using a repeated measures ANOVA with a Bonferroni Post Hoc test. 
In vivo experiments were compared with a Krukall Wallis test followed by a non-
parametric Mann-Whitney test to compare individual groups. For in vitro studies 
a two-tailed Student’s t-test was used. P-values <0.05 were regarded significant.
Results 
Mast cells, C5a and C5aR in murine vein grafts
The presence of mast cells and expression levels of C5a and C5aR were assessed 
byimmunohistochemistry and RT-PCR (primer sequences; Supplementary 
material online; Table S2) in vein grafts interpositioned in carotid arteries of 
hypercholesterolaemic apolipoprotein E-deficient mice. The vein grafts were 
harvested at several time points after surgery (n=3-4 per time point). Mast cells 
were found in small quantities in the adventitia of the ungrafted caval veins. 
Directly after engraftment the number of peri-vascular mast cells decreased and 
from 3 days on the number of mast cells increased profoundly (t=6h: 0.4±0.1 mast 
cells/mm² vein graft vs. 28 days: 4.2±0.6 mast cells/mm² vein graft, p=0.045, Figure 
1A). Mast cells in the atherosclerotic lesion itself were very rare. Both resting and 
activated mast cells were found in the perivascular tissue (figure 1B). No differences 
in the activation status of the mast cells were found between the different time 
points (data not shown). 
An increase in C5 mRNA expression was seen at 6 h (p=0.015) after surgery (Figure 
1C), which is in agreement with the finding of increased C5a protein expression at 
this time point (Figure 1D). C5a was detected in leucocytes adhering to the lumen 
and in the adventitia, where mast cells particularly reside. C5a was also detected in 
the regenerating endothelium from 7 days on. At later time points (14 and 28 days), 
the expression of C5a was also seen in macrophages and some smooth muscle 
cells (SMCs) associated with thickening of the graft. C5aR mRNA was maximally 
expressed (nine-fold increase vs. ungrafted vein p=0.043) at 1 day after surgery 
and declined after 3 days to a three-fold increase in relative expression (p=0.073) 
(Figure 1E). In the first days after surgery C5aR protein expression was seen in 




Figure 1. A. Peri-vascular mast cells were scored in caval veins (0) and vein grafts at 6h 
(0.25 day), 1, 3, 7, 14 and 28 days after surgery (three-four vein grafts/ time point). Mast 
cell numbers increased from 3 days  on to a significant increase (compared with vein graft 
at 0.25 day) at day 14 and 28 B. Both resting (black arrow) and activated (white arrow) 
mast cells were found in the adventitia of the vein grafts. C5a and C5a-receptor expression 
on mRNA (C and E) and protein level (D and F) were assessed in time in vein grafts. Relative 
expression of both C5a and C5aR increased rapidly immediately after surgery due to the 
influx of positive inflammatory cells.  At later time points the expression decreased due 
to the  influx in the vein graft of C5a- and C5aR-negative cells and extracellular matrix. * 
indicates p<0.05, representative scale bars are added to the photographs.
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Figure 2. A. A decrease in the Kit(W-sh/W-sh) lesion area was seen when compared with control 
C57bl/6 lesions 28 days after surgery (*p<0.05). B. Representative cross-sections of vein 
grafts in C57BL/6 and Kit(W-sh/W-sh) mice (HPS staining, magnification 20x). Black line indicates 
the thickness of the lesion. 
Effect of mast cell deficiency and mast cell stimulation on vein graft morphology
To investigate whether there is a causal relation between mast cell accumulation 
and the development of VGD, mast cell deficient Kit(W-sh/W-sh) and control C57BL/6 
mice underwent vein graft surgery. At 28 days after surgery, a decrease in VGT of 
36% was seen in the Kit(W-sh/W-sh) mice when compared with control mice (0.52±0.18 
vs. 0.33±0.13mm2 respectively, p=0.036, Figure 2). The total vessel area (lesion area 
+ lumen area) (0.89±0.22 vs. 0.71±0.22mm2, p=0.141) and the lumen area (0.38±0.09 
vs. 0.38±0.10mm2, p=0.753) were not significantly different. Consequently, no effect 
on outward remodeling could be detected. 
Next, skin-sensitized ApoE-/- mice were challenged locally at the vein graft with DNP, 
which results in acute mast cell activation, or vehicle control to study the effects 
of mast cell activation on VGD. Mast cell activation resulted in a 46% increase in 
the lesion area compared with the controls (0.36±0.08 vs. 0.52±0.20mm2 p=0.011, 
Figure 3A, B). No significant differences were found in the total vessel area and the 
lumen area (data not shown). Plaque phenotype analysis revealed that the DNP 
group showed a 50% reduction in lesional SMCs (DNP: 12±6%, vehicle: 25±5%, 
p=0.001, Figure 3C), especially in the cap region. The relative collagen content (DNP: 
27±6%, vehicle: 25±10%, p=0.457, Figure 3D) and the macrophage content (DNP: 
18±3%, vehicle: 17±7%, p=0.341, Figure 3E) did not differ significantly between the
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Figure 3. A. Local treatment of ApoE-/- mice with dinitrofluorobenzene (DNP) in pluronic gel 
resulted in increased vein graft lesion areas at 28 days after surgery when compared with 
the vehicle treated group. B. Typical cross-sections of vein grafts after treatment with vehicle 
or DNP (HPS staining, magnification 20x, insets, magnification 5x). Note the erosion in the 
DNP-treated group (#). DNP treatment resulted in more disruptions of the vein grafts [8/12 
(DNP) vs.3/12 (PBS)]  C. Percentage of positive smooth muscle cells (SMC) was significantly 
decreased after DNP challenge D. The relative collagen content did not differ between 
the groups E. Percentage of the macrophage content was not affected by DNP challenge. 
Whereas DNP treatment affected endothelium coverage significantly (F), which resulted in 
a significantly increased fibrin content in the DNP group (G and H). * indicates p<0.05; black 
lines in the photographs indicate the thickness of the lesions. 
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groups. At 28 days after DNP challenge no differences in the number of mast cells 
were seen, nor did we detect a difference in the activation status (data not shown). 
Strikingly, vein grafts in the DNP group did show severe signs of plaque rupture 
complications17. Half of the vein grafts treated with DNP (n=12) showed lesions with 
de-endothelialized areas and intramural thrombus (erosions) and two vein grafts 
showed a dissection, in which a tear starting at the lumen and up to the outer vein 
graft wall, filled with erythrocytes was seen. 
In contrast, only three vein grafts of the vehicle-treated group (n=12) showed 
lesions with erosion (p=0.05, Figure 3B). Plaque erosion is characterized by a loss 
of endothelial cells and therefore we scored the coverage of the lumen with CD31 
positive cells.  DNP treatment resulted in a 40% reduction in coverage compared 
with controls (p=0.001, Figure 3G and 3H). Not only sections with intramural thrombi 
were devoid of endothelial cells, but also apparently asymptomatic lesions in the 
DNP group showed less endothelial coverage.  De-endothelialization can result in 
enhanced fibrin deposition and indeed, the DNP group demonstrated a two-fold 
increase in the fibrin content (DNP; 17±3%, vehicle; 8±4% p=0.001, Figure 3F).
Effect of C5a application and C5aR antagonist PMX205 on vein graft morphology
C5a induced mast cell activation was demonstrated by the release of tryptase and a 
concentration dependent release of CCL2 from cultured bone marrow derived mast 
cells (Supplementary material online, Table S3). To study the involvement of C5a in 
the development of VGT, recombinant C5a was applied in increasing concentrations 
(0, 0.5 and 5µg) directly to the vein graft at the time of surgery. Topical application
of C5a resulted in a dose-dependent increase in lesion area (control: 0.24±0.05, 
0.5µg C5a: 0.29±0.1, 5µg C5a: 0.41±0.1mm2, Figure 4A, B). The total vessel area and 
the luminal area were however comparable between the three groups (data not 
shown).
Remarkably, at 28 days after surgery peri-vascular mast cell numbers show a trend 
towards an increase after C5a application (control: 2.77±1.7 cells/mm2 vein graft, 
0.5µg C5a: 4.36±1.6 cells/mm2 vein graft, p=0.100, 5µg C5a: 5.47±3.2 cells/mm2 vein 
graft, p=0.086 compared with control, Figure 4C). Since C5a is a potent chemotactic 
factor for monocytes/macrophages, the macrophage content was studied. A dose-
dependent increase in macrophage contribution to the VGT was seen in C5a-treated 
vein grafts (Figure 4D). The amount of macrophages increased from 20±5% in the 
controls to 22%±9% (p=0.110 compared with control) in mice treated with 0.5µg 
C5a, and even up to 33±7% in mice which received 5 µg C5a (p<0.05 compared with 
both groups, Figure 4D). Next, the effect of C5aR blockade by systemic treatment 
with the C5aR antagonist, PMX205 was delineated. Analysis of the thickened vein 
graft after 28 days revealed that treatment with PMX205 resulted in a 41% decrease 
in the lesion area, when compared with controls (control: 0.39±0.16, PMX205 
0.23±0.07 mm², p=0.035 Figure 4E, F). The VGT consisted for 24±8% of macrophages. 
In PMX205-treated vein grafts, the macrophage contribution was 16±8% (p=0.012, 
Figure 4G). Strikingly, adventitial mast cells were found to be reduced after PMX205
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Figure 4. A. Representative cross-sections of vein grafts, 28 days after surgery, treated 
with PBS or  0.5 or 5 µg C5a (HPS staining, magnification 20x). B. Quantification of the 
vein graft lesion areas reveals a dose-dependent increase in the lesion size. C. Peri-vascular 
mast cell numbers tend to increase after C5a application, although this did not reach 
significance. D. The relative macrophage content of the vein graft wall, tend to increase 
after 0.5µg C5a application. Application of 5µg C5a to the grafts significantly increased 
macrophage content (*p=0.001 compared with control grafts; #p=0.008 compared with 
grafts treated with 0.5µg C5a). E. Direct effects of the C5aR blockade on vein graft disease 
was assessed by systemic treatment with a C5aR antagonist, hydrocinnamate-[OP-(D-Cha)
WR] (PMX205). Representative cross-sections of vein grafts, 28 days after surgery (HPS 
staining, magnification 20x). F. PMX205 treatment resulted in a significant decrease in the 
lesion area compared with control mice G. A significant reduction in relative macrophage 
contribution can be seen in the PMX205 treated vein grafts. H. The number of adventitial 
mast cells was significantly reduced after PMX205 treatment. * indicates p<0.05; black lines 
in the photographs indicate the thickness of the lesions.
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treatment (PMX205: 2.32±0.6 cells/mm² vein graft, control: 4.14±2.0 cells/mm² 
vein graft, p=0.042, Figure 4H). No differences in rupture complications were seen 
between the groups.
C5a induced vein graft thickening is abolished by mast cell stabilization
To elucidate the mast cell-dependent effects of C5a in VGD, mice were locally 
treated with either a PBS or C5a (5 µg) loaded pluronic gel (n=20/group). Of each 
group, 10 mice were treated twice weekly with the mast cell inhibitor Cro or PBS 
control (ip). Cro treatment resulted in a decrease in the lesion area of 22% (PBS/
PBS 0.38±0.1, PBS/Cro 0.29±0.06 mm²; p=0.044, Figure 5A, B) and a decrease in the 
total vessel area of 19% (p=0.037), whereas the lumen area was not affected. As 
shown previously, local C5a treatment resulted in an increase in the lesion area of 
79% (C5a/PBS 0.68±0.11mm² p=0.001) compared with the control group (Figure 5A, 
B). Strikingly, treatment with both C5a and Cro (C5a/Cro 0.32±0.12mm²) resulted in 
a major decrease in the lesion area (compared with the C5a/PBS group, p=0.001) to 
the level of the group treated with Cro only. A decrease in the total vessel area of 
30% (p=0.003) was seen, whereas no differences were observed in the lumen area 
when comparing C5a/Cro vs. C5a/PBS treatment. The relative SMC content was 
demonstrated to be reduced in the C5a/PBS group by 41% when compared with 
the PBS/PBS group (p=0.002) and a decrease of 31% compared with the PBS/Cro 
group was found (p=0.021, Figure 5C). The collagen content did not differ between 
the groups (PBS/PBS 26±6%, PBS/Cro 24±12%, C5a/PBS 26±14%, C5a/Cro 27±11, 
p=0.499, Figure 5D). In contrast, Cro treatment alone resulted in a 25% reduction 
in the macrophage content when compared with controls (p=0.038), which could 
be caused by inhibition of endogenous mast cell activation during the development 
of VGD (Figure 5E). The C5a/PBS group showed a 44% increase in macrophage 
content when compared with the PBS/PBS group (p=0.001). When compared with 
the C5a/PBS treated mice, the C5a/Cro group displayed a decrease of 61% in the 
macrophage content (p=0.001) as a result of the Cro treatment. Although local C5a 
treatment resulted in a more unstable morphology, no differences were found in 
the occurrence of plaque rupture complications (PBS/PBS 3/10, PBS/Cro 3/10, C5a/
PBS1/10 and C5a/Cro 2/10). 
Expression of mast cells and C5a(R) in human vein graft and carotid endarterectomy 
specimens
To confirm whether C5a activation of mast cells is an endogenous and functional 
pathway in human atherosclerotic lesions, we analysed the presence of mast 
cells, C5a and C5aR in human saphenous vein grafts and carotid endarterectomy 
specimens. Mast cells were detected throughout the entire lesion in both types 
of tissue and were especially found in regions of neovascularization, either in 
the adventitia or in the intima (Figure 6). C5aR staining was abundantly present 
in all layers in both types of specimen. In SMCs, endothelial cells and regions of 
inflammatory cells, including mast cells, C5aR expression was detectable. C5a
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Figure 5. A. the quantification of the vein graft wall area, 28 days after vein graft surgery, 
in ApoE-/- mice treated with a  combination of PBS or with 5 µg C5a locally in pluronic gel 
and twice weekly injections with either PBS or cromolyn (Cro).  Cro treatment resulted in a 
decrease in the lesion area (*p<0.05 compared with the control group) C5a treatment results 
in increased lesion areas (*p<0.05 when compared with the control group). Treatment with 
both C5a and Cro resulted in lesion areas comparable with that of the Cro-alone-treated 
group (#p<0.05 compared to the c5a treated group) B. Representative cross-sections of vein 
grafts, (HPS staining, magnification 20x, black  lines indicate the thickness of the lesions). C. 
the percentage SMCs was significantly decreased after C5a application. D. Quantification 
of the relative collagen content did not show significant differences between all groups. 
E. the relative macrophage content was significantly decreased after Cro treatment and 
C5a application resulted in a significant increase in the macrophage content which could be 
abolished by Cro, * (p<0.05).
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staining was less pronounced and mostly limited to regions of intimal SMCs, 
inflammatory cells, near necrotic cores and neovascularization.
Discussion
We have demonstrated that mast cells and complement factor C5a, both innate 
immunity members, are inextricably linked in the contribution to VGD. Mast cells, 
C5a and C5aR were demonstrated to be present in diseased human vein grafts as 
well as in carotid endarterectomy specimen. This is in accordance with colocalization 
of C5a and the C5aR with mast cells in other types of atherosclerotic lesions as 
shown previously8,18. The expression of C5aR was shown in neointimal lesions and 
Figure 6. The presence and localization of mast cells, C5a and C5a-receptor in 
human saphenous vein grafts, and carotid endarterectomy material was assessed by 
immunohistochemistry. A. Mast cells (black arrows), were found throughout all layers of 
the lesion but primarily in the adventitial and intimal regions near neovessels. B. Abundant 
staining of C5aR was seen in all major cell types present in the lesions; inflammatory cells, 
smooth muscle cells and endothelial cells. C. C5a presence was seen near necrotic cores and 
neovessels. Furthermore colocalization of  C5a with smooth muscle cells and inflammatory 
cells was seen frequently (NC depicts necrotic core, N; Neovessels, L; Lumen and A; Adventitia).
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brachiocephalic artery plaques19,20  and we now demonstrate co-expression 
and colocalization of mast cells, C5a and C5a receptor in murine vein grafts. This 
identifies the C5a-C5aR axis as a potential endogenous mast cell activation route. 
Local mast cell challenge with C5a resulted in an increase in the number of perivascular 
mast cells together with a dose-dependent increase in VGD. Interestingly, treatment 
of vein grafts with a specific C5aR antagonist (PMX205) resulted in decreased VGT, 
which coincides with recent findings of decreased neointimal lesion development 
after C5aR targeting using C5aR specific antibodies or the related C5aR antagonist 
PMX5319,20. Morphologic analysis also revealed a strong reduction in the macrophage 
content.  Recruitment of monocytes/macrophages into the atherosclerotic plaques 
requires up-regulation of adhesion molecules and CCL221. Shagdarsuren et al 
found that treatment with PMX53 resulted in decreased macrophage content and 
reduced VCAM-1 expression19. In addition, C5aR antagonism in a renal allograft 
model resulted in attenuated macrophage infiltration due to reduced levels of CCL2 
and ICAM-122. Interestingly,  adhesion molecules and the CCR2/CCL2 pathway have 
previously been shown to be involved in the recruitment of mast cells23, which 
suggests that a reduction in CCL2 may have accounted for the reduced number of 
mast cells we found after C5aR treatment. In vitro studies demonstrated that C5a 
mediated mast cell activation not only led to the release of the mast cell protease 
tryptase, but also to a dose-dependent release of chemokine CCL2, which may 
have, at least in part, caused the increased levels of lesional macrophages and mast 
cells that were seen in the C5a treated mice. 
To demonstrate a causal role for C5a activation of mast cells in VGD, vein grafts were 
treated locally with C5a while simultaneously mast cell activation was blocked by 
use of Cro. Cro was shown to completely reverse the C5a-induced adverse effects 
on vein graft atherosclerosis, by decreasing the vein graft lesion size comparable 
with that of mice treated with Cro only. We have previously shown that Cro is a 
specific inhibitor of mast cells with no effects on macrophages or other cell types 
present in atherosclerotic plaques4.  This demonstrates that C5a mainly acts on vein 
graft atherosclerosis through mast cell activation. 
Mast cells do not only play a role in atherosclerotic lesion growth but are also 
involved in plaque destabilization and plaque complications as rupture and 
erosions24. We investigated the effect on plaque stability after modulation of mast 
cell activation or C5a intervention. Interestingly, challenge with DNP resulted in a 
major increase in plaque complications and in particular plaque erosions. Plaque 
erosion, a frequent cause of acute coronary death, is characterized by a loss of 
endothelial cells25. Moreover, sub-endothelial mast cells have been demonstrated 
to colocalize with sites of atheromatous erosions26. In this study, mast cell activation 
by DNP challenge resulted in diminished endothelial cell coverage, which may be 
a consequence of endothelial cell apoptosis due to mast cell activation4.  Mast 
cell mediators, such as chymase, TNF-α, histamine and tryptase have separately 
been reported to induce increased endothelial cell permeability and apoptosis27-29, 
suggesting that mast cells can actively induce plaque erosion. Furthermore, mast 
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cells can also induce SMC30,31 and macrophage apoptosis4 and secrete and activate 
matrix metalloproteinases32,33, all important promoters of plaque destabilization 
and rupture. Interestingly, factors involved in intramural thrombus formation 
(plasmin, thrombin) can cleave C5 into C5a34. This C5a could in turn attract and 
activate mast cells in the vicinity of the plaque which can result in an on-going 
loop of atherothrombosis.  We have previously shown that mast cell activation by 
means of a DNP challenge induced acute intraplaque haemorrhage in collar-induced 
atherosclerosis4 and we now show that a single DNP challenge directly after surgery 
resulted in vein graft destabilization and plaque disruptions. Together, these data 
provide clear evidence that mast cell degranulation can result in atherothrombotic 
events. 
The increase in vein graft atherosclerosis after C5a application was accompanied 
by a decrease in plaque stability due to a reduction in relative SMC content and an 
increase in the macrophage content compared with the control group. In contrast, 
the C5a/Cro treated group revealed a more stable composition (more SMC, less 
macrophages) than the C5a treated group. Although there is evidence that C5a can 
induce rupture8,18,35, we did not observe more rupture-associated complications in 
the lesions after C5a application when compared with control or Cro treatment. This 
may be caused by the difference in the activation route of C5a vs. DNP, which results 
in different mast cell releasate compositions14.  This may thus affect endothelial 
survival differently. It is also described that C5a can inhibit angiogenesis36, an 
important factor affecting plaque instability. 
In this study, we conclusively demonstrate that mast cells actively contribute to 
the progression and destabilization of VGD.  Furthermore, the complement factor 
C5a promotes mast cell-dependent VGT, suggesting that complement activation 
is an important endogenous route of mast cell activation in VGD. Previously, C5 
inhibition was demonstrated to be effective in a phase III cardiovascular disease 
trial13. Our finding that mast cells and C5a colocalize in human endarterectomy 
and vein graft specimens is of importance for the working mechanism of C5 in 
cardiovascular disease. Although the mouse vein graft model used in the study 
shows strong homology with human VGD, it should be realized that differences 
exist between murine and human vein grafts. Despite these differences, we here 
conclude that C5a-mediated mast cell activation can be a promising therapeutic 
route of intervention to the prevention of VGD that definitely deserves further 
investigation.
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All animal work was performed in compliance with Dutch government guidelines. 
Male mast cell deficient Kit(W-sh/W-sh) mice and apolipoprotein E–deficient (ApoE-/-) 
mice (cross bred for more than eighteen generations on a C57BL/6 background) and 
bred in the local animal facility and male C57BL/6 mice (Charles River Laboratories), 
were used for all experiments. All mice were between 10-20 weeks old at time of 
surgery. Before surgery ApoE-/- mice were randomized to the different groups on 
basis of plasma cholesterol levels (Roche Diagnostics) and body weight. At sacrifice 
(28 days after surgery, with exception of the time courses) cholesterol levels and 
body weight were not significantly different between the treatment groups and 
their controls. Furthermore, sysmex analysis of blood cells was performed for 
all experiments and no significant differences were detected in the % of WBC 
populations between the treatment groups and their appropriate controls. In 
Supplemental table I white blood cell analysis of the C5a and cromolyn experiment 
is shown.
In vivo experimental setup
A detailed flow-chart displaying the in vivo experimental setup is shown in 
Supplemental Figure 1. The presence of mast cells, C5a and C5aR was determined 
in vein grafts of hypercholesterolemic ApoE-/- mice.  For this, immunohistochemistry 
and RT-PCR analysis were performed on time courses of paraffin and RNA material 
of 3-4 mice per time point. To demonstrate the contribution of mast cells to vein 
graft disease, autologous vein grafts were placed in mast cell deficient Kit(W-sh/W-
sh) mice and control C57BL/6 mice (n=8/group).To determine the effect of local 
mast cell activation ApoE-/- mice were skin-sensitized for 2 consecutive days with 
dinitrofluorobenzene (DNFB, 0.5% v/v, Janssen Chimica) or vehicle control solution 
(acetone: olive oil 4:1, n=12 per group) as previous described1. One week after skin-
sensitization and directly after surgery 50 µg dinitrophenyl hapten (DNP) in pluronic 
gel (25% wt/vol, Sigma)2 or pluronic gel alone was applied around the vein grafts. 
The effect of modulation of C5a signaling was investigated by challenging ApoE-
/- mice perivascularly with either 0.5µg or 5µg of recombinant mouse C5a 
(HyCult Biotechnology) or vehicle control, which was applied around the vein 
grafts in pluronic gel (25% wt/vol) directly after surgery (n=7/group). In order to 
inhibit C5a function, mice were treated daily, starting 1 day prior to surgery, with 
subcutaneous injections of 0.3mg/kg hydrocinnamate-[OP-(D-Cha)WR] (PMX205)3 
or vehicle solution (propylene glycol: sterile water 3:7, n=7/group).  PMX205 displays 
potent antagonizing activity for the C5a receptor and was synthesized as described 
previously4. To determine the mast cell dependent C5a effects, a group of C5a (5µg) 
208
stimulated mice were treated twice weekly with intraperitoneal injection of the 
specific mast cell stabilizer, cromolyn (50 mg/kg, Sigma) versus C5a (5µg), cromolyn 
and PBS treated mice (n=9/group).
Vein Graft Surgery 
Before surgery and at sacrifice, mice were anesthetized by an intra-peritoneal 
injection with midazolam (5 mg/kg, Roche), medetomidine (0.5 mg/kg, Orion) 
and fentanyl (0.05 mg/kg, Janssen). After the surgery mice were antagonized with 
subcutaneous injection of atipamezol (2.5 mg/kg, Orion), fluminasemid (0.5 mg/
kg, Braun) and buprenorphine (0.05 mg/kg, Schering-Plough). The adequacy of 
the anaesthesia was monitored by keeping track of the breathing frequency and 
the response to toe pinching of the mice.  Vein graft surgery was performed as 
described previously5. In brief, thoracal caval veins from donor littermates were 
harvested. In recipients, the right carotid artery was dissected and cut in the middle. 
The artery was everted around the cuffs that were placed at both ends of the artery 
and ligated with 8.0 sutures. The caval vein was sleeved over the two cuffs, and 
ligated. At sacrifice, after 3 minutes of in vivo perfusion-fixation, vein grafts were 
harvested and fixated in 4% formaldehyde, dehydrated and paraffin-embedded for 
histology or snap frozen for RNA analysis. 
RNA isolation, cDNA synthesis and RT-PCR
Total RNA was isolated from vein grafts harvested on several time points (3-4 vein 
grafts/time point, 6h, 24h, 3d; 7d; 14d and 28d after surgery). Also, caval veins 
of donor mice were included. RNA was isolated and cDNA was synthesized as 
described previously6. Intron-spanning polymerase chain reaction (PCR) primer sets 
were designed using Primer Express 1.5 software (Supplemental table II).  Relative 
mRNA expression levels (ΔCt) were calculated by subtracting the average cycle 
threshold (Ct) per time point from Ct value of the housekeeping gene hypoxanthine 
phosphoribosyl transferase (HPRT) (ΔCt = Ct target gene– Ct average housekeeping 
genes). The ΔCt levels at each time point were compared with the mRNA expression 
levels of C5a and C5aR in the non-transplanted caval veins (ΔΔCt) and a mean fold 
induction was calculated as 2–ΔΔCt.
Histological and immunohistochemical assessment of vein grafts
Six consecutive sections, with 150 µm interspace (30 sections of 5 µm thick), 
per vessel segment were routinely stained with hematoxylin-phloxine-saffron 
(HPS). Picrosirius red staining was used to visualize collagen content. Mast cells 
were visualized with aqueous toluidine (Sigma), whilst mast cell activation status 
was detected with an enzymatic kit (Naphtol-CAE, Sigma). Mast cells were 
marked as activated when granules could be detected near the mast cells.  The 
following antibodies were used for immunohistochemical stainings; C5a (HyCult 
Biotechnology) C5aR (CD188, SantaCruz), MAC3 (macrophages, BD-Pharmingen), 
smooth muscle cell actin (Sigma), fibrin (Quickzyme), CD31 (Endothelial cells, 
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Abcam) and neutrophil (Serotec) as described previously2,7. For each antibody, 
isotype-matched antibodies were used as negative controls and staining was absent 
in sections incubated with these antibodies (data not shown).
Morphometric analysis of vein grafts
Vein grafting in normocholesterolemic mice results in vessel wall thickening primarily 
caused by smooth muscle cell accumulation. Whereas under hypercholesterolemic 
conditions foam cell accumulation and accelerated atherosclerosis are observed. 
Since elastic laminae do not exist in these grafts of venous origin, we analyzed 
the putative vessel wall area (or lesion area) by measuring total vessel area (the 
area of the vessel within the adventitia) and the lumen area. Next the lesion area 
was calculated (total vessel area – lumen area).  Plaque rupture complications 
were categorized in three categories7. Plaque hemorrhage; when extravasated 
erythrocytes were found adjacent to neovessels.  A dissection was defined as a 
connection between the lumen and the part of the vessel wall underneath the 
adventitia filled with fibrin and erythrocytes. In case fibrin was found at the luminal 
side underneath a denudated endothelial layer, coinciding with erythrocytes and 
neutrophils, this was defined as erosion with intramural thrombosis. In this model 
occlusive thrombosis is rarely seen.
Quantitative morphometric analysis (Qwin, Leica) of vein grafts was performed on 
six HPS stained, equally spaced, sections. (Immuno) histochemical stainings were 
quantified by computer assisted analysis (Qwin, Leica)8. The immuno-positive area 
measured is expressed as a percentage of the lesion area. Mast cell presence was 
counted manually in four sections of each vein graft and expressed as number of 
mast cell per mm² vein graft. Endothelial coverage of the lumen was analyzed in 
6 sections per vein graft. For this, sections were attributed to 3 grades; 0 for no 
endothelial cell coverage, 1 when partially coverage was detected and 2 for full 
coverage.
Cell culture
Bone marrow derived mast cells (BMMCs) were cultured as described before9. 
After 4 weeks in culture, BMMCs were degranulated in HEPES-tyrode supplemented 
with 0.1% fatty acid free BSA (Sigma) with either recombinant mouse C5a (Hycult) 
or 0.5 mg/mL compound 48/80 (Sigma-Aldrich)  for 30 minutes at 37°C. Cells 
were centrifuged (1,500 rpm, 5 minutes) and the releasate was used for further 
experiments. Tryptase release was determined as shown previously2. To determine 
release of CCL2, a mouse CCL2 ELISA kit (Biosource Diagnostics) was used according 
to manufacturer’s protocol. Results were plotted as percentage of total release, 
which was measured in mast cells lysed with 10% Triton-X100 (Sigma), while 
supernatant of non-degranulated mast cell was used as control (0%).
Human Vascular Material Analysis
Vein graft (n=8) and endarterectomy (n=25) tissues were obtained in accordance
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with guidelines set out by the ‘Code for Proper Secondary Use of Human Tissue’ 
of the Dutch Federation of Biomedical Scientific Societies (Federa). Samples were 
collected, paraffin embedded and 5 µm sections were prepared. Antibodies against 
Tryptase (Dako) C5aR (SantaCruz) and C5a (Abcam) were used to detect mast cells, 
C5a and C5a Receptor in consecutive sections. 
Supplemental Table S1  White Blood Cell analysis (sysmex) of the C5a and cromolyn 
experiment




All data are presented as mean ± SD. Statistical analysis was performed using SPSS 
17.0 for Windows. For the time courses, statistical analysis was performed using a 
repeated measures ANOVA with a Bonferroni Post Hoc test. To determine statistical 
significance for the in vivo experiments, comparisons were made using the non-
parametric Kruskal-Wallis test. In case of significance, each group was separately 
compared to the control group using the Mann-Whitney test. For in vitro studies a 
2-tailed Student’s t-test was used to compare individual groups. Probability-values 
<0.05 were regarded significant.
Supplemental Table S2  Primer sequences of housekeeping gene HPRT, Complement factor 
C5a, and its receptor, C5aR.
Supplemental Table S3 Tryptase and CCL2 content of bone marrow derived mast cells 
(BMMC) releasate after C5a and compound 48/80 stimulation indicated as % of total 
release. Stimulation of C5a resulted in a release of tryptase comparable to that of the 
positive control, compound 48/80. Furthermore, C5a stimulation of BMMC led to a dose-
dependent release of CCL2.
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summary and general discussion 
Vein graft surgery to treat occlusive arterial disease is a general applied procedure. 
Each year surgeons perform more than two million coronary vein graft surgeries and 
peripheral vein graft procedures worldwide.  A significant drawback of vein grafting 
is that, within 10 years after vein graft surgery, 50-60 % of the vein grafts suffer 
from patency loss due to thrombosis, smooth muscle cell rich intimal hyperplasia 
formation, accelerated atherosclerosis and rupture1,2. Inflammation is a key trigger 
in all these processes. The time in which vein graft failure develops can last weeks, 
in case of acute thrombosis to months and years depending on individual patients. 
Endogenous factors orchestrate the outcome in all these phases.
Investigating the role of endogenous constituents on vein graft remodeling can 
serve two purposes. First, it can enhance the basic knowledge of the involvement of 
these factors in the different phases of vein graft development; even extrapolation 
of this knowledge to cardiovascular remodeling processes is possible. Secondly, by 
interfering in the function of endogenous factors, as we showed in this thesis, vein 
graft remodeling was negatively or positively influenced depending on the factor 
and strategy used. New therapeutic strategies can be developed based on this 
knowledge. 
In chapter two, we studied the effects of TIMP overexpression via electroporation 
mediated intramuscular plasmid transfection on vein graft remodeling and especially 
on the effect on plaque rupture complications. Complications like dissection, 
erosion and intra-plaque hemorrhage due to leaky vessels occur frequently in 
hypercholesterolemic ApoE3*Leiden mice as a result of increased shear stress, de-
endothelialization or decreased maturation of plaque neovessels. We showed that 
both TIMP-1 and TIMP-3 reduced vein graft thickening, but only TIMP-1 is capable 
of preventing plaque instability by preventing plaque rupture complications. 
Targeting TIMPs, especially TIMP-1, can be an attractive strategy to reduce both 
lesion size as well as plaque instability. The effect of overexpression of the hybrid 
protein TIMP-1.ATF (consisting of TIMP-1 and the receptor-binding amino terminal 
fragment (ATF) of urokinase) on vein graft thickening was studied in chapter three. 
This TIMP-1.ATF achieves MMP inhibition at the cell surface by binding of TIMP-1 
to the u-PA receptor and thereby hampering the binding of u-PA to its receptor. 
Before overexpression TIMP-1.ATF we confirmed the presence of essential MMPs; 
MMP2, MMP9 and MT-MMP as well as u-PA and u-PA receptor in a time course of 
murine vein grafts.  Overexpression of TIMP-1.ATF resulted in abrogation of vein 
graft thickening that was stronger than TIMP-1 or ATF alone. Furthermore, TIMP-1.
ATF lead to a more favorable lumen/total vessel wall ratio. Because TIMP-1.ATF 
binds selectively to the u-PA receptor, and at the mean time blocks both MMP and 
plasmin activity on the cell-surface, this approach may contribute to prevention of 
vein graft disease in patients.  
In chapter four, we evaluated the effects of human Annexin A5 (huAnxA5) 
application on key elements that drive vascular diseases such as vascular function, 
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vascular remodeling and local vascular and systemic inflammation. Systemic 
treatment with huAnxA5 resulted in a marked reduction in circulating plasma 
concentrations of IFNγ, G-CSF and CCL4. Furthermore, endothelial function was 
ameliorated after huAnxA5 administration. In a cuff induced vascular injury model, 
we observed in the huAnxA5 treatment group, reduced early inflammatory cell 
recruitment, adhesion and infiltration in the vessel wall. Whereas in the vein graft 
model, vein graft thickening, inflammatory cell infiltrations, as well as, plaque 
rupture complications were found reduced.  The capability of huAnxA5 to target 
different biological systems makes huAnxA5 an attractive compound to put forward 
into the clinics.
The contribution of lesion neovascularization to vein graft thickening and 
intraplaque hemorrhage was studied in chapter five. This was achieved by 
evaluating the effects of VEGF receptor2 (VEGFR2) blockade via systemic antibody 
administration. VEGFR2 blockade resulted in diminished intraplaque hemorrhage, 
which was accompanied by a decrease in extravasated erythrocytes. Interestingly, 
in the group treated with VEGFR2 blocking antibodies, we observed a decrease in 
both Angiopoietin 1 and Angiopoietin 2. Furthermore, VEGFR2 blockade resulted 
in decreased vein graft wall thickening.  In addition, increased plaque stabilization 
was observed since we found more smooth muscle cells and stabilizing collagen 
depositions in the vein graft lesions of the VEGFR2 group. This was not a result of 
decreased vascular inflammation since the number of leukocytes was not different 
from that in the control group but, most probably, due to increased maturation of 
the plaque neovessels.
The NK cell and especially, the role of the C57bl/6 NK gene complex were studied in 
chapter six. NK cell depletion was investigated by using either NK cell deficient mice 
or NK1.1 depleting antibodies, both resulting in a profound reduction of vascular 
remodeling. Interestingly, NKT deficient mice did not show an effect on vascular 
remodeling. Furthermore, we studied the effects of cuff placement and vein 
grafting in C57BL/6, BALB/c mice and CMV1r mice that have a BALB/c background 
but contain the C57BL/6 NKC region. These CMV1r mice display a phenotype similar 
to C57BL/6 mice and show a profound increase in intimal hyperplasia compared 
to BALB/c mice.  The C57BL/6 NKC in CMV1r mice is responsible for a shift of the 
(BALB/c) Th2 inflammatory response towards a (C57BL/6) Th1 response as shown 
by inflammatory cell infiltrations and IFN-γ expression. NK cells of CMV1r mice show 
comparable responsiveness to C57BL/6 derived NK cells in an experiment in which 
we measured intracellular IFNγ in NK cells upon cross linking of their activating 
receptors, whereas BALB/c derived NK cells show hypo-responsiveness.  From this 
we can conclude, that the presence of the C57BL/6 NKC results in an increased 
inflammatory cascade, which contributes to an increased vascular remodeling 
phenotype. 
The role of Toll like receptors (TLRs) in vein graft remodeling was studied in chapter
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seven  and eight. TLRs share the ability with complement factors to interact with 
adaptive immune factors, vessel wall components and other endogenous systems. 
Interestingly, complement factors and TLRs cross-react frequently. We demonstrate 
in chapter seven that endogenous ligands for TLRs, and especially TLR4, such 
as HSP60, HMGB1, Tenascin C and Biglycan are present in vein graft lesions. 
Furthermore, we observed a significant role for TLR4 in vein graft remodeling 
since TLR4 deficient (C3H-Tlr4LPS-d) mice showed a significant reduction in vein graft 
thickening and a decrease in outward remodeling after vein grafting. Moreover, 
local TLR4 gene silencing via lentiviral application of shRNA against TLR4 in 
hypercholesterolemic ApoE3*Leiden mice led to a reduction in vein graft thickening 
and a beneficial lumen/total cross-sectional area ratio. This was supported by a 
decrease in macrophages and SMC-actin positive cells in the lesions and a focal 
decrease in TLR4 expression. Therefore, we conclude that TLR4 is a key regulator of 
vein graft remodeling. 
Ligand binding of TLRs results in activation of the MyD88 and NFĸB pathway which 
leads to induction of inflammatory cytokines.  In vascular disease models, this leads 
to pro-inflammatory profiles, which result in augmentation of lesion formation 
and extensive remodeling. Interestingly, TLR3 is unique among the TLRs, since 
TLR3 signalling occurs in a MyD88 independent manner, via activation of TRIF and 
key interferon regulating factors, IRF3 and IRF7 resulting in induction of type I 
interferons. The aim of the study described in chapter eight was to investigate the 
role of the TLR3 pathway in vein graft remodeling. Tlr3-/- animals, as well as IRF3-/- 
and IRF7-/- mice, showed increased vessel wall thickening and outward remodeling in 
their vein grafts. The increased remodeling in these knockout mice is the result of a 
pro- inflammatory response as reflected by increased macrophages in the vein graft 
wall, whereas Type I Interferon inducible genes were down regulated. In MyD88 
dependent TLR4-/- mice we observed decreased vein graft remodeling. No regulation 
of pro- inflammatory cytokines and Type I Interferon inducible genes was observed 
in these 28 days old vein graft, however less leukocytes were found in the vein graft 
walls. In contrast, TLR2-/- mice, which signal solely via Myd88, showed no effects 
on vein graft remodeling in comparison to control mice. Interestingly, TLR2-/-  vein 
graft did demonstrate down regulation of Type I Interferon inducible genes.  From 
these date, we can conclude that Type I Interferon (inducible) genes, in addition to 
pro- inflammatory cytokines, are highly involved in vein graft remodeling. This was 
confirmed by gene set analysis, which showed that the TLRs and Type I Interferon 
genes belong to the top 15 of regulated pathways in ApoE3*Leiden vein grafts.
In chapters nine, ten and eleven the role of various components of the complement 
cascade on vein graft development and remodeling were studied. The complement 
system is an appealing target for new therapeutic strategies since it interacts with 
many biological systems. Besides its role in innate immunity resolution, it cross 
reacts with factors of the adaptive immune system as well as factors involved in 
hemostasis, coagulation system components and cells of the vessel wall3. In
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chapter nine, the effects of C1-esterase inhibitor (C1inh) on vein graft remodeling 
were investigated. Application of C1inh in an in vitro perfusion model for vein 
grafting, based on perfused human saphenous veins, resulted in significant more 
depositions of C1inh in the vein wall. This coincided with a significant 47% reduction 
in endothelial loss and deposition of C3d and C4d in the vein wall, compared to 
vein segments perfused without supplemented C1inh. Complement activation is 
an important mechanism underlying acute shear stress-induced endothelial loss 
and medial damage, which is inhibited by C1inh in this system.  This was further 
confirmed in vivo where administration of C1inh significantly protected the whole 
vessel wall, including the endothelial lining, against arterial pressure induced vein 
graft remodeling in hypercholesterolemic ApoE3*Leiden mice. Taken together, 
C1inh significantly reduced endothelial loss in perfused human saphenous veins and 
protected vein grafts against accelerated atherosclerotic in mice. In chapter ten, we 
demonstrated the presence of various complement factors (C1q, C3 and C9) and 
complement regulatory proteins (Crry and CD59) in vein graft lesions. Since most 
of these factors were demonstrated at both the protein and RNA level, we showed 
that the vessel wall can produce complement factors as an extrahepatic source. 
Inhibition of the central complement component C3 by Crry Ig (an inhibitor of C3 
convertases) resulted in abrogated vein graft thickening in hypercholesterolemic 
ApoE3*Leiden mice. This was associated with an early decrease in influx of 
leukocytes. 28 days after surgery, the lesion composition of the vein grafts showed 
that the number of SMCs exceeded the presence of macrophages in the Crry Ig 
treated group. A comparable reduction in vein graft thickening was shown after 
treatment with Cobra Venom Factor (a C3 activator inhibitor) indicating that 
activation of C3, and thereby the whole complement cascade, is an important 
early trigger for vein graft thickening. Chapter eleven focuses on the role of C5a 
in relation to mast cells in vein graft disease. First we demonstrated the individual 
contribution of mast cells to the process of vein graft remodeling by showing that 
mast cell deficient mice showed decreased vein graft thickening whereas activation 
of mast cells with dinitrophenyl (DNP) resulted in enhanced vein graft thickening 
with enhanced plaque rupture complications. The role of C5a was studied by local 
application of C5a in a pluronic gel around the vein graft resulting in massive vein 
graft thickening. Whereas inhibition of C5 function, via administration of a systemic 
C5 receptor antagonist, resulted in decreased vein graft thickening. Furthermore, 
systemic inhibition of mast cells by cromolyn inhibited the C5a induced vein graft 
thickening. Finally, we demonstrated co- expression and colocalization of mast 
cells, C5a and C5a receptor in murine as well as human vein grafts. Together this 
identifies the C5a-C5aR axis as an important endogenous mast cell activation route 
in vein graft disease. 
Conclusions and future perspectives
This thesis encompasses a number of preclinical studies that investigate the role of 
endogenous factors such as TIMPs and Annexin A5, and innate immune
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components in vein graft remodeling and failure. With the research described 
here we first provided more insight in the mechanism of endogenous pathways, 
factors and immune cells involved in vein graft remodeling. Secondly, we indicated 
several potential targets for therapy and finally, we established a model for plaque 
instability and plaque rupture complications, which remain the most pivotal risk 
factors for cardiovascular morbidity. 
This thesis provides evidence of active involvement of individual components of 
the innate immune system in vein graft remodeling.  The majority of the factors 
examined here attenuate the inflammatory profile of the vein grafts by establishing 
a pro-inflammatory milieu. By enhancing chemotaxis and increasing leukocyte 
recruitment, a boost of cytokine and growth factors is released that stimulates 
smooth muscle cell to migrate, proliferate and deposit extracellular matrix in the 
vessel wall. It is remarkable that TLR3 and downstream IRF3 and IRF7 were found 
to exhibit an opposite response, because vein grafts in mice deficient for these 
genes displayed increased vein graft remodeling and vein graft thickening. Type I 
Interferons, and downstream genes, therefore, would be particularly interesting to 
study in future research.
Interestingly, most cells and factors that we investigated in these studies show a 
wide variety of interactions with each other through the production of cytokines 
or via direct cell-receptor interactions as, for example, described in chapter 11; 
the mast cell and complement factor C5a. Also TLRs and complement factors 
crossreact, most likely via interactions of downstream NFĸB and MAPKs4,5. NK cells 
express TLRs and complement receptors, whereas NK cell-secreted IFNƴ attracts 
leukocytes and especially macrophages. In contrast, IFNƴ also inhibits smooth 
muscle cell proliferation6. The relationship between plaque neovascularization and 
mast cells is well established7. Further unraveling of these complex relationships and 
their role in vein graft remodeling will be an exciting challenge for future research, 
especially when using techniques as gene arrays and gene set enrichment analysis 
as described in chapter eight. 
All innate immune components studied in this thesis demonstrate pronounced 
effects on vein graft development rendering these endogenous factors very 
promising for therapeutic targets. The big question is, which of all these 
endogenous factors are useful and realistic therapeutic targets in a clinical setting. 
Some endogenous components have key regulatory functions in various biological 
systems, and therefore systemic application can result in serious adverse side-
effects, off-target effects or give rise to unwanted immune-suppression. Local 
application of these new therapeutic factors might by an approach to prevent 
systemic side effect, in case of vein graft surgery this is certainly a feasible option. 
The timeframe of activity is an important determinant for the therapeutic window. 
For instance, TLR4 has been found to be predominantly active in the first days after 
vein graft surgery, therefore, targeting this key regulating factor for a longer period 
would, due to its general regulator function, inevitably result in serious side effects. 
Combinational therapy by targeting multiple factors truly has potential to block
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vein graft disease, for instance TLR4 and C5a to dampen the early inflammatory 
response in combination with a targeted approach on vasa vasorum and plaque 
neovessels, by VEGFR2 blockade, to prevent atherothrombosis and lesion growth.
An  unstable lesion is regarded as the most important hallmark of clinical 
atherosclerotic complications as pathology studies have demonstrated8,9. Preclinical 
animal models and especially small animal models lack critical characteristics of 
human unstable atherosclerotic disease especially thrombotic complications10. 
In this thesis we demonstrate that the vein graft model in hypercholesterolemic 
mice, exhibits certain of these unstable plaque characteristics such as plaque 
neovascularization, intraplaque hemorrhage, mural thrombi, erosions and 
dissections. This model substantially contributes to the toolbox of preclinical 
models of atherothrombotic disease, since we here demonstrated that pivotal 
contributors to plaque rupture such as matrix metalloproteases (chapter two), 
plaque neovascularization (chapter five) and mast cells (chapter eleven) can be 
modulated to stabilize atherosclerotic lesions. 
In this thesis, we have demonstrated the importance of endogenous constituents 
in vein graft remodeling and failure, in a preclinical setting. However before moving 
new therapeutics forward to the clinical setting, some considerations should be 
taken in account.
It is known that preclinical animal models are not always predictive for efficacy 
of therapeutics in humans11.  Although the majority of genes involved in disease 
processes are alike between most mammals, the availability of factors and biological 
function of certain factors can differ between rodents and humans. Humanized 
animal models such as the ApoE3*Leiden mice, used in several studies described in 
this thesis are, therefore, indispensable for good preclinical research. Furthermore, 
focus should be given to the timespan of treatment and concentrations to be used 
in clinics that can be aberrant between animal models and humans. 
Interestingly, vein graft disease offers several advantages compared to other 
vascular diseases regarding (new) therapeutic strategies. One major benefit is that 
the starting point of treatment is very clear: directly after the start of the operation. 
Furthermore, since vein graft disease is localized to a specific area: the vein graft, 
local application is very achievable. Even ex vivo treatment is applicable, making 
vein grafts an ideal object for experimental techniques such as external stenting12, 
13 and gene therapy14.  In chapter two, three, and eight gene therapy techniques 
such as plasmid electroporation and lentiviral overexpression of a short hairpin 
RNA are used. These strategies result in extensive protective effects on vein graft 
remodeling. In follow up, efforts should be made to produce safe and efficient 
vectors for delivery of genes for usage in clinical practice.
An important additional consideration is that both the balance between factors are 
present in the vessel wall and the perivascular area, as well as the concentration in 
which they are available, ultimately depicts the extent of vein graft remodeling and 
failure. Vein grafts that suffer from extensive SMC-rich intimal hyperplasia require
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another therapeutic approach than vein grafts that suffer from unstable accelerated 
atherosclerotic lesions. This form of personalized medicine can only be achieved by 
extensive knowledge of the local vein graft constitution. Imaging, a fast growing 
discipline that reaches from MRI, PET, SPECT, CT, IVUS to molecular techniques 
such as Near-InfraRed-Fluorescence imaging as used in chapter two, is the most 
obvious technique to achieve this15. The use of targeted molecular imaging agents 
can further increase the specificity of the imaging techniques resulting in adequate 
knowledge on the appearance of the vein graft, to realize a tailor-made therapeutic 
strategy.
  
Finally, it can be concluded that the studies described in this thesis contribute 
to a better understanding of pathways involved in vein graft development and 
failure, and as such are extremely helpful in defining new therapeutic strategies 
based on the factors studied here, although all above mentioned considerations 
on specificity, side effects and local action and concentrations should be taken 
account. This thesis definitely contributes to a better understanding of vein graft 
disease and the development of new therapeutic options. 
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Hart- en vaatziekten behoren tot de top van dodelijkste ziekten in de westerse wereld, 
en zijn daarnaast sterk opkomend in laag- en middeninkomen landen. Risicofactoren 
voor hart- en vaatziekten zijn een hoge bloeddruk, suikerziekte, ongezonde 
leefstijlgewoontes en genetische factoren. De belangrijkste onderliggende 
oorzaak van de meeste hart- en vaataandoeningen is atherosclerose, ook wel 
aderverkalking genoemd. De vorming van een atherosclerotische plaque start met 
activatie van endotheel cellen, cellen die de binnenkant van bloedvaten bekleden. 
Dit wordt veroorzaakt door verhoogde druk op de vaatwand en vetophopingen 
in de vaatwand in de vorm van geoxideerde lipoproteïnen. Een verstoorde 
afweerreactie, ofwel immuunrespons zorgt voor een verergering van de situatie. 
Atherosclerotische plaques starten als laesies die voornamelijk uit met vet gevulde 
macrofagen (schuimcellen) bestaan en kunnen doorgroeien tot zeer complexe 
instabiele laesies waarin schuimcellen, gladde spiercellen, necrotische kernen, 
calcificaties, cholesterol kristallen en kleine nieuwe bloedvaatjes(neovascularisaties) 
voorkomen. Klinische symptomen kunnen veroorzaakt worden door ernstige 
vernauwingen (>70%) van arteriële vaten, maar veel vaker is het scheuren 
(ruptureren) van een atherosclerotische plaque de oorzaak van een hartinfarct of 
herseninfarct. Plaques ruptureren als het gevolg van een instabiele samenstelling 
van de plaque. Afhankelijk van het aangedane orgaan kan een gescheurde plaque 
leiden tot een hartaanval, herseninfarct of perifeer atherosclerotisch lijden, met de 
daarbij behorende morbiditeit en mortaliteit. Strategieën om atherosclerotische 
laesies te behandelen bestaan, naast medicatie, uit invasieve behandelingen, zoals 
dotter- en stentoperaties, of het plaatsen van een bypass  om het weefsel, distaal 
gelegen van het dichtgeslibde vaatsegment, weer van bloed te voorzien. Helaas 
hebben al deze strategieën ook hun eigen specifieke nadelen. In het geval van een 
bypass operatie is het in 50% van de gevallen noodzakelijk om binnen 10 jaar een 
nieuwe behandeling toe te passen doordat de bypass of veneuze graft geheel of 
gedeeltelijk is dichtgeslibd als gevolg van veneuze graft falen. Dit wordt veroorzaakt 
door gladde spiercel migratie en proliferatie, extracellulaire matrix deposities en 
versnelde atherosclerose. 
In dit proefschrift wordt de ontwikkeling van veneuze grafts en het falen van deze 
grafts bestudeerd, waarbij de nadruk ligt op de werking van een aantal lichaamseigen 
mechanistische factoren en aangeboren immuunsysteem componenten. Daarnaast 
wordt er gekeken of een aantal van deze componenten geschikt zijn om als doel te 
dienen voor nieuw te ontwikkelen medicatie.
In hoofdstuk twee en drie onderzoeken we de effecten van Tissue Inhibitors of 
MatrixMetalloProteases (TIMPs) op vein graft remodulering. TIMPs reguleren de 
opbouw en afbraak van extracellulaire matrix in de vaatwand. In hoofdstuk twee 
beschrijven we het voorkomen van diverse aspecten van plaque ruptuur in veneuze 
grafts in atherosclerose gevoelige ApoE3*Leiden muizen. Overexpressie (door 
middel van electroporatie) van de MatrixMetalloProtease (MMP) remmer TIMP-1 
in deze muizen leidt tot een vermindering van de MMP activiteit in de veneuze
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grafts, wat gepaard gaat met een afname van de vaatwand dikte. Daarnaast zien we 
in de met TIMP-1 behandelde veneuze grafts significant minder plaque rupturen. 
Dit is het gevolg van een stabielere plaquevorming door een toename van plaque 
stabiliserende factoren, zoals gladde spiercellen en collageen en een afname van 
plaque destabiliserende factoren; schuimcellen en fibrine deposities. Hoofdstuk drie 
beschrijft de effecten op veneuze graft ontwikkeling na overexpressie van een nieuw 
ontwikkelde factor die bestaat uit TIMP-1, gekoppeld aan het receptorbindende 
gedeelte van urokinase (het amino terminale fragment; ATF). Dit TIMP-1.ATF laat 
een sterkere vermindering van de vaatwand dikte zien in vergelijking met enkel 
ATF of TIMP-1 overexpressie. Verder zorgt TIMP-1.ATF voor een zeer gunstige 
lumen/vaatwand ratio. Het ATF gedeelte van TIMP-1.ATF zorgt voor remming 
van de MMP activiteit aan het celoppervlak naast de reguliere remming van de 
plasmine-activiteit. Dit zorgt ervoor dat TIMP-1.ATF als een zeer interessante factor 
met klinisch potentieel gezien wordt. De rol van humaan Annexine A5 in vasculaire 
ziekten processen is onderzocht in hoofdstuk vier. Systemische toediening 
van AnxA5 leidt tot een verbetering van de endotheelfunctie alsmede tot een 
vermindering van de systemische ontstekingsrespons en een vermindering van 
ontstekingscellen in de vaatwand.  Dit tezamen resulteert dat AnxA5 toediening 
een vermindering van arteriële vaatwandverdikking in het cuff model als ook een 
vermindering van veneuze graft verdikking veroorzaakt. In de veneuze grafts, 
behandeld met AnxA5, zagen we ook een vermindering van plaque ruptuur 
gerelateerde complicaties. De brede werking op belangrijke processen betrokken 
bij vasculaire remodulering, maakt dat AnxA5 een groot potentieel heeft als een 
nieuw te ontwikkelen medicijn. In hoofdstuk vijf focussen we ons op een specifiek 
onderdeel van de plaquevorming, namelijk de contributie van nieuw gevormde 
vaatjes (neovascularisatie) aan vaatwandverdikking. In hoofdstuk twee hebben 
we al laten zien dat neovascularisatie, en dan in het bijzonder lekkende vaatjes, 
sterk bijdragen aan de groei van de vaatwand in veneuze grafts evenals aan plaque 
instabiliteit en ruptuur complicaties. Wanneer we antilichamen tegen Vascular 
Endothelial Growth Factor receptor 2 (VEGFR2) toedienen zien we een afname van 
de vaatwanddikte als resultaat van een verminderde ophoping van rode bloedcellen 
in de vaatwand. Dit laatste wordt veroorzaakt door een vermindering van de 
lekkende vaten in de atherosclerotische plaques in de met VEGFR2 behandelde 
veneuze grafts ten opzichte van de controlegroep. Hiermee bewijzen we dat de 
rijping van de neovascularisatie in de veneuze grafts laesies invloed heeft op de 
uiteindelijke vaatverdikking, maar nog belangrijker,  het is sterk bepalend voor de 
plaque stabiliteit.
In hoofdstuk zes onderzoeken we de rol van de Natural Killer (NK) cellen in vasculaire 
remodulering. NK cellen behoren tot de aangeboren afweer en zijn betrokken bij 
de verdediging tegen pathogenen door het actief doden van geïnfecteerde cellen. 
In dit hoofdstuk laten we zien dat zonder NK cellen, door gebruik te maken van NK 
deficiënte dieren of door het weghalen van NK cellen (met behulp van antilichamen 
tegen NK cellen), er een vermindering van vaatwand verdikking plaatsvindt in een
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model van arteriële remodulering. Activatie van NK cellen wordt sterk gereguleerd 
door het Natural Killer gen complex (NKC). Interessant genoeg verschillen de 
twee muizenstammen, C57BL/6 en BALB/c, sterk in hun vasculaire remodulering-
fenotype, als ook in de genen die in het NKC tot expressie komen. Om de rol van 
het NKC in vasculaire remodulering te onderzoeken, hebben we naast deze twee 
stammen gebruik gemaakt van een BALB/c muizenstam die het C57BL/6 NKC tot 
expressie brengt; de CMV1r muizenstam. In zowel het arteriële cuff model als 
het veneuze graft model zagen we een sterke vaatwandverdikking in de CMV1r 
muizen, vergelijkbaar met de effecten die we zien in de C57BL/6 muizen. De BALB/c 
echter laten bijna geen vaatwandverdikking zien. Verder hebben we aangetoond 
dat de NK cellen van de CMV1r muizen een ontstekingspatroon laten zien welke 
vergelijkbaar is met dat van de C57BL/6 muizen. Hieruit concluderen we dat NK 
cellen en in het bijzonder het NKC sterk betrokken zijn bij de ontstekingsrespons 
in vasculaire remodulering. In hoofdstuk zeven en acht onderzoeken we de rol 
van Toll-like receptoren (TLRs) in veneuze graft remodulering. TLRs worden 
geactiveerd door microbiële componenten, maar ook door lichaamseigen factoren 
die vrijkomen na vaatschade. TLRs kunnen verder interacties aangaan met factoren 
van het adaptieve immuunsysteem,  met componenten uit de vaatwand en andere 
endogene systemen, zoals de complement cascade.  Gedurende de ontwikkeling 
van veneuze graft worden endogene liganden voor TLRs sterk opgereguleerd, 
zoals aangetoond wordt in hoofdstuk zeven. In deze studie tonen we verder aan 
dat TLR4 zeer sterk betrokken is bij de remodulering van veneuze grafts, doordat 
muizen deficiënt voor TLR4 of door lokale overexpressie van een shRNA tegen TLR4 
(met behulp van een lentivirale factor), een remming van de vaatwand verdikking 
laten zien. Dit wordt veroorzaakt door zowel een afname van aantal macrofagen 
als een afname van het totaal aantal gladde spiercellen. De meeste TLRs signaleren 
via de MyD88- en NFĸB-signalerings-route resulterend in een ontstekingsrespons 
door het opreguleren van pro-inflammatoire cytokines. TLR3, en ook in bepaalde 
situaties TLR4, signaleren via het TRIF pathway, resulterend in transcriptie van type 
I interferonen via activatie van interferon  regulerende factoren (IRF)3 en IRF7.  In 
hoofdstuk acht laten we zien dat in een array analyse van veneuze grafts in muizen 
op een hoog cholesterol dieet zowel de MyD88 signaleringsroute als ook de type 
I interferon signaleringsroute  sterk opgereguleerd worden in de tijd. Vervolgens 
hebben we de effecten van deze twee TLR signaleringsroutes op veneuze graft 
remodulering onderzocht door gebruik te maken van diverse transgene dieren. 
Opvallend hierbij was dat TLR3 deficiënte dieren als ook IRF7 deficiënte dieren 
een sterke toename lieten zien van de vaatwandverdikking, dit ging gepaard met 
een toename van inflammatoire cellen en een afname van type I interferonen en 
downstream interferon reactieve genen in de vaatwand van veneuze grafts. Hieruit 
kunnen we concluderen dat TLR3 en downstream IRFs, in tegenstelling tot andere 
Toll-like receptoren, een beschermende functie hebben in het proces van veneuze 
graft remodulering.
In hoofdstuk negen, tien en elf wordt de rol van een aantal componenten van het
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complement systeem in veneuze grafts bestudeerd. Het complement systeem is 
een complex systeem dat uit meer dan 30 factoren bestaat. Deze factoren vormen 
een cascade van activatie. Dit resulteert uiteindelijk in activatie van het “membrane 
attack complex” dat cellen en microbiotica direct kan doden. Complement systeem 
componenten gaan ook vele interacties aan met factoren uit andere biologische 
systemen, zoals het adaptieve immuunsysteem, coagulatiesysteem, maar ook met 
cellen uit de vaatwand. Dit maakt het bestuderen van de rol van het complement 
systeem in veneuze graft ontwikkeling des te relevanter. In hoofdstuk negen worden 
de effecten van een natuurlijk voorkomende C1 remmer (C1inh) onderzocht. 
Toediening van C1inh in een in vitro model resulteerde in hogere concentraties 
van C1inh in de vaatwand. In vergelijking met controle vaten zagen we een 
vermindering van de endotheel beschadiging als ook een toename in deposities 
van C3d en C4d. Toediening van C1inh aan hypercholesterolemische ApoE3*Leiden 
muizen resulteerde in een vermindering van de vaatwandverdikking van veneuze 
grafts ten opzichte van controle muizen. Dit ging gepaard met een vermindering 
van, door shear stress veroorzaakte, endotheel-verlies evenals een vermindering 
van ontstekingseffecten via een complement gereguleerd mechanisme. In 
hoofdstuk tien laten we zien dat diverse complement componenten aanwezig zijn 
in de vaatwand van geremoduleerde veneuze grafts zoals C1q, C3 en C9 als ook 
complement regulerende eiwitten zoals Crry en CD59. Remming van de centrale 
complement-factor C3 door Crry-Ig (een remmer van C3 convertases) resulteerde 
in een vermindering van veneuze graft verdikking door een vermindering van het 
aantal infiltrerende leukocyten. Dit resulteerde na 28 dagen in een stabielere 
vaatwand samenstelling door een toename van gladde spiercellen en een afname 
van schuimcellen ten opzichte van controle behandelde dieren. Vergelijkbare 
resultaten werden gevonden na het toedienen van Cobra Venom Factor (een 
C3 activatie remmer). Dit leidt tot de conclusie dat het complementsysteem, en 
in het bijzonder de centrale complement component C3, een belangrijke factor 
is in vroege veneuze graft remodulering. Hoofdstuk elf beschrijft de mestcel 
activerende effecten van complement factor C5 en de effecten van beide op 
vaatwandontwikkeling en remodulering. Mestcellen behoren tot het aangeboren 
immuunsysteem en reageren na activatie met uitscheiden van granules gevuld met 
histamine, chymase, tryptase, chemokines en groeifactoren. Eerst laten we zien 
dat het ontbreken van mestcellen door het gebruik van mestcel deficiënte muizen 
leidt tot een vermindering van veneuze graft verdikking. Wanneer anderzijds 
mestcellen gestimuleerd worden in atherosclerose gevoelige muizen, resulteert 
dit in een toename van de vaatwanddikte wat gepaard gaat met een toename 
in plaque rupturen. De rol van C5 werd bestudeerd door het lokaal aanbrengen 
van C5a rond de veneuze graft, wat resulteerde in een toename van veneuze graft 
remodulering. Het remmen van de C5 functie door het systemisch toedienen van 
een C5a-receptor antagonist leidt tot een afname van veneuze graft remodulering. 
Wanneer tegelijkertijd C5a lokaal aangebracht wordt rond de veneuze graft en 
mestcellen systemisch geremd worden door middel van cromolyn, zien we een
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mestcel afhankelijke afname van de stimulerende effecten van C5a op de veneuze 
graftwand. Colokalisatie van C5a en mestcellen in humane veneuze grafts toont de 
klinische relevantie van dit mechanisme aan.
Dit proefschrift bevat een aantal studies welke de rol van lichaamseigen factoren 
op veneuze graft ontwikkeling en veneuze graft falen beschrijven. Samenvattend 
kunnen we stellen dat we hier bewijzen dat veel van deze factoren zeer sterk 
betrokken zijn bij veneuze graft ontwikkeling. Daarnaast laten we zien dat veel 
van deze factoren potentie hebben om gebruikt te worden als doelwit om nieuwe 
therapeutische strategieën te ontwikkelen. Als laatste laten we zien dat het 
veneuze graft model in muizen met een atherosclerotische achtergrond niet alleen 
als model kan dienen voor veneuze bypasses maar ook als model voor instabiele 
atherosclerotische plaques en plaque rupturen. 
In de studies beschreven in dit proefschrift demonstreren we dat veel van de 
onderzochte endogene factoren zoals de complement factoren, NK cellen als 
ook mest cellen, veneuze graft remodulering beïnvloeden door het creëren van 
een ontstekingsbevorderend milieu waarbij een verhoogd aantal leukocyten 
en dan vooral macrofagen, naar de vaatwand aangetrokken worden wat leidt 
tot verhoogde ophopingen van gladde spiercellen en extracellulaire matrix in de 
vaatwand. Opvallend was dat een aantal factoren in de TLR3 signaleringsroute een 
tegengesteld effect liet zien. Type I interferonen, genen die geactiveerd worden 
via deze route, zijn daarom zeer interessant om in de nabije toekomst verder te 
onderzoeken. Daarnaast hebben we aangetoond dat de hier onderzochte factoren 
elkaar direct, via celreceptor interacties of indirect via cytokines beïnvloeden 
en hiermee het proces van vaatwand remodulering reguleren zoals de hier 
aangetoonde interacties tussen complement factor C5a en mestcellen. Onderzoek 
naar deze interacties is zeer complex maar met behulp van technieken als array 
analyse waarbij naar >40.000 genen tegelijkertijd gekeken wordt, zoals we hebben 
gedaan in relatie tot de TLRs, is dit zeer wel mogelijk.
De volgende overwegingen zijn belangrijk voor een therapeutische factor 
om uiteindelijk in een klinische toepassing gebruikt te kunnen worden. Veel 
lichaamseigen factoren hebben in belangrijke (systemische) processen een sterk 
regulerende rol. Systemische toediening van deze factoren zou kunnen leiden 
tot ernstige bijwerkingen zoals off-target effecten en immuno-supressie. Lokale 
toepassing van de endogene factor om systemische bijwerkingen te vermijden 
lijkt een goede strategie te zijn. Een belangrijke voorwaarde voor de klinische 
toepasbaarheid van een factor is dat deze factor krachtig en specifiek genoeg zijn. 
De tijdspanne waarin een factor actief is zeer bepalend voor de geschiktheid als 
therapeuticum. TLR4 bijvoorbeeld, komt vooral in de eerste dagen na de veneuze 
graft verhoogd tot expressie, zoals we hier laten zien. Lange termijn remming 
van TLR4 zal door de centrale regulerende rol van TLR4 zeker tot ongewenste 
bijwerkingen lijden. Een interessante optie is om een therapeutische behandeling 
te ontwikkelen waarbij verschillende endogene factoren worden aangedaan. 
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zowel TLR4 als C5a in de vroege fase om ontstekingseffecten te verminderen met 
Bijvoorbeeld het remmen van daarbij een VEGFR2 blokkade om de eventueel 
ontstane plaques te stabiliseren. 
Een belangrijke observatie beschreven in dit proefschrift is het onderzoek naar 
plaque instabiliteit in de veneuze grafts van hypercholesterolemische muizen. 
Naast dat we de pathologie van de verschillende ruptuur complicaties beschrijven 
laten we ook zien dat we door het remmen van belangrijke ruptuur mediatoren 
zoals mest cellen, matrix metalloproteases en neovascularisatie, plaque ruptuur 
gerelateerde complicaties zoals dissecties en intraplaque bloedingen voorkomen 
kunnen worden, iets waarvoor het gebruikte vein graft model vrij uniek in is.
De behandeling van vein graft falen biedt, ten opzichte van andere vasculaire ziekten, 
een aantal interessante voordelen. Allereerst is het startpunt van de behandeling 
zeer duidelijk, namelijk meteen vanaf de start van de operatie. Daarnaast, betreft 
het aangedane weefsel primair de vein graft, waardoor lokale behandeling en zelfs 
ex vivo behandelingsstrategieën zeer toepasbaar zijn. Dit maakt weer dat vein 
grafts zeer interessant zijn voor nieuwe lokale experimentele technieken zoals het 
plaatsen van gen therapeutische technieken zoals toegepast in hoofdstuk twee, 
drie en zeven. Dit zijn allen veelbelovende technieken maar behoeven nog verder 
onderzoek om vectoren veiliger en efficiënter te maken voor klinische toepassingen. 
De balans tussen factoren die lokaal rond de vein graft aanwezig zijn bepalen in sterke 
mate de uiteindelijke ontwikkeling van de veneuze vaatwand. De ideale situatie 
voor het behandelen van een patiënt met vein graft falen zou een behandeling zijn 
die rekening houdt met de lokale omstandigheden van de vein graft. Om kennis te 
nemen van deze omstandigheden zijn beeldvormende technieken zoals MRI, PET, 
SPECT, CT, IVUS maar ook nieuwe moleculaire beeldvormende technieken zoals 
Near-InfraRed-Fluorescence imaging (NIRF, hoofdstuk twee) van essentieel belang.
De kennis die opgedaan is uit de studies beschreven in dit proefschrift, is zeer 
relevant voor het basale begrip van de ontwikkeling van vein grafts, maar kan ook 
als uitgaansmaat dienen voor nieuw te ontwikkelen medicatie, hoewel voor dit 
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